0001099800-23-000021.txt : 20230428 0001099800-23-000021.hdr.sgml : 20230428 20230428164904 ACCESSION NUMBER: 0001099800-23-000021 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 96 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230428 DATE AS OF CHANGE: 20230428 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Edwards Lifesciences Corp CENTRAL INDEX KEY: 0001099800 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 364316614 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-15525 FILM NUMBER: 23867601 BUSINESS ADDRESS: STREET 1: ONE EDWARDS WAY CITY: IRVINE STATE: CA ZIP: 92614 BUSINESS PHONE: 9492502500 MAIL ADDRESS: STREET 1: ONE EDWARDS WAY CITY: IRVINE STATE: CA ZIP: 92614 FORMER COMPANY: FORMER CONFORMED NAME: EDWARDS LIFESCIENCES CORP. DATE OF NAME CHANGE: 20090225 FORMER COMPANY: FORMER CONFORMED NAME: EDWARDS LIFESCIENCES CORP DATE OF NAME CHANGE: 20000203 FORMER COMPANY: FORMER CONFORMED NAME: CVG CONTROLLED INC DATE OF NAME CHANGE: 19991126 10-Q 1 ew-20230331.htm 10-Q ew-20230331
000109980012/312023Q1falsehttp://fasb.org/us-gaap/2022#OtherAssetsCurrent http://fasb.org/us-gaap/2022#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2022#OtherAssetsCurrent http://fasb.org/us-gaap/2022#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent http://www.edwards.com/20230331#AccruedAndOtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent http://www.edwards.com/20230331#AccruedAndOtherLiabilitiesCurrent00010998002023-01-012023-03-3100010998002023-04-25xbrli:shares00010998002023-03-31iso4217:USD00010998002022-12-31iso4217:USDxbrli:shares00010998002022-01-012022-03-3100010998002021-12-3100010998002022-03-310001099800us-gaap:CommonStockMember2022-12-310001099800us-gaap:TreasuryStockCommonMember2022-12-310001099800us-gaap:AdditionalPaidInCapitalMember2022-12-310001099800us-gaap:RetainedEarningsMember2022-12-310001099800us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001099800us-gaap:ParentMember2022-12-310001099800us-gaap:NoncontrollingInterestMember2022-12-310001099800us-gaap:RetainedEarningsMember2023-01-012023-03-310001099800us-gaap:ParentMember2023-01-012023-03-310001099800us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001099800us-gaap:CommonStockMember2023-01-012023-03-310001099800us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001099800us-gaap:TreasuryStockCommonMember2023-01-012023-03-310001099800us-gaap:NoncontrollingInterestMember2023-01-012023-03-310001099800us-gaap:CommonStockMember2023-03-310001099800us-gaap:TreasuryStockCommonMember2023-03-310001099800us-gaap:AdditionalPaidInCapitalMember2023-03-310001099800us-gaap:RetainedEarningsMember2023-03-310001099800us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001099800us-gaap:ParentMember2023-03-310001099800us-gaap:NoncontrollingInterestMember2023-03-310001099800us-gaap:CommonStockMember2021-12-310001099800us-gaap:TreasuryStockCommonMember2021-12-310001099800us-gaap:AdditionalPaidInCapitalMember2021-12-310001099800us-gaap:RetainedEarningsMember2021-12-310001099800us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001099800us-gaap:RetainedEarningsMember2022-01-012022-03-310001099800us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001099800us-gaap:CommonStockMember2022-01-012022-03-310001099800us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001099800us-gaap:TreasuryStockCommonMember2022-01-012022-03-310001099800us-gaap:CommonStockMember2022-03-310001099800us-gaap:TreasuryStockCommonMember2022-03-310001099800us-gaap:AdditionalPaidInCapitalMember2022-03-310001099800us-gaap:RetainedEarningsMember2022-03-310001099800us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001099800us-gaap:SubsequentEventMember2023-04-122023-04-120001099800ew:MedtronicIncMemberus-gaap:SubsequentEventMember2023-04-122023-04-120001099800ew:MedtronicIncMember2023-03-012023-03-310001099800ew:MedtronicIncMemberus-gaap:SubsequentEventMember2023-04-280001099800ew:MedtronicIncMemberus-gaap:SubsequentEventMember2023-04-012023-04-280001099800us-gaap:BankTimeDepositsMember2023-03-310001099800us-gaap:BankTimeDepositsMember2022-12-310001099800us-gaap:USTreasuryAndGovernmentMember2023-03-310001099800us-gaap:USTreasuryAndGovernmentMember2022-12-310001099800us-gaap:AssetBackedSecuritiesMember2023-03-310001099800us-gaap:AssetBackedSecuritiesMember2022-12-310001099800us-gaap:CorporateDebtSecuritiesMember2023-03-310001099800us-gaap:CorporateDebtSecuritiesMember2022-12-310001099800us-gaap:MunicipalBondsMember2023-03-310001099800us-gaap:MunicipalBondsMember2022-12-310001099800us-gaap:LimitedLiabilityCompanyMemberew:NewMarketsTaxCreditMember2023-03-31xbrli:pure0001099800us-gaap:LimitedLiabilityCompanyMember2023-01-012023-03-310001099800us-gaap:OtherNonoperatingIncomeExpenseMember2023-03-310001099800ew:MedicalDeviceCompanyMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2023-03-012023-03-310001099800ew:MedicalDeviceCompanyMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2023-03-312023-03-310001099800ew:MedicalDeviceCompanyMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberew:ConvertiblePromissoryNoteMember2023-03-310001099800ew:MedicalDeviceCompanyMember2023-01-310001099800ew:MedicalDeviceCompanyMember2021-12-310001099800ew:MedicalDeviceCompanyMemberus-gaap:EquitySecuritiesMember2021-12-310001099800ew:MedicalDeviceCompanyMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2022-08-012022-08-310001099800ew:MedicalDeviceCompanyMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2022-08-310001099800ew:MedicalDeviceCompanyMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2022-06-012022-06-300001099800ew:MedicalDeviceCompanyMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2023-03-310001099800ew:MedicalDeviceCompanyMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2019-01-012019-12-310001099800ew:MedicalTechnologyCompanyMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2022-05-012022-05-310001099800ew:MedicalTechnologyCompanyMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2021-01-012021-12-310001099800ew:MedicalTechnologyCompanyMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2022-05-310001099800ew:MedicalTechnologyCompanyMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-02-280001099800ew:MedicalTechnologyCompanyMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-02-282023-02-280001099800us-gaap:FairValueInputsLevel2Member2023-03-310001099800us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-03-310001099800us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-03-310001099800us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-03-310001099800us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-03-310001099800us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-03-310001099800us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-03-310001099800us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-03-310001099800us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-03-310001099800us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:AssetBackedSecuritiesMember2023-03-310001099800us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:AssetBackedSecuritiesMember2023-03-310001099800us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:AssetBackedSecuritiesMember2023-03-310001099800us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:AssetBackedSecuritiesMember2023-03-310001099800us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-03-310001099800us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-03-310001099800us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-03-310001099800us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-03-310001099800us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:MunicipalBondsMember2023-03-310001099800us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:MunicipalBondsMember2023-03-310001099800us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:MunicipalBondsMember2023-03-310001099800us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:MunicipalBondsMember2023-03-310001099800us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001099800us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001099800us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001099800us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001099800us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001099800us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001099800us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001099800us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001099800us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:AssetBackedSecuritiesMember2022-12-310001099800us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:AssetBackedSecuritiesMember2022-12-310001099800us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:AssetBackedSecuritiesMember2022-12-310001099800us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:AssetBackedSecuritiesMember2022-12-310001099800us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001099800us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001099800us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001099800us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001099800us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:MunicipalBondsMember2022-12-310001099800us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:MunicipalBondsMember2022-12-310001099800us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:MunicipalBondsMember2022-12-310001099800us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:MunicipalBondsMember2022-12-310001099800us-gaap:ObligationsMemberus-gaap:MeasurementInputDiscountRateMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Member2023-03-310001099800us-gaap:ObligationsMemberus-gaap:MeasurementInputDiscountRateMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Member2023-03-310001099800us-gaap:ObligationsMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:FairValueInputsLevel3Membersrt:WeightedAverageMember2023-03-310001099800us-gaap:ObligationsMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberew:MeasurementInputProbabilityOfMilestoneAchievementMember2023-03-310001099800us-gaap:ObligationsMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberew:MeasurementInputProbabilityOfMilestoneAchievementMember2023-03-310001099800us-gaap:ObligationsMemberus-gaap:FairValueInputsLevel3Memberew:MeasurementInputProbabilityOfMilestoneAchievementMembersrt:WeightedAverageMember2023-03-310001099800ew:ContingentConsiderationLiabilityMember2022-12-310001099800us-gaap:OtherLiabilitiesMember2022-12-310001099800ew:ContingentConsiderationLiabilityMember2023-01-012023-03-310001099800us-gaap:OtherLiabilitiesMember2023-01-012023-03-310001099800ew:ContingentConsiderationLiabilityMember2023-03-310001099800us-gaap:OtherLiabilitiesMember2023-03-310001099800ew:ContingentConsiderationLiabilityMember2021-12-310001099800us-gaap:OtherLiabilitiesMember2021-12-310001099800ew:ContingentConsiderationLiabilityMember2022-01-012022-03-310001099800us-gaap:OtherLiabilitiesMember2022-01-012022-03-310001099800ew:ContingentConsiderationLiabilityMember2022-03-310001099800us-gaap:OtherLiabilitiesMember2022-03-310001099800us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2023-03-310001099800us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2022-12-310001099800us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMember2023-03-310001099800us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMember2022-12-310001099800us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2023-03-310001099800us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2022-12-310001099800ew:AccruedAndOtherLiabilitiesCurrentMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2023-03-310001099800ew:AccruedAndOtherLiabilitiesCurrentMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2022-12-310001099800us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2023-03-310001099800us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2022-12-310001099800us-gaap:ForeignExchangeContractMember2023-03-310001099800us-gaap:CurrencySwapMember2023-03-310001099800us-gaap:ForeignExchangeContractMember2022-12-310001099800us-gaap:CurrencySwapMember2022-12-310001099800us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2023-01-012023-03-310001099800us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2022-01-012022-03-310001099800us-gaap:CostOfSalesMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2023-01-012023-03-310001099800us-gaap:CostOfSalesMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2022-01-012022-03-310001099800us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMember2023-01-012023-03-310001099800us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMember2022-01-012022-03-310001099800us-gaap:InterestIncomeMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMember2023-01-012023-03-310001099800us-gaap:InterestIncomeMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMember2022-01-012022-03-310001099800us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMember2023-03-31iso4217:EUR0001099800us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2023-01-012023-03-310001099800us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2022-01-012022-03-310001099800us-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMember2023-01-012023-03-310001099800us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:ForeignExchangeContractMember2023-01-012023-03-310001099800us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMember2023-01-012023-03-310001099800us-gaap:CostOfSalesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2023-01-012023-03-310001099800us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2023-01-012023-03-310001099800us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2023-01-012023-03-310001099800us-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMember2022-01-012022-03-310001099800us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:ForeignExchangeContractMember2022-01-012022-03-310001099800us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMember2022-01-012022-03-310001099800us-gaap:CostOfSalesMember2023-01-012023-03-310001099800us-gaap:CostOfSalesMember2022-01-012022-03-310001099800us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-03-310001099800us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-03-310001099800us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310001099800us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-310001099800ew:EmployeeAndNonemployeeStockOptionsMember2023-01-012023-03-310001099800ew:EmployeeAndNonemployeeStockOptionsMember2022-01-012022-03-310001099800us-gaap:EmployeeStockMember2023-01-012023-03-310001099800us-gaap:EmployeeStockMember2022-01-012022-03-310001099800ew:InitialDeliveryOfSharesSettledJanuary2022Member2022-01-310001099800ew:InitialDeliveryOfSharesSettledJanuary2022Member2022-01-012022-01-310001099800ew:January2022StockRepurchaseProgramSharesSoldInFebruary2022Member2022-02-012022-02-280001099800ew:InitialDeliveryOfSharesSettledFebruary2023Member2023-02-280001099800ew:InitialDeliveryOfSharesSettledFebruary2023Member2023-02-012023-02-280001099800ew:February2023StockRepurchaseProgramSharesSoldInMarch2023Member2023-03-012023-03-31ew:lawsuit0001099800us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310001099800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310001099800us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-12-310001099800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310001099800us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-03-310001099800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-03-310001099800us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-03-310001099800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-03-310001099800us-gaap:AccumulatedTranslationAdjustmentMember2023-03-310001099800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-03-310001099800us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-03-310001099800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-03-310001099800us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310001099800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310001099800us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-12-310001099800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-310001099800us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-03-310001099800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-03-310001099800us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-01-012022-03-310001099800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-012022-03-310001099800us-gaap:AccumulatedTranslationAdjustmentMember2022-03-310001099800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-03-310001099800us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-03-310001099800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-03-310001099800us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-03-310001099800us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-03-310001099800us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-03-310001099800us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-03-310001099800us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-03-310001099800us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-01-012022-03-310001099800us-gaap:StockCompensationPlanMember2023-01-012023-03-310001099800us-gaap:StockCompensationPlanMember2022-01-012022-03-3100010998002021-01-012021-12-310001099800us-gaap:OperatingSegmentsMemberew:UnitedStatesSegmentMember2023-01-012023-03-310001099800us-gaap:OperatingSegmentsMemberew:UnitedStatesSegmentMember2022-01-012022-03-310001099800us-gaap:OperatingSegmentsMemberew:EuropeSegmentMember2023-01-012023-03-310001099800us-gaap:OperatingSegmentsMemberew:EuropeSegmentMember2022-01-012022-03-310001099800us-gaap:OperatingSegmentsMemberew:JapanSegmentMember2023-01-012023-03-310001099800us-gaap:OperatingSegmentsMemberew:JapanSegmentMember2022-01-012022-03-310001099800us-gaap:OperatingSegmentsMemberew:RestOfWorldSegmentMember2023-01-012023-03-310001099800us-gaap:OperatingSegmentsMemberew:RestOfWorldSegmentMember2022-01-012022-03-310001099800us-gaap:OperatingSegmentsMember2023-01-012023-03-310001099800us-gaap:OperatingSegmentsMember2022-01-012022-03-310001099800us-gaap:MaterialReconcilingItemsMember2023-01-012023-03-310001099800us-gaap:MaterialReconcilingItemsMember2022-01-012022-03-310001099800us-gaap:CorporateNonSegmentMember2023-01-012023-03-310001099800us-gaap:CorporateNonSegmentMember2022-01-012022-03-310001099800country:US2023-01-012023-03-310001099800country:US2022-01-012022-03-310001099800srt:EuropeMember2023-01-012023-03-310001099800srt:EuropeMember2022-01-012022-03-310001099800country:JP2023-01-012023-03-310001099800country:JP2022-01-012022-03-310001099800ew:RestOfWorldMember2023-01-012023-03-310001099800ew:RestOfWorldMember2022-01-012022-03-310001099800ew:TranscatheterAorticValveReplacementMember2023-01-012023-03-310001099800ew:TranscatheterAorticValveReplacementMember2022-01-012022-03-310001099800ew:TranscatheterMitralAndTricuspidTherapiesMember2023-01-012023-03-310001099800ew:TranscatheterMitralAndTricuspidTherapiesMember2022-01-012022-03-310001099800ew:SurgicalHeartValveTherapyMember2023-01-012023-03-310001099800ew:SurgicalHeartValveTherapyMember2022-01-012022-03-310001099800ew:CriticalCareMember2023-01-012023-03-310001099800ew:CriticalCareMember2022-01-012022-03-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended March 31, 2023
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
            For the transition period from                                    to            
Commission file number 1-15525
EDWARDS LIFESCIENCES CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
36-4316614
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)

One Edwards Way
Irvine, California 92614
(Address of principal executive offices and zip code)

(949) 250-2500
(Registrant's telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $1.00 per shareEWNew York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒    No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒    No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒Accelerated filer☐Non-accelerated filer☐Smaller reporting company☐Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐    No ☒
The number of shares outstanding of the registrant's common stock, $1.00 par value, as of April 25, 2023 was 606,218,215.


EDWARDS LIFESCIENCES CORPORATION
FORM 10-Q
For the quarterly period ended March 31, 2023

TABLE OF CONTENTS


NOTE REGARDING FORWARD-LOOKING STATEMENTS
This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. We intend the forward-looking statements contained in this report to be covered by the safe harbor provisions of such Acts. Statements other than statements of historical or current fact in this report or referred to or incorporated by reference into this report are "forward-looking statements" for purposes of these sections. These statements include, among other things, the expected impact of COVID-19 on our business, the expected impact of macroeconomic conditions on our business, any predictions, opinions, expectations, plans, strategies, objectives and any statements of assumptions underlying any of the foregoing relating to our current and future business and operations, including, but not limited to, financial matters, development activities, clinical trials and regulatory matters, manufacturing and supply operations, and product sales and demand. These statements can sometimes be identified by the use of the forward-looking words such as "may," "believe," "will," "expect," "project," "estimate," "should," "anticipate," "plan," "goal," "continue," "seek," "pro forma," "forecast," "intend," "guidance," "optimistic," "aspire," "confident," other forms of these words or similar words or expressions or the negative thereof. Statements of past performance, efforts, or results about which inferences or assumptions may be made can also be forward-looking statements and are not indicative of future performance or results; these statements can be identified by the use of words such as "preliminary," "initial," diligence," "industry-leading," "compliant," "indications," or "early feedback" or other forms of these words or similar words or expressions or the negative thereof. These forward-looking statements are subject to substantial risks and uncertainties that could cause our results or future business, financial condition, results of operations or performance to differ materially from our historical results or experiences or those expressed or implied in any forward-looking statements contained in this report. These risks and uncertainties include, but are not limited to: our success in developing new products and avoiding manufacturing and quality issues; clinical trial or commercial results or new product approvals and therapy adoption; the impact of public health crises, including the COVID-19 pandemic; the impact of domestic and global conditions; competitive dynamics in the markets in which we operate; our reliance on vendors, suppliers, and other third parties; damage, failure or interruption of our information technology systems; consolidation in the healthcare industry; our ability to protect our intellectual property; our compliance with applicable regulations; our exposure to product liability claims; use of our products in unapproved circumstances; changes to reimbursement for our products; the impact of currency exchange rates; unanticipated actions by the United States Food and Drug Administration and other regulatory agencies; changes to tax laws; unexpected impacts or expenses of litigation or internal or government investigations; and other risks detailed under “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2022, as such risks and uncertainties may be amended, supplemented or superseded from time to time by our subsequent reports on Forms 10-Q and 8-K we file with the United States Securities and Exchange Commission. These forward-looking statements speak only as of the date on which they are made and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. If we do update or correct one or more of these statements, investors and others should not conclude that we will make additional updates or corrections.

Unless otherwise indicated or otherwise required by the context, the terms "we," "our," "it," "its," "Company," "Edwards," and "Edwards Lifesciences" refer to Edwards Lifesciences Corporation and its subsidiaries.


Part I. Financial Information
Item 1.    Financial Statements
EDWARDS LIFESCIENCES CORPORATION
CONSOLIDATED CONDENSED BALANCE SHEETS
(in millions, except par value; unaudited)
 March 31,
2023		December 31,
2022
ASSETS  
Current assets  
Cash and cash equivalents$872.5 $769.0 
Short-term investments (Note 4)381.7 446.3 
Accounts receivable, net of allowances of $7.6 and $7.9, respectively
717.7 643.0 
Other receivables61.6 56.1 
Inventories (Note 2)914.3 875.5 
Prepaid expenses119.1 110.0 
Other current assets190.3 195.9 
Total current assets3,257.2 3,095.8 
Long-term investments (Note 4)1,066.7 1,239.0 
Property, plant, and equipment, net1,646.0 1,632.8 
Operating lease right-of-use assets 88.5 92.3 
Goodwill 1,308.4 1,164.3 
Other intangible assets, net (Note 6) 446.8 285.2 
Deferred income taxes544.0 484.0 
Other assets (Note 5)293.6 299.1 
Total assets$8,651.2 $8,292.5 
LIABILITIES AND STOCKHOLDERS' EQUITY  
Current liabilities  
Accounts payable$180.8 $201.9 
Accrued and other liabilities (Note 2)876.1 795.0 
Operating lease liabilities25.1 25.5 
Total current liabilities1,082.0 1,022.4 
Long-term debt 596.5 596.3 
Contingent consideration liabilities (Note 7)26.9 26.2 
Taxes payable143.4 143.4 
Operating lease liabilities 66.2 69.5 
Uncertain tax positions284.0 267.5 
Litigation agreement accrual (Note 2)130.1 143.0 
Other liabilities260.1 217.5 
Total liabilities2,589.2 2,485.8 
Commitments and contingencies (Note 11)
Stockholders' equity  
Preferred stock, $0.01 par value, authorized 50.0 shares, no shares outstanding          
— — 
Common stock, $1.00 par value, 1,050.0 shares authorized, 647.1 and 646.3 shares issued, and 606.0 and 608.3 shares outstanding, respectively
647.1 646.3 
Additional paid-in capital2,049.3 1,969.3 
Retained earnings7,930.5 7,590.0 
Accumulated other comprehensive loss (Note 12)(255.4)(254.9)
Treasury stock, at cost, 41.1 and 38.0 shares, respectively
(4,393.5)(4,144.0)
Total Edwards Lifesciences, Inc. stockholders' equity5,978.0 5,806.7 
Noncontrolling interest84.0 — 
Total stockholders' equity6,062.0 5,806.7 
Total liabilities and equity$8,651.2 $8,292.5 
The accompanying notes are an integral part of these
consolidated condensed financial statements.
1
EDWARDS LIFESCIENCES CORPORATION
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
(in millions, except per share information; unaudited)
 Three Months Ended
March 31,
 20232022
Net sales$1,459.6 $1,341.2 
Cost of sales329.5 299.3 
Gross profit1,130.1 1,041.9 
Selling, general, and administrative expenses436.3 370.3 
Research and development expenses261.2 228.6 
Intellectual property agreement and litigation expenses, net (Note 3)43.5 7.1 
Change in fair value of contingent consideration liabilities, net (Note 7)0.7 (2.9)
Operating income388.4 438.8 
Interest income, net(8.6)(0.6)
Other (income) expense, net(1.6)3.3 
Income before provision for income taxes398.6 436.1 
Provision for income taxes58.1 62.5 
Net income$340.5 $373.6 
Share information (Note 13)
  
Earnings per share:  
Basic$0.56 $0.60 
Diluted$0.56 $0.59 
Weighted-average number of common shares outstanding:  
Basic607.5 622.1 
Diluted610.9 629.4 
The accompanying notes are an integral part of these
consolidated condensed financial statements.
2
EDWARDS LIFESCIENCES CORPORATION
CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME
(in millions; unaudited)
 Three Months Ended
March 31,
 20232022
Net income$340.5 $373.6 
Other comprehensive loss, net of tax (Note 12):
Foreign currency translation adjustments3.8 (10.0)
Unrealized (loss) gain on hedges(17.2)13.4 
Unrealized pension costs(0.1)— 
Unrealized gain (loss) on available-for-sale investments9.0 (37.1)
Reclassification of realized investment losses to earnings4.0 4.8 
Other comprehensive loss(0.5)(28.9)
Comprehensive income$340.0 $344.7 
The accompanying notes are an integral part of these
consolidated condensed financial statements.
3
EDWARDS LIFESCIENCES CORPORATION
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
(in millions; unaudited)
 Three Months Ended
March 31,
 20232022
Cash flows from operating activities  
Net income$340.5 $373.6 
Adjustments to reconcile net income to net cash provided by operating activities:  
Depreciation and amortization35.2 34.7 
Non-cash operating lease cost6.8 7.1 
Stock-based compensation (Note 9)38.9 32.4 
Change in fair value of contingent consideration liabilities, net (Note 7)0.7 (2.9)
Deferred income taxes(51.8)(42.6)
Other0.4 20.4 
Changes in operating assets and liabilities:  
Accounts and other receivables, net(77.5)(57.8)
Inventories(32.8)(24.0)
Accounts payable and accrued liabilities(45.2)(109.2)
Income taxes87.2 82.9 
Prepaid expenses and other current assets(23.8)1.7 
Intellectual property agreement accrual29.3 (10.0)
Other6.2 (13.0)
Net cash provided by operating activities314.1 293.3 
Cash flows from investing activities  
Capital expenditures(61.5)(72.7)
Purchases of held-to-maturity investments (Note 4)(12.5)(128.0)
Proceeds from held-to-maturity investments (Note 4)80.5 130.0 
Purchases of available-for-sale investments (Note 4)(3.2)(74.1)
Proceeds from available-for-sale investments (Note 4)183.4 372.0 
Business combination, net of cash (Note 6)(141.2)— 
Payment for acquisition options (Note 5)(15.0)— 
Issuances of notes receivable(15.0)(10.5)
Collections of notes receivable— 18.0 
Other(15.0)(5.2)
Net cash provided by investing activities0.5 229.5 
Cash flows from financing activities  
Purchases of treasury stock(249.3)(405.6)
Proceeds from stock plans41.9 37.5 
Other0.8 — 
Net cash used in financing activities(206.6)(368.1)
Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash(4.2)13.2 
Net increase in cash, cash equivalents, and restricted cash103.8 167.9 
Cash, cash equivalents, and restricted cash at beginning of period772.6 867.4 
Cash, cash equivalents, and restricted cash at end of period$876.4 $1,035.3 
The accompanying notes are an integral part of these
consolidated condensed financial statements.
4
EDWARDS LIFESCIENCES CORPORATION
CONSOLIDATED CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY
(in millions; unaudited)
 Common StockTreasury Stock
 SharesPar ValueSharesAmountAdditional Paid-in CapitalRetained EarningsAccumulated Other Comprehensive LossTotal Edwards Lifesciences, Inc. Stockholders' EquityNoncontrolling InterestTotal Stockholders' Equity
Balance at December 31, 2022646.3 $646.3 38.0 $(4,144.0)$1,969.3 $7,590.0 $(254.9)$5,806.7 $— $5,806.7 
Net income     340.5  340.5 — 340.5 
Other comprehensive loss, net of tax      (0.5)(0.5)(0.5)
Common stock issued under stock plans0.8 0.8   41.1   41.9 41.9 
Stock-based compensation expense    38.9   38.9 38.9 
Purchases of treasury stock  3.1 (249.5)  (249.5)(249.5)
Changes to noncontrolling interest  — 84.0 84.0 
Balance at March 31, 2023
647.1 $647.1 41.1 $(4,393.5)$2,049.3 $7,930.5 $(255.4)$5,978.0 $84.0 $6,062.0 
The accompanying notes are an integral part of these
consolidated condensed financial statements.

5
EDWARDS LIFESCIENCES CORPORATION
CONSOLIDATED CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY
(in millions; unaudited)
 Common StockTreasury Stock
 SharesPar ValueSharesAmountAdditional Paid-in CapitalRetained EarningsAccumulated Other Comprehensive LossTotal Equity
Balance at December 31, 2021642.0 $642.0 17.9 $(2,416.9)$1,700.4 $6,068.1 $(157.7)$5,835.9 
Net income     373.6  373.6 
Other comprehensive loss, net of tax      (28.9)(28.9)
Common stock issued under stock plans0.9 0.9   36.6   37.5 
Stock-based compensation expense    32.4   32.4 
Purchases of treasury stock  3.6 (405.6)  (405.6)
Balance at March 31, 2022
642.9 $642.9 21.5 $(2,822.5)$1,769.4 $6,441.7 $(186.6)$5,844.9 
The accompanying notes are an integral part of these
consolidated condensed financial statements.
6

1.     BASIS OF PRESENTATION

The accompanying interim consolidated condensed financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") and should be read in conjunction with the consolidated financial statements and notes included in Edwards Lifesciences' Annual Report on Form 10-K for the year ended December 31, 2022. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") have been condensed or omitted.

The consolidated condensed financial statements include the accounts of all wholly-owned subsidiaries and variable interest entities for which the Company is the primary beneficiary. All intercompany accounts and transactions have been eliminated in consolidation.

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.

In the opinion of management, the interim consolidated condensed financial statements reflect all adjustments necessary for a fair statement of the results for the interim periods presented. All such adjustments, unless otherwise noted herein, are of a normal, recurring nature. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.

There have been no material changes to the Company's significant accounting policies from those described in the Company's Annual Report on Form 10-K for the year ended December 31, 2022.

New Accounting Standards Not Yet Adopted

In March 2023, the Financial Accounting Standards Board ("FASB") issued an amendment to the accounting guidance on investments in tax credit structures to allow entities to elect to account for their tax equity investments, regardless of the tax credit program from which the income tax credits are received, using the proportional amortization method if certain conditions are met. The guidance is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. The Company does not expect the adoption of this guidance will have a material impact on its consolidated financial results.

2.     OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS

Composition of Certain Financial Statement Captions
(in millions)

Components of selected captions in the consolidated condensed balance sheets consisted of the following:
March 31, 2023December 31, 2022
Inventories
Raw materials$164.6 $156.4 
Work in process206.4 177.4 
Finished products543.3 541.7 
$914.3 $875.5 

At March 31, 2023 and December 31, 2022, $146.1 million and $128.6 million, respectively, of the Company's finished products inventories were held on consignment.

7
March 31, 2023December 31, 2022
Accrued and other liabilities 
Employee compensation and withholdings$225.8 $268.7 
Taxes payable120.8 50.6 
Property, payroll, and other taxes53.6 45.6 
Research and development accruals67.7 66.9 
Accrued rebates112.3 116.1 
Fair value of derivatives23.4 20.7 
Accrued marketing expenses13.2 17.0 
Legal and insurance29.1 28.1 
Intellectual property agreements (a)
95.4 53.3 
Accrued relocation costs26.2 25.2 
Accrued professional services10.6 6.6 
Accrued realignment reserves14.8 15.6 
Other accrued liabilities83.2 80.6 
$876.1 $795.0 
_______________________________________
(a)     As of March 31, 2023, $95.4 million was accrued in "Accrued and other liabilities" and $130.1 million was accrued in "Litigation agreement accrual" on the consolidated condensed balance sheet related to intellectual property agreements with Abbott Laboratories and its direct and indirect subsidiaries, and Medtronic, Inc.

Supplemental Cash Flow Information
(in millions)
Three Months Ended
March 31,
20232022
Cash paid during the year for:
Amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases
$7.1 $7.6 
Non-cash investing and financing transactions:  
Right-of-use assets obtained in exchange for new lease liabilities$2.2 $6.4 
Capital expenditures accruals$26.5 $23.8 

Cash, Cash Equivalents, and Restricted Cash
(in millions)
March 31, 2023December 31, 2022
Cash and cash equivalents$872.5 $769.0 
Restricted cash included in other current assets0.6 0.5 
Restricted cash included in other assets3.3 3.1 
Total cash, cash equivalents, and restricted cash$876.4 $772.6 

Amounts included in restricted cash primarily represent funds placed in escrow related to litigation.

3.    INTELLECTUAL PROPERTY AGREEMENT AND LITIGATION EXPENSES

On April 12, 2023, Edwards entered into an Intellectual Property Agreement ("Agreement") with Medtronic, Inc. ("Medtronic") pursuant to which the parties agreed to a 15-year global covenant not to sue ("CNS") for infringement of certain patents in the structural heart space owned or controlled by each other. In consideration for the global CNS and related mutual access to certain intellectual property rights, Edwards will pay to Medtronic a one-time, lump sum payment of $300.0 million and annual royalty payments that are tied to net sales of certain Edwards products. Based upon the terms of the Agreement, the Company identified the relevant elements for accounting purposes and allocated the $300.0 million upfront payment based on their fair values. The Company recorded a $37.0 million pre-tax charge in March 2023 related primarily to prior commercial sales incurred through March 31, 2023. The Company recorded a prepaid royalty asset of $124.0 million in April 2023 related
8
to future commercial sales, which will be amortized as expense during the term of the Agreement. Separately, the Company recorded a $139.0 million pre-tax charge in April 2023 related to products currently in development.

4.     INVESTMENTS

Debt Securities

Investments in debt securities at the end of each period were as follows (in millions):
 March 31, 2023December 31, 2022
Held-to-maturityAmortized CostGross Unrealized GainsGross Unrealized LossesFair ValueAmortized CostGross Unrealized GainsGross Unrealized LossesFair Value
Bank time deposits$28.0 $— $— $28.0 $96.0 $— $— $96.0 
Available-for-sale
U.S government and agency securities108.6 — (4.9)103.7 137.7 — (6.1)131.6 
Asset-backed securities304.2 — (11.2)293.0 380.6 — (14.0)366.6 
Corporate debt securities948.8 — (38.8)910.0 1,028.1 — (47.8)980.3 
Municipal securities2.8 — (0.2)2.6 2.7 — (0.2)2.5 
Total$1,364.4 $— $(55.1)$1,309.3 $1,549.1 $— $(68.1)$1,481.0 
The cost and fair value of investments in debt securities, by contractual maturity, as of March 31, 2023, were as follows:
Held-to-MaturityAvailable-for-Sale
 Amortized CostFair ValueAmortized CostFair Value
 (in millions)
Due in 1 year or less$23.5 $23.5 $366.5 $358.2 
Due after 1 year through 5 years4.5 4.5 647.3 614.8 
Due after 5 years through 10 years— — 5.2 5.1 
Instruments not due at a single maturity date (a)
— — 345.4 331.2 
$28.0 $28.0 $1,364.4 $1,309.3 
_______________________________________
(a)     Consists of mortgage- and asset-backed securities.
Actual maturities may differ from the contractual maturities due to call or prepayment rights.
The following tables present gross unrealized losses and fair values for those investments that were in an unrealized loss position as of March 31, 2023 and December 31, 2022, aggregated by investment category and the length of time that individual securities have been in a continuous loss position (in millions):

March 31, 2023
Less than 12 Months12 Months or GreaterTotal
Fair ValueGross Unrealized LossesFair ValueGross Unrealized LossesFair ValueGross Unrealized Losses
U.S. government and agency securities$10.6 $(0.1)$92.2 $(4.8)$102.8 $(4.9)
Asset-backed securities59.1 (0.8)224.7 (10.4)283.8 (11.2)
Corporate debt securities30.8 (0.1)871.7 (38.7)902.5 (38.8)
Municipal securities— — 2.6 (0.2)2.6 (0.2)
$100.5 $(1.0)$1,191.2 $(54.1)$1,291.7 $(55.1)
9
December 31, 2022
Less than 12 Months12 Months or GreaterTotal
Fair ValueGross Unrealized LossesFair ValueGross Unrealized LossesFair ValueGross Unrealized Losses
U.S. government and agency securities$61.6 $(1.5)$69.5 $(4.6)$131.1 $(6.1)
Asset-backed securities103.3 (1.3)254.6 (12.7)357.9 (14.0)
Corporate debt securities189.0 (5.3)784.8 (42.5)973.8 (47.8)
Municipal securities— — 2.5 (0.2)2.5 (0.2)
$353.9 $(8.1)$1,111.4 $(60.0)$1,465.3 $(68.1)

The Company reviews its investments in debt securities to determine if there has been an other-than-temporary decline in fair value. Consideration is given to 1) the length of time and the extent to which the security's fair value has been below cost, 2) the financial condition and near term prospects of the issuer, including the credit quality of the security's issuer, 3) the Company's intent to sell the security, and 4) whether it is more likely than not the Company will have to sell the security before recovery of its amortized cost. The decline in fair value of the debt securities was largely due to changes in interest rates, not credit quality, and as of March 31, 2023, the Company did not intend to sell the securities, and it was not more likely than not that it will be required to sell the securities before recovery of the unrealized losses, and, therefore, the unrealized losses are considered temporary.

Investments in Unconsolidated Entities

The Company has a number of equity investments in unconsolidated entities. These investments are recorded in "Long-term Investments" on the consolidated condensed balance sheets, and are as follows:
 March 31,
2023		December 31,
2022
 (in millions)
Equity method investments  
Carrying value of equity method investments$24.2 $21.4 
Equity securities  
Carrying value of non-marketable equity securities86.9 86.9 
Total investments in unconsolidated entities$111.1 $108.3 

During the three months ended March 31, 2023, the Company made $1.7 million of equity investments in limited liability companies that invest in qualified community development entities ("CDEs") through the New Markets Tax Credit ("NMTC") program. The NMTC program provides federal tax incentives to investors to make investments in distressed communities and promotes economic improvements through the development of successful businesses in these communities. The NMTC is equal to 39% of the qualified investment and is taken over seven years. These limited liability companies are variable interest entities ("VIEs"). The Company determined that it is not the primary beneficiary of the VIEs because it does not have the power to direct the activities that most significantly impact the economic performance of the VIEs, and therefore the Company does not consolidate these entities. Instead, the NMTC investments are accounted for as equity method investments.

Non-marketable equity securities consist of investments in privately held companies without readily determinable fair values, and are reported at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. As of March 31, 2023, the Company had recorded cumulative upward adjustments of $8.8 million based on observable price changes, and cumulative downward adjustments of $3.1 million due to impairments and observable price changes.

During the three months ended March 31, 2023, the gross realized gains or losses from sales of available-for-sale investments were not material.

10
5.     INVESTMENTS IN VARIABLE INTEREST ENTITIES

The Company reviews its investments in other entities to determine whether the Company is the primary beneficiary of a variable interest entity ("VIE"). The Company would be the primary beneficiary of the VIE, and would be required to consolidate the VIE, if it has the power to direct the significant activities of the entity and the obligation to absorb losses or receive benefits from the entity that may be significant to the VIE. The Company's maximum loss exposure to variable interest entities, prior to the exercise of options to acquire the entities, is limited to its investment in the variable interest entities, which include equity investments, options to acquire, and promissory notes.

Consolidated VIEs

In February 2023, the Company entered into a preferred stock purchase agreement to acquire a majority equity interest in a medical technology company and an option agreement to acquire the remaining equity interest. Edwards concluded that it is the primary beneficiary and consolidated the VIE. See Note 6 for additional information.

Unconsolidated VIEs

Edwards has relationships with various VIEs that it does not consolidate as Edwards lacks the power to direct the activities that significantly impact the economic success of these entities.

In March 2023, the Company agreed to pay a medical device company up to $45 million as consideration for an option to acquire the medical device company, of which $15.0 million has been paid as of March 31, 2023. Also, in March 2023, Edwards advanced $5 million to the medical device company under a convertible promissory note. The option and the note are included in "Other Assets" on the consolidated condensed balance sheet.
In January 2023, the Company loaned a privately-held medical device company (the "Investee") $10 million under a $45 million secured promissory note agreement. Previously, in 2021, the Company invested $39.3 million, included in "Long-term Investments," in the Investee's preferred equity securities and paid $13.1 million, included in "Other Assets," for an option to acquire the Investee. Per the agreement, the Company may be required to invest up to an additional $6.5 million in the Investee's preferred equity securities and up to an additional $14.4 million for the option to acquire the Investee.

In August 2022, the Company entered into an option agreement with a medical device company. Under the option agreement, Edwards paid $47.1 million for an option to acquire the medical device company. The $47.1 million option is included in "Other Assets" on the consolidated condensed balance sheet.

In June 2022, the Company entered into a convertible promissory note and amended its existing warrant agreement with a medical device company. Under the convertible promissory note agreement, the Company agreed to loan the medical device company up to $47.5 million, of which $32.5 million has been advanced as of March 31, 2023. In addition, in 2019 the Company paid $35.0 million for an option to acquire the medical device company. The $35.0 million warrant and the $32.5 million note receivable are included in "Other Assets" on the consolidated condensed balance sheet.

In May 2022, the Company entered into an option agreement with a medical technology company. Under the option agreement, Edwards paid $60.0 million for an option to acquire the medical technology company, of which $10 million was paid in 2021. The $60.0 million option is included in "Other Assets" on the consolidated condensed balance sheet.

In addition, Edwards has made equity investments through the NMTC program in limited liability companies that are considered VIEs. For more information, see Note 4.

6.     BUSINESS COMBINATION

On February 28, 2023, the Company acquired 61% of the then outstanding shares of a medical technology company in an all cash transaction. The Company determined it was the primary beneficiary of this VIE, and the VIE has been consolidated in the Company's consolidated condensed financial statements. In addition, the Company amended and restated its previous option agreement with the medical technology company. The option agreement gives Edwards the option to acquire the remaining equity interest in the medical technology company.

11
The medical technology company is dedicated to developing technologies for detecting and managing patients with cardiovascular disease. The transaction was accounted for as a business combination. Tangible and intangible assets and liabilities acquired were recorded based on their estimated fair values at the acquisition date. The excess of the purchase price over the fair value of net assets acquired was recorded to goodwill. The Company is in the process of finalizing its purchase price allocation. Therefore, the amounts reflected below are subject to change and will be finalized during 2023. The following table summarizes the preliminary fair values of the assets acquired and liabilities assumed (in millions):

Assets$7.5 
Goodwill143.0 
In-process research and development150.5 
Liabilities assumed(16.1)
Deferred tax liabilities(25.1)
Fair value of net assets acquired259.8 
Less: Noncontrolling interest (a)
(84.0)
Total purchase price
175.8 
Less: cash acquired(6.8)
Total purchase price, net of cash acquired (b)
$169.0 
_______________________________________
(a) Includes the fair value of the noncontrolling interest of $99.0 million offset by the purchase consideration allocated to the option of $15.0 million, which was ascribed to the noncontrolling interest.
(b)     Includes $22.5 million paid in a previous year under option agreements and $5.3 million for the settlement of a pre-existing note.

Goodwill includes expected synergies and other benefits the Company believes will result from the acquisition. Goodwill was assigned to the Company’s Rest of World segment and is not deductible for tax purposes.

The results of operations for the medical technology company since the date of acquisition were immaterial. Pro forma results have not been presented as the results of the medical technology company are not material in relation to the consolidated financial statements of Edwards Lifesciences.

7.     FAIR VALUE MEASUREMENTS

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. The Company prioritizes the inputs used to determine fair values in one of the following three categories:

Level 1—Quoted market prices in active markets for identical assets or liabilities.
Level 2—Inputs, other than quoted prices in active markets, that are observable, either directly or indirectly.
Level 3—Unobservable inputs that are not corroborated by market data.

In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement in its entirety.

The consolidated condensed financial statements include financial instruments for which the fair market value of such instruments may differ from amounts reflected on a historical cost basis. Financial instruments of the Company consist of cash deposits, accounts and other receivables, investments, accounts payable, certain accrued liabilities, and borrowings under a revolving credit agreement. The carrying value of these financial instruments generally approximates fair value due to their short-term nature. Financial instruments also include notes payable. As of March 31, 2023, the fair value of the notes payable, based on Level 2 inputs, was $598.5 million.

12
Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table summarizes the Company's financial instruments which are measured at fair value on a recurring basis (in millions):
March 31, 2023Level 1Level 2Level 3Total
Assets    
Cash equivalents$9.0 $— $— $9.0 
Available-for-sale investments:
Corporate debt securities
— 910.0 — 910.0 
Asset-backed securities
— 293.0 — 293.0 
United States government and agency securities53.1 50.6 — 103.7 
Municipal securities
— 2.6 — 2.6 
Investments held for deferred compensation plans117.8 — — 117.8 
Derivatives— 51.7 — 51.7 
$179.9 $1,307.9 $— $1,487.8 
Liabilities    
Derivatives$— $23.4 $— $23.4 
Contingent consideration liabilities— — 26.9 26.9 
Other liability— — 14.0 14.0 
$— $23.4 $40.9 $64.3 
December 31, 2022    
Assets    
Cash equivalents$0.4 $— $— $0.4 
Available-for-sale investments:
Corporate debt securities
— 980.3 — 980.3 
Asset-backed securities
— 366.6 — 366.6 
United States government and agency securities37.1 94.5 — 131.6 
Municipal securities
— 2.5 — 2.5 
Investments held for deferred compensation plans112.1 — — 112.1 
Derivatives— 65.5 — 65.5 
$149.6 $1,509.4 $— $1,659.0 
Liabilities    
Derivatives$— $27.2 $— $27.2 
Contingent consideration liabilities— — 26.2 26.2 
Other liability— — 14.0 14.0 
$— $27.2 $40.2 $67.4 

Cash Equivalents and Available-for-sale Investments

The Company estimates the fair values of its money market funds based on quoted prices in active markets for identical assets. The Company estimates the fair values of its time deposits, commercial paper, United States and foreign government and agency securities, municipal securities, asset-backed securities, and corporate debt securities by taking into consideration valuations obtained from third-party pricing services. The pricing services use industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades and broker-dealer quotes on the same or similar securities, benchmark yields, credit spreads, prepayment and default projections based on historical data, and other observable inputs. The Company independently reviews and validates the pricing received from the third-party pricing service by comparing the prices to prices reported by a secondary pricing source. The Company’s validation procedures have not resulted in an adjustment to the pricing received from the pricing service.

Deferred Compensation Plans

The Company holds investments in trading securities related to its deferred compensation plans. The investments are in a variety of stock, bond and money market mutual funds. The fair values of these investments are based on quoted market prices.

13
Derivative Instruments

The Company uses derivative financial instruments in the form of foreign currency forward exchange contracts and cross currency swap contracts to manage foreign currency exposures. All derivatives contracts are recognized on the balance sheet at their fair value. The fair value of the derivative financial instruments was estimated based on quoted market foreign exchange rates, cross currency swap basis rates, and market discount rates. Judgment was employed in interpreting market data to develop estimates of fair value; accordingly, the estimates presented herein are not necessarily indicative of the amounts that the Company could realize in a current market exchange. The use of different market assumptions or valuation methodologies could have a material effect on the estimated fair value amounts.

Contingent Consideration Liabilities

Certain of the Company's acquisitions involve contingent consideration arrangements. Payment of additional consideration is contingent upon the acquired company reaching certain performance milestones, such as attaining specified sales levels or obtaining regulatory approvals. These contingent consideration liabilities are measured at estimated fair value using either a probability weighted discounted cash flow analysis or a Monte Carlo simulation model, both of which consider significant unobservable inputs. These inputs as of March 31, 2023 include (1) the discount rate used to present value the projected cash flows (ranging from 3.5% to 13.8%; weighted average of 3.7%), (2) the probability of milestone achievement (ranging from 0% to 50%; weighted average of 39.6%), and (3) the projected payment dates (2026). The weighted average of each of the above inputs was determined based on the relative fair value of each obligation. The use of different assumptions could have a material effect on the estimated fair value amounts.

The following tables summarize the changes in fair value of the contingent consideration and the other liability (in millions):
 Contingent ConsiderationOther liabilityTotal
Balance at December 31, 2022
$26.2 $14.0 $40.2 
Changes in fair value0.7 — 0.7 
Balance at March 31, 2023$26.9 $14.0 $40.9 
Contingent ConsiderationOther liabilityTotal
Balance at December 31, 2021
$62.0 $14.0 $76.0 
Changes in fair value(2.9)— (2.9)
Balance at March 31, 2022$59.1 $14.0 $73.1 

8.    DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

The Company uses derivative financial instruments to manage its currency exchange rate risk and its interest rate risk as summarized below. Notional amounts are stated in United States dollar equivalents at spot exchange rates at the respective dates. The Company does not enter into these arrangements for trading or speculation purposes.
 Notional Amount
 March 31, 2023December 31, 2022
 (in millions)
Foreign currency forward exchange contracts$1,712.2 $1,678.4 
Cross currency swap contracts300.0 300.0 

Derivative financial instruments involve credit risk in the event the counterparty should default. It is the Company's policy to execute such instruments with global financial institutions that the Company believes to be creditworthy. The Company diversifies its derivative financial instruments among counterparties to minimize exposure to any one of these entities. The Company also uses International Swap Dealers Association master-netting agreements. The master-netting agreements provide for the net settlement of all contracts through a single payment in a single currency in the event of default, as defined by the agreements.

14
The Company uses foreign currency forward exchange contracts and cross currency swap contracts to manage its exposure to changes in currency exchange rates from (a) future cash flows associated with intercompany transactions and certain local currency expenses expected to occur within the next 13 months (designated as cash flow hedges), (b) its net investment in certain foreign subsidiaries (designated as net investment hedges) and (c) foreign currency denominated assets or liabilities (designated as fair value hedges). The Company also uses foreign currency forward exchange contracts that are not designated as hedging instruments to offset the transaction gains and losses associated with revaluation of certain assets and liabilities denominated in currencies other than their functional currencies (resulting principally from intercompany and local currency transactions).

All derivative financial instruments are recognized at fair value in the consolidated condensed balance sheets. For each derivative instrument that is designated as a fair value hedge, the gain or loss on the derivative included in the assessment of hedge effectiveness is recognized immediately to earnings, and offsets the loss or gain on the underlying hedged item. The Company reports in "Accumulated Other Comprehensive Loss" the gain or loss on derivative financial instruments that are designated, and that qualify, as cash flow hedges. The Company reclassifies these gains and losses into earnings in the same line item and in the same period in which the underlying hedged transactions affect earnings. Changes in the fair value of net investment hedges are reported in "Accumulated Other Comprehensive Loss" as a part of the cumulative translation adjustment and would be reclassified into earnings if the underlying net investment is sold or substantially liquidated. The portion of the change in fair value related to components excluded from the hedge effectiveness assessment are amortized into earnings over the life of the derivative. The gains and losses on derivative financial instruments for which the Company does not elect hedge accounting treatment are recognized in the consolidated statements of operations in each period based upon the change in the fair value of the derivative financial instrument. Cash flows from net investment hedges are reported as investing activities in the consolidated statements of cash flows, and cash flows from all other derivative financial instruments are reported as operating activities.

The following table presents the location and fair value amounts of derivative instruments reported in the consolidated condensed balance sheets (in millions):
  Fair Value
Derivatives designated as hedging instrumentsBalance Sheet
Location		March 31, 2023December 31, 2022
Assets   
Foreign currency contractsOther current assets$13.6 $24.9 
Cross currency swap contractsOther assets$38.1 $40.6 
Liabilities   
Foreign currency contractsAccrued and other liabilities$23.4 $20.7 
Foreign currency contractsOther liabilities$— $6.5 

The following table presents the effect of master-netting agreements and rights of offset on the consolidated condensed balance sheets (in millions):
    Gross Amounts
Not Offset in
the Consolidated
Balance Sheet		 
  Gross Amounts
Offset in the
Consolidated
Balance Sheet		 
  Net Amounts
Presented in the
Consolidated
Balance Sheet
March 31, 2023Gross
Amounts		Financial
Instruments		Cash
Collateral
Received		Net
Amount
Derivative assets      
Foreign currency contracts$13.6 $— $13.6 $(6.7)$— $6.9 
Cross currency swap contracts$38.1 $— $38.1 $— $— $38.1 
Derivative liabilities      
Foreign currency contracts$23.4 $— $23.4 $(6.7)$— $16.7 
December 31, 2022      
Derivative assets      
Foreign currency contracts$24.9 $— $24.9 $(12.0)$— $12.9 
Cross currency swap contracts$40.6 $— $40.6 $— $— $40.6 
Derivative liabilities   
Foreign currency contracts$27.2 $— $27.2 $(12.0)$— $15.2 
15
The following tables present the effect of derivative and non-derivative hedging instruments on the consolidated condensed statements of operations and consolidated condensed statements of comprehensive income (in millions):
 Amount of Gain or (Loss)
Recognized in OCI
on Derivative
(Effective Portion)		 Amount of Gain or (Loss)
Reclassified from
Accumulated OCI
into Income
(Effective Portion)
 Three Months Ended
March 31,		 Location of Gain or
(Loss) Reclassified from
Accumulated OCI
into Income		Three Months Ended
March 31,
 
2023202220232022
Cash flow hedges
Foreign currency contracts$3.7 $24.7 Cost of sales$29.8 $7.3 

 Amount of Gain or (Loss)
Recognized in OCI
on Derivative
(Effective Portion)		 Amount of Gain or (Loss)
Recognized in Income on Derivative (Amount Excluded from
Effectiveness Testing)
 Three Months Ended
March 31,		 Location of Gain or
(Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing)		Three Months Ended
March 31,
 
2023202220232022
Net investment hedges
Cross currency swap contracts$(2.5)$3.9 Interest income, net$1.7 $1.6 

The cross currency swap contracts have an expiration date of June 15, 2028. At maturity of the cross currency swap contracts, the Company will deliver the notional amount of €257.2 million and will receive $300.0 million from the counterparties. The Company will receive semi-annual interest payments from the counterparties based on a fixed interest rate until maturity of the agreements.
  Amount of Gain or (Loss)
Recognized in Income on
Derivative
  Three Months Ended
March 31,
 Location of Gain or (Loss)
Recognized in Income on
Derivative
20232022
Derivatives not designated as hedging instruments
Foreign currency contractsOther (income) expense, net$(5.4)$15.5 
16
The following tables present the effect of fair value and cash flow hedge accounting on the consolidated condensed statements of operations (in millions):
 Location and Amount of Gain or (Loss) Recognized in Income on Fair Value and Cash Flow Hedging Relationships
 Three Months Ended
March 31, 2023
 Cost of salesSelling, general, and administrative expensesOther (Income) Expense, net
Total amounts of income and expense line items presented in the consolidated condensed statements of operations in which the effects of fair value or cash flow hedges are recorded$(329.5)$(436.3)$1.6 
The effects of cash flow hedging:
Gain (loss) on fair value hedging relationships:
Foreign currency contracts:
Hedged items
$— $— $1.2 
Derivatives designated as hedging instruments
$— $— $(1.2)
Amount excluded from effectiveness testing recognized in earnings based on an amortization approach
$— $— $1.2 
Gain (loss) on cash flow hedging relationships:
Foreign currency contracts:
Amount of gain (loss) reclassified from accumulated OCI into income
$29.8 $— $— 
 Location and Amount of Gain or (Loss) Recognized in Income on Fair Value and Cash Flow Hedging Relationships
 Three Months Ended
March 31, 2022
 Cost of salesSelling, general, and administrative expensesOther (Income) Expense, net
Total amounts of income and expense line items presented in the consolidated condensed statements of operations in which the effects of fair value or cash flow hedges are recorded$(299.3)$(370.3)$(3.3)
The effects of fair value and cash flow hedging:
Gain (loss) on cash flow hedging relationships:
Foreign currency contracts:
Amount of gain (loss) reclassified from accumulated OCI into income
$7.3 $— $— 

The Company expects that during the next twelve months it will reclassify to earnings a $13.6 million gain currently recorded in "Accumulated Other Comprehensive Loss."

17
9.    STOCK-BASED COMPENSATION

Stock-based compensation expense related to awards issued under the Company's incentive compensation plans for the three months ended March 31, 2023 and 2022 was as follows (in millions):
 Three Months Ended
March 31,
 20232022
Cost of sales$7.0 $6.2 
Selling, general, and administrative expenses22.3 18.7 
Research and development expenses9.6 7.5 
Total stock-based compensation expense38.9 32.4 
Income tax benefit(4.7)(4.4)
Total stock-based compensation expense, net of tax$34.2 $28.0 

At March 31, 2023, the total remaining compensation cost related to nonvested stock options, restricted stock units, market-based restricted stock units, and employee stock purchase plan ("ESPP") subscription awards amounted to $187.9 million, which will be amortized on a straight-line basis over each award's requisite service period. The weighted-average remaining requisite service period is 28 months.

Fair Value Disclosures

The following table includes the weighted-average grant-date fair values of stock options granted during the periods indicated and the related weighted-average assumptions used in the Black-Scholes option pricing model:
 Option Awards
Three Months Ended
March 31,
 20232022
Risk-free interest rate4.1 %1.9 %
Expected dividend yieldNoneNone
Expected volatility31.3 %33.5 %
Expected term (years)5.35.3
Fair value, per option$27.77 $35.66 
The following table includes the weighted-average grant-date fair values for ESPP subscriptions granted during the periods indicated and the related weighted-average assumptions used in the Black-Scholes option pricing model:
 ESPP
Three Months Ended
March 31,
 20232022
Risk-free interest rate4.6 %0.2 %
Expected dividend yieldNoneNone
Expected volatility31.5 %32.2 %
Expected term (years)0.60.6
Fair value, per share$21.10 $29.52 

18
10.    ACCELERATED SHARE REPURCHASE

During 2023 and 2022, the Company entered into accelerated share repurchase ("ASR") agreements providing for the repurchase of the Company's common stock based on the volume-weighted average price ("VWAP") of the Company's common stock during the term of the applicable agreement, less a discount. The following table summarizes the terms of the ASR agreements (dollars and shares in millions, except per share data):
  Initial DeliveryFinal Settlement
Agreement DateAmount
Paid		Shares
Received		Price per
Share		Value of
Shares as %
of Contract
Value		Settlement
Date		Total Shares
Received		Average Price
per Share
January 2022$250.0 1.9 $104.87 80 %February 20222.3 $110.31 
February 2023$200.0 2.0 $80.44 80 %March 20232.5 $79.28 

The ASR agreements were each accounted for as two separate transactions: (1) the value of the initial delivery of shares was recorded as shares of common stock acquired in a treasury stock transaction on the acquisition date, and (2) the remaining amount of the purchase price paid was recorded as a forward contract indexed to the Company's own common stock and was initially recorded in "Additional Paid-in Capital" and subsequently, upon settlement, was transferred to "Treasury Stock" on the consolidated condensed balance sheets. The initial delivery of shares resulted in an immediate reduction of the outstanding shares used to calculate the weighted-average common shares outstanding for basic and diluted earnings per share. The Company determined that the forward contracts indexed to the Company's common stock met all the applicable criteria for equity classification and, therefore, were not accounted for as a derivative instrument.

11.    COMMITMENTS AND CONTINGENCIES

The Company is reviewing and investigating whether business activities in Japan and other markets violate certain provisions of the Foreign Corrupt Practices Act ("FCPA"). The Company voluntarily notified the SEC and the United States Department of Justice ("DOJ") during 2021 that it has engaged outside counsel to conduct this review and investigation. The Company has provided status updates to the SEC and DOJ since that time. Any determination that the Company’s operations or activities are not in compliance with existing laws, including the FCPA, could result in the imposition of fines, penalties, and equitable remedies. The Company cannot currently predict the outcome of the review and investigation or the potential impact on its financial statements.

On September 28, 2021, Aortic Innovations LLC, a non-practicing entity, filed a lawsuit against Edwards Lifesciences Corporation and certain of its subsidiaries ("Edwards") in the United States District Court for the District of Delaware alleging that Edwards’ SAPIEN 3 Ultra product infringes certain of its patents. The Company is unable to predict the ultimate outcome of this matter or estimate a range of possible exposure; therefore, no amounts have been accrued. The Company intends to vigorously defend itself in this litigation.

The Company is or may be a party to, or may otherwise be responsible for, pending or threatened lawsuits including those related to products and services currently or formerly manufactured or performed, as applicable, by the Company, workplace and employment matters, matters involving real estate, Company operations or health care regulations, or governmental investigations (the "Lawsuits"). The Lawsuits raise difficult and complex factual and legal issues and are subject to many uncertainties, including, but not limited to, the facts and circumstances of each particular case or claim, the jurisdiction in which each suit is brought, and differences in applicable law. Management does not believe that any loss relating to the Lawsuits would have a material adverse effect on the Company's overall financial condition, results of operations or cash flows. However, the resolution of one or more of the Lawsuits in any reporting period, could have a material adverse impact on the Company's financial results for that period. The Company is not able to estimate the amount or range of any loss for legal contingencies related to the Lawsuits for which there is no reserve or additional loss for matters already reserved.


19
12.    ACCUMULATED OTHER COMPREHENSIVE LOSS

The following tables summarize the activity for each component of "Accumulated Other Comprehensive Loss" (in millions):
 Foreign
Currency
Translation
Adjustments		Unrealized Gain on Hedges
Unrealized Loss on Available-for-sale Investments		Unrealized
Pension
Credits		Total
Accumulated
Other
Comprehensive
Loss
December 31, 2022$(218.8)$23.8 $(65.6)$5.7 $(254.9)
Other comprehensive gain (loss) before reclassifications4.9 6.7 9.0 (0.1)20.5 
Amounts reclassified from accumulated other comprehensive loss(1.7)(29.8)4.0 — (27.5)
Deferred income tax benefit 0.6 5.9 — — 6.5 
March 31, 2023$(215.0)$6.6 $(52.6)$5.6 $(255.4)

 Foreign
Currency
Translation
Adjustments		Unrealized Gain on Hedges
Unrealized Loss on Available-for-sale Investments		Unrealized
Pension
Costs		Total
Accumulated
Other
Comprehensive
Loss
December 31, 2021$(172.5)$29.7 $(6.9)$(8.0)$(157.7)
Other comprehensive (loss) gain before reclassifications(7.4)24.7 (47.6)— (30.3)
Amounts reclassified from accumulated other comprehensive loss(1.6)(7.3)4.8 — (4.1)
Deferred income tax (expense) benefit(1.0)(4.0)10.5 — 5.5 
March 31, 2022$(182.5)$43.1 $(39.2)$(8.0)$(186.6)

The following table provides information about amounts reclassified from "Accumulated Other Comprehensive Loss" (in millions):
 Three Months Ended
March 31,		 
 Affected Line on Consolidated Condensed
Statements of Operations
Details about Accumulated Other
Comprehensive Loss Components
20232022
Foreign currency translation adjustments$1.7 $1.6 Other (income) expense, net
(0.4)(0.4)Provision for income taxes
$1.3 $1.2 Net of tax
Gain on hedges$29.8 $7.3 Cost of sales
(7.1)(2.1)Provision for income taxes
$22.7 $5.2 Net of tax
Loss on available-for-sale investments$(4.0)$(4.8)Other (income) expense, net
1.0 1.2 Provision for income taxes
$(3.0)$(3.6)Net of tax

20
13.    EARNINGS PER SHARE

Basic earnings per share is computed by dividing net income by the weighted-average common shares outstanding during the period. Diluted earnings per share is computed based on the weighted-average common shares outstanding plus the effect of dilutive potential common shares outstanding during the period calculated using the treasury stock method. Dilutive potential common shares include employee equity share options, nonvested shares, and similar equity instruments granted by the Company. Potential common share equivalents have been excluded where their inclusion would be anti-dilutive.

The table below presents the computation of basic and diluted earnings per share (in millions, except for per share information):
 Three Months Ended
March 31,
 20232022
Basic:  
Net income attributable to Edwards Lifesciences, Inc.$340.5 $373.6 
Weighted-average shares outstanding607.5 622.1 
Basic earnings per share$0.56 $0.60 
Diluted:  
Net income attributable to Edwards Lifesciences, Inc.$340.5 $373.6 
Weighted-average shares outstanding607.5 622.1 
Dilutive effect of stock plans3.4 7.3 
Dilutive weighted-average shares outstanding610.9 629.4 
Diluted earnings per share$0.56 $0.59 

Stock options, restricted stock units, and market-based restricted stock units to purchase an aggregate of 5.2 million and 1.7 million common shares for the three months ended March 31, 2023 and 2022, respectively, were outstanding, but were not included in the computation of diluted earnings per share for such periods because the effect would have been anti-dilutive.

14.    INCOME TAXES

The Company's effective income tax rates were 14.6% and 14.3% for the three months ended March 31, 2023 and 2022, respectively. The increase in the effective rate between the three months ended March 31, 2023 and 2022 is primarily due to a reduced tax benefit from employee share-based compensation. In addition, the effective rates for the three months ended March 31, 2023 and 2022 were lower than the federal statutory rate of 21% primarily due to (1) foreign earnings taxed at lower rates, (2) Federal and California research and development credits, and (3) the tax benefit from employee share-based compensation. The effective rates include a tax benefit from employee share-based compensation of $2.9 million and $13.4 million for the three months ended March 31, 2023 and 2022, respectively.

In the normal course of business, the Internal Revenue Service (“IRS”) and other taxing authorities are in different stages of examining various years of the Company's tax filings. During these audits the Company may receive proposed audit adjustments that could be material. Therefore, there is a possibility that an adverse outcome in these audits could have a material effect on the Company's results of operations and financial condition. The Company strives to resolve open matters with each tax authority at the examination level and could reach agreement with a tax authority at any time. While the Company has accrued for matters it believes are more likely than not to require settlement, the final outcome with a tax authority may result in a tax liability that is more or less than that reflected in the consolidated condensed financial statements. Furthermore, the Company may later decide to challenge any assessments, if made, and may exercise its right to appeal. The uncertain tax positions are reviewed quarterly and adjusted as events occur that affect potential liabilities for additional taxes, such as lapsing of applicable statutes of limitations, proposed assessments by tax authorities, negotiations between tax authorities, identification of new issues, and issuance of new legislation, regulations, or case law.

As of March 31, 2023 and December 31, 2022, the gross liability recorded for income taxes associated with uncertain tax positions was $496.8 million and $475.3 million, respectively. The Company estimates that these liabilities would be reduced by $194.3 million and $182.1 million, respectively, from offsetting tax benefits associated with the correlative effects of potential transfer pricing adjustments, state income taxes, and timing adjustments. The net amounts of $302.5 million and $293.2 million, respectively, if not required, would favorably affect the Company's effective tax rate.

21
The Company executed an Advance Pricing Agreement ("APA") in 2018 between the United States and Switzerland governments for tax years 2009 through 2020 covering various, but not all, transfer pricing matters. The unagreed transfer pricing matters, namely Surgical Structural Heart and Transcatheter Aortic Valve Replacement (collectively “Surgical/TAVR”) intercompany royalty transactions, then reverted to IRS Examination for further consideration as part of the respective years' regular tax audits. In addition, the Company executed other bilateral APAs as follows: during 2017, an APA between the United States and Japan covering tax years 2015 through 2019; and during 2018, APAs between Japan and Singapore and between Switzerland and Japan covering tax years 2015 through 2019. The Company has filed to renew all of the APAs which cover transactions with Japan for the years 2020 and forward. An APA between Switzerland and Japan covering tax years 2020 through 2024 was executed in 2021. The execution of some or all of these APA renewals depends on many variables outside of the Company's control.

The audits of the Company’s United States federal income tax returns through 2014 have been closed. The IRS audit field work for the 2015 through 2017 tax years was completed during the second quarter of 2021, except for certain transfer pricing and related matters. The IRS began its examination of the 2018 through 2020 tax years during the first quarter of 2022.

The audits of the Company's material state, local, and foreign income tax matters have been concluded for years through 2015. While not material, the Company continues to address matters in India for years from 2010 and on.

During 2021, the Company received a Notice of Proposed Adjustment (“NOPA”) from the IRS for the 2015-2017 tax years relating to transfer pricing involving certain Surgical/TAVR intercompany royalty transactions between the Company's United States and Switzerland subsidiaries. The NOPA proposes an increase to the Company's United States taxable income, which could result in additional tax expense for this period of approximately $210 million and represents a significant change to previously agreed upon transfer pricing methodologies for these types of transactions. The Company has formally disagreed with the NOPA and submitted a formal protest on the matter during the fourth quarter of 2021. During the second quarter of 2022, the Company received the IRS's rebuttal to its protest and was notified that the case had been transferred to the IRS Independent Office of Appeals ("Appeals"). The opening conference was held with Appeals during the first quarter of 2023 and discussions are ongoing. The Company continues to evaluate all possible remedies available to it. The Company believes the amounts previously accrued related to this uncertain tax position are sufficient and, accordingly, has not accrued any additional amount based on the NOPA received or as a result of the ongoing Appeals. While no payment of any amount related to the NOPA is required to be made, if at all, until all applicable proceedings have been completed, the Company made an advance payment of tax in November 2022 to prevent the further accrual of interest on that portion of any potential deficiency.

Certain Surgical/TAVR intercompany royalty transactions covering tax years 2018-2022 that were not resolved under the APA program remain subject to IRS examination, and those transactions and related tax positions remain uncertain as of March 31, 2023. The Company has considered this information, as well as information regarding the NOPA, the rebuttal and ongoing Appeals described above, in its evaluation of its uncertain tax positions. The impact of these unresolved transfer pricing matters, net of any correlative repatriation tax adjustment, may be significant to the Company’s consolidated condensed financial statements. Based on the information currently available and numerous possible outcomes, the Company cannot reasonably estimate what, if any, changes in its existing uncertain tax positions may occur in the next 12 months and, therefore, has continued to record the uncertain tax positions as a long-term liability.

15.    SEGMENT INFORMATION

Edwards Lifesciences conducts operations worldwide and is managed in the following geographical regions: United States, Europe, Japan, and Rest of World. All regions sell products that are used to treat advanced cardiovascular disease.

The Company's geographic segments are reported based on the financial information provided to the Chief Operating Decision Maker (the Chief Executive Officer). The Company evaluates the performance of its geographic segments based on net sales and operating income. Segment net sales and segment operating income are based on internally derived foreign exchange rates and do not include inter-segment profits. Because of the interdependence of the reportable segments, the operating profit as presented may not be representative of the geographical distribution that would occur if the segments were not interdependent. Net sales by geographic area are based on the location of the customer. There were no customers that represented 10% or more of the Company's total net sales.

Certain items are maintained at the corporate level and are not allocated to the segments. The non-allocated items include net interest income, global marketing expenses, corporate research and development expenses, manufacturing variances, corporate headquarters costs, special gains and charges, stock-based compensation, foreign currency hedging activities, certain litigation costs, changes in the fair value of contingent consideration liabilities, and most of the Company's amortization expense. Although most of the Company's depreciation expense is included in segment operating income, due to the Company's
22
methodology for cost build-up, it is impractical to determine the amount of depreciation expense included in each segment and, therefore, a portion is maintained at the corporate level. The Company neither discretely allocates assets to its operating segments, nor evaluates the operating segments using discrete asset information.

The table below presents information about Edwards Lifesciences' reportable segments (in millions):
 Three Months Ended
March 31,
 20232022
Segment Net Sales  
United States$849.1 $749.5 
Europe335.4 300.1 
Japan104.3 140.9 
Rest of World165.6 142.3 
Total segment net sales$1,454.4 $1,332.8 
Segment Operating Income  
United States$563.4 $511.5 
Europe181.7 166.6 
Japan63.4 99.5 
Rest of World70.5 59.7 
Total segment operating income$879.0 $837.3 
The table below presents reconciliations of segment net sales to consolidated net sales and segment operating income to consolidated pre-tax income (in millions):
 Three Months Ended
March 31,
 20232022
Net Sales Reconciliation  
Segment net sales$1,454.4 $1,332.8 
Foreign currency5.2 8.4 
Consolidated net sales$1,459.6 $1,341.2 
Pre-tax Income Reconciliation  
Segment operating income$879.0 $837.3 
Unallocated amounts:  
Corporate items(468.9)(419.4)
Intellectual property agreement and litigation expenses, net(43.5)(7.1)
Change in fair value of contingent consideration liabilities, net(0.7)2.9 
Foreign currency22.5 25.1 
Consolidated operating income388.4 438.8 
Non-operating income (expense)10.2 (2.7)
Consolidated pre-tax income$398.6 $436.1 
23

Enterprise-wide Information
(in millions)

The following enterprise-wide information is based on actual foreign exchange rates used in the Company's consolidated condensed financial statements.
 Three Months Ended
March 31,
 20232022
Net Sales by Geographic Area  
United States$849.1 $749.5 
Europe331.1 311.1 
Japan114.1 135.5 
Rest of World165.3 145.1 
$1,459.6 $1,341.2 
Net Sales by Major Product Area  
Transcatheter Aortic Valve Replacement$947.9 $881.3 
Transcatheter Mitral and Tricuspid Therapies41.6 27.0 
Surgical Structural Heart248.2 220.8 
Critical Care221.9 212.1 
$1,459.6 $1,341.2 

24
Item 2.    Management's Discussion and Analysis of Financial Condition and Results of Operations        
Overview

The following discussion and analysis contains forward-looking statements within the meaning of the federal securities laws, and should be read in conjunction with the disclosures we make concerning risks and other factors that may affect our business and operating results. See “Note Regarding Forward-Looking Statements” preceding Part I, Item 1 in this Quarterly Report on Form 10-Q.

We are the global leader in patient-focused medical innovations for structural heart disease and critical care monitoring. Driven by a passion to help patients, we partner with the world's leading clinicians and researchers and invest in research and development to transform care for those impacted by structural heart disease or who require hemodynamic monitoring during surgery or in intensive care. We conduct operations worldwide and are managed in the following geographical regions: United States, Europe, Japan, and Rest of World. Our products are categorized into the following areas: Transcatheter Aortic Valve Replacement ("TAVR"), Transcatheter Mitral and Tricuspid Therapies ("TMTT"), Surgical Structural Heart ("Surgical"), and Critical Care.

Financial Highlights and Market Update
12001201
COVID-19 and Macroeconomic Uncertainties

The COVID-19 pandemic has adversely impacted, and may further adversely impact, nearly all aspects of our business and markets, including our workforce and the operations of our customers, suppliers, and business partners. Our priority has been to maintain access for patients to our life-saving technologies while providing continuous front-line support to our clinician partners, and protecting the well-being of our employees. Our manufacturing operations have continued to respond to impacts related to COVID-19, and we have been able to supply our technologies around the world. Across the organization, we are proactively managing inventory, assessing alternative logistics options, and closely monitoring the supply of components to address potential supply constraints.

During the first quarter of 2022, the Omicron variant had a pronounced impact on hospital capacity, resources, and procedure volumes in January 2022, especially in the United States. Outside the United States, we experienced a less pronounced year-over-year impact from the pandemic. During the first quarter of 2023, Japan faced lingering COVID headwinds and in Europe there were persistent disruptions related to hospital staffing shortages.

In addition to the impacts described above, the global economy, including the financial and credit markets, has recently experienced extreme volatility and disruptions, including increases to inflation rates, rising interest rates, declines in consumer confidence, declines in economic growth, and uncertainty about economic stability. The severity and duration of the impact of these conditions on our business cannot be predicted. See Item 1A, "Risk Factors," of our Annual Report on Form 10-K for the year ended December 31, 2022 for additional information.

25

Financial Highlights

Despite the challenges to our business due to COVID-19 and macroeconomic factors, our net sales for the first three months of 2023 were $1.5 billion, representing an increase of $118.4 million over the first three months of 2022, driven primarily by sales of our TAVR products.

Our gross profit increase in the three months ended March 31, 2023 was driven by our sales growth. Gross profit as a percentage of sales decreased primarily due to the impact of foreign currency exchange rate fluctuations. The decrease in our diluted earnings per share in the three months ended March 31, 2023 was driven by an after-tax charge of $30.5 million in the three months ended March 31, 2023 related to an intellectual property agreement.
Healthcare Environment, Opportunities, and Challenges

The medical technology industry is highly competitive and continues to evolve. Our success is measured both by the development of innovative products and the value we bring to our stakeholders. We are committed to developing new technologies and providing innovative patient care, and we are committed to defending our intellectual property in support of those developments. Despite the challenges of the COVID-19 pandemic, our dedicated field teams have found creative ways to support physicians, our engineers continued to advance innovation, and our colleagues worked diligently to keep our clinical trials on track.In the first three months of 2023, we invested 17.9% of our net sales in research and development.

We are dedicated to generating robust clinical, economic, and quality-of-life evidence increasingly expected by patients, clinicians, and payors in the current healthcare environment, with the goal of encouraging the adoption of innovative new medical therapies that demonstrate superior outcomes.

New Accounting Standards

Information on new accounting standards is included in Note 1 to the "Consolidated Condensed Financial Statements."

Results of Operations

Net Sales by Region
(dollars in millions)
 Three Months Ended
March 31,
 Percent Change
 20232022Change
United States$849.1 $749.5 $99.6 13.3 %
Europe331.1 311.1 20.0 6.5 %
Japan114.1 135.5 (21.4)(15.8)%
Rest of World165.3 145.1 20.2 13.8 %
Outside of the United States610.5 591.7 18.8 3.2 %
Total net sales$1,459.6 $1,341.2 $118.4 8.8 %

Net sales outside of the United States include the impact of foreign currency exchange rate fluctuations. The impact of foreign currency exchange rate fluctuations on net sales is not necessarily indicative of the impact on net income due to the corresponding effect of foreign currency exchange rate fluctuations on international manufacturing and operating costs, and our hedging activities.
26

Net Sales by Product Group
(dollars in millions)
 Three Months Ended
March 31,
 Percent Change
 20232022Change
Transcatheter Aortic Valve Replacement$947.9 $881.3 $66.6 7.6 %
Transcatheter Mitral and Tricuspid Therapies41.6 27.0 14.6 53.6 %
Surgical Structural Heart248.2 220.8 27.4 12.4 %
Critical Care221.9 212.1 9.8 4.6 %
Total net sales$1,459.6 $1,341.2 $118.4 8.8 %

Transcatheter Aortic Valve Replacement Sales
566
Net sales of TAVR products increased for the three months ended March 31, 2023 driven by:

•higher sales of the Edwards SAPIEN platform in 2023, primarily the Edwards SAPIEN 3 Ultra valve in the United States;

partially offset by:

•foreign currency exchange rate fluctuations, which decreased net sales outside of the United States by $25.2 million for the three months ended March 31, 2023, primarily due to the weakening of the Euro and the Japanese yen against the United States dollar.

During the first three months of 2023, we continued to enroll our PROGRESS pivotal trial, studying moderate aortic stenosis patients. In March 2023, we launched the Edwards SAPIEN 3 Ultra RESILIA valve in Japan.

27
Transcatheter Mitral and Tricuspid Therapies Sales
1621
Net sales of TMTT products increased for the three months ended March 31, 2023 primarily due to continued adoption of our PASCAL system in Europe and the initial launch in the United States.

During the first quarter of 2023, we continued to enroll the CLASP IIF pivotal trial with PASCAL for patients with functional mitral regurgitation. In mitral replacement, enrollment continued in the ENCIRCLE pivotal trial for SAPIEN M3. In tricuspid, we completed the enrollment of the full cohort of the TRISCEND II pivotal trial of the EVOQUE replacement system. In the United States, the Food and Drug Administration approved expanded access allowing hospitals that were involved in the clinical trial to continue to have EVOQUE as a therapy option. In addition, enrollment continued in the CLASP IITR pivotal trial with the PASCAL repair system in patients with symptomatic, severe tricuspid regurgitation.

28

Surgical Structural Heart Sales
2517
Net sales of Surgical products increased for the three months ended March 31, 2023 primarily due to increased sales of the INSPIRIS RESILIA aortic valve, primarily in the United States and Europe, and the MITRIS RESILIA valve, primarily in the United States. These increases were partially offset by the impact of foreign currency exchange rate fluctuations, which decreased net sales outside of the United States by $8.4 million for the three months ended March 31, 2023 primarily due to the weakening of the Japanese yen and the Euro against the United States dollar.
In early 2023, we began enrolling patients in our MOMENTIS clinical study to demonstrate the durability of RESILIA tissue in the mitral position.

29
Critical Care Sales
3378
Net sales of Critical Care products increased for the three months ended March 31, 2023 primarily due to:

•increased demand for our enhanced surgical recovery products and pressure monitoring products, primarily in the United States;

partially offset by:

•foreign currency exchange rate fluctuations, which decreased net sales outside of the United States by $8.8 million for the three months ended March 31, 2023, primarily due to the weakening of the Japanese yen and the Euro against the United States dollar.






30
Gross Profit
3874
The decrease in gross profit as a percentage of net sales for the three months ended March 31, 2023 was driven by a 0.7 percentage point decrease from the impact of foreign currency exchange rate fluctuations, primarily the strengthening of the United States dollar against the Euro and the Japanese yen.

Selling, General, and Administrative ("SG&A") Expenses
4307
SG&A expenses increased for the three months ended March 31, 2023 primarily due to higher field-based personnel-related costs, primarily TAVR and TMTT in the United States. Foreign currency exchange rate fluctuations decreased expenses by $8.5 million for the three months ended March 31, 2023 primarily due to the strengthening of the United States dollar against the Euro and the Japanese yen.
31

Research and Development ("R&D") Expenses
4773
R&D expenses increased for the three months ended March 31, 2023 primarily due to continued investments in our transcatheter aortic valve innovations, including increased clinical trial activity.

Intellectual Property Agreement and Litigation Expenses, net

We incurred intellectual property agreement and litigation expenses of $43.5 million and $7.1 million during the three months ended March 31, 2023 and 2022, respectively. On April 12, 2023, we entered into a Intellectual Property Agreement with Medtronic, Inc. and recorded a $37.0 million charge during the three months ended March 31, 2023. For more information, see Note 3 to the "Consolidated Condensed Financial Statements."

Change in Fair Value of Contingent Consideration Liabilities, net

The change in fair value of contingent consideration liabilities resulted in expense of $0.7 million and a gain of $2.9 million for the three months ended March 31, 2023 and 2022, respectively. The changes in fair value were due to changes in interest rates and the accretion of interest due to the passage of time. For further information, see Note 7 to the "Consolidated Condensed Financial Statements."

Other (Income) Expense, net
(in millions)
 Three Months Ended
March 31,
 20232022
Foreign exchange (gains) losses, net$(1.3)$2.5 
(Gain) loss on investments(0.1)0.9 
Other(0.2)(0.1)
Other (income) expense, net$(1.6)$3.3 
The net foreign exchange (gains) losses relate to the foreign currency fluctuations primarily in our global trade and intercompany receivable and payable balances, partially offset by the gains and losses on foreign currency derivative instruments.

The (gain) loss on investments primarily represents our net share of gains and losses in investments accounted for under the equity method, and realized gains and losses on investments in equity securities.

32
Provision for Income Taxes

The provision for income taxes consists of provisions for federal, state, and foreign income taxes. We operate in an international environment with significant operations in various locations outside the United States which have statutory tax rates typically lower than the United States tax rate. Accordingly, the consolidated income tax rate is a composite rate reflecting the earnings in the various locations and the applicable rates.

Our effective income tax rate was 14.6% and 14.3% for the three months ended March 31, 2023 and 2022, respectively. The increase in the effective rate between the three months ended March 31, 2023 and 2022 was primarily due to a reduced tax benefit from employee share-based compensation. In addition, the effective rates for the three months ended March 31, 2023 and 2022 were lower than the federal statutory rate of 21% primarily due to (1) foreign earnings taxed at lower rates, (2) Federal and California research and development credits, and (3) the tax benefit from employee share-based compensation.

In the normal course of business, the Internal Revenue Service (“IRS”) and other taxing authorities are in different stages of examining various years of our tax filings. During these audits we may receive proposed audit adjustments that could be material. Therefore, there is a possibility that an adverse outcome in these audits could have a material effect on our results of operations and financial condition. We strive to resolve open matters with each tax authority at the examination level and could reach agreement with a tax authority at any time. While we have accrued for matters we believe are more likely than not to require settlement, the eventual outcome with a tax authority may result in a tax liability that is more or less than that reflected in the consolidated condensed financial statements. Furthermore, we may later decide to challenge any assessments, if made, and may exercise our right to appeal. The uncertain tax positions are reviewed quarterly and adjusted as events occur that affect potential liabilities for additional taxes, such as lapsing of applicable statutes of limitations, proposed assessments by tax authorities, negotiations between tax authorities, identification of new issues, and issuance of new legislation, regulations, or case law.

We executed an Advance Pricing Agreement ("APA") in 2018 between the United States and Switzerland governments for tax years 2009 through 2020 covering various, but not all, transfer pricing matters. The unagreed transfer pricing matters, namely Surgical Structural Heart and Transcatheter Aortic Valve Replacement (collectively "Surgical/TAVR") intercompany royalty transactions, then reverted to IRS Examination for further consideration as part of the respective years' regular tax audits. In addition, we executed other bilateral APAs as follows: during 2017, an APA between the United States and Japan covering tax years 2015 through 2019; and during 2018, APAs between Japan and Singapore and between Switzerland and Japan covering tax years 2015 through 2019. We have filed to renew all the APAs which cover transactions with Japan for the years 2020 and forward. An APA between Switzerland and Japan covering tax years 2020 through 2024 was executed in 2021. The execution of some or all these APA renewals depends on many variables outside of our control.

The audits of our United States federal income tax returns through 2014 have been closed. The IRS audit field work for the 2015 through 2017 tax years was completed during the second quarter of 2021, except for certain transfer pricing and related matters. The IRS began its examination of the 2018 through 2020 tax years during the first quarter of 2022.

The audits of our material state, local, and foreign income tax matters have been concluded for years through 2015. While not material, we continue to address matters in India for years from 2010.

The audits of our United States federal income tax returns through 2014 have been closed. The IRS audit field work for the 2015 through 2017 tax years was completed during the urth quarter of 2020, except for certain transfer pricing and related matters. The IRS began its examination of the 2018 through 2020 tax years during the first quarter of 2022.

During 2021, we received a Notice of Proposed Adjustment (“NOPA”) from the IRS for the 2015-2017 tax years relating to transfer pricing involving certain Surgical/TAVR intercompany royalty transactions between our United States and Switzerland subsidiaries. The NOPA proposes an increase to our United States taxable income, which could result in additional tax expense for this period of approximately $210 million and represents a significant change to previously agreed upon transfer pricing methodologies for these types of transactions. We have formally disagreed with the NOPA and submitted a formal protest on the matter during the fourth quarter of 2021. During the second quarter of 2022, we received the IRS's rebuttal to our protest and were notified that the case had been transferred to the IRS Independent Office of Appeals ("Appeals"). The opening conference was held with Appeals during the first quarter of 2023 and discussions are ongoing. We continue to evaluate all possible remedies available to us. We believe the amounts previously accrued related to this uncertain tax position are sufficient and, accordingly, have not accrued any additional amount based on the NOPA received or as a result of the ongoing Appeals. While no payment of any amount related to the NOPA is required to be made, if at all, until all applicable
33
proceedings have been completed, we made an advance payment of tax in November 2022 to prevent the further accrual of interest on that portion of any potential deficiency.

Certain Surgical/TAVR intercompany royalty transactions covering tax years 2018-2022 that were not resolved under the APA program remain subject to IRS examination, and those transactions and related tax positions remain uncertain as of March 31, 2023. We have considered this information, as well as information regarding the NOPA, the rebuttal and ongoing Appeals described above, in our evaluation of our uncertain tax positions. The impact of these unresolved transfer pricing matters, net of any correlative repatriation tax adjustment, may be significant to our consolidated condensed financial statements. Based on the information currently available and numerous possible outcomes, we cannot reasonably estimate what, if any, changes in our existing uncertain tax positions may occur in the next 12 months and, therefore, have continued to record the uncertain tax positions as a long-term liability.

On August 16, 2022, the Inflation Reduction Act of 2022 (“IRA”) was signed into law. The IRA includes, among other provisions, changes to the U.S. corporate income tax system, including a 15% minimum tax based on “adjusted financial statement income,” which is effective for tax years beginning after December 31, 2022, and a one percent excise tax on net repurchases of stock after December 31, 2022. Based upon our analysis to date, we do not expect the IRA will have a material impact on our consolidated financial statements.

Liquidity and Capital Resources

Our sources of cash liquidity include cash and cash equivalents, short-term investments, cash from operations, and amounts available under credit facilities. We believe that these sources are sufficient to fund the current and long-term requirements of working capital, capital expenditures, and other financial commitments. However, we periodically consider various financing alternatives and may, from time to time, seek to take advantage of favorable interest rate environments or other market conditions.

As of March 31, 2023, cash and cash equivalents and short-term investments held in the United States and outside of the United States were $902.2 million and $352.0 million, respectively.

We have a Five-year Credit Agreement (the "Credit Agreement") which provides for a $750.0 million multi-currency unsecured revolving credit facility and matures on July 15, 2027. We may increase the amount available under the Credit Agreement by up to an additional $250.0 million in the aggregate and extend the maturity date for an additional year, subject to agreement of the lenders. As of March 31, 2023, no amounts were outstanding under the Credit Agreement.

In June 2018, we issued $600.0 million of 4.3% fixed-rate unsecured senior notes (the "2018 Notes") due June 15, 2028. As of March 31, 2023, the carrying value of the 2018 Notes was $596.5 million.

From time to time, we repurchase shares of our common stock under share repurchase programs authorized by the Board of Directors. We consider several factors in determining when to execute share repurchases, including, among other things, expected dilution from stock plans, cash capacity, and the market price of our common stock. During the three months ended March 31, 2023, under the Board authorized repurchase program, we repurchased a total of 3.2 million shares at an aggregate cost of $249.1 million. See Part II, Item 2, “Unregistered Sales of Equity Securities and Use of Proceeds,” for additional information about our share repurchase program. As of March 31, 2023, we had remaining authority to purchase $666.5 million of our common stock under the share repurchase program.

On April 12, 2023, we entered into a Intellectual Property Agreement with Medtronic, Inc. ("Medtronic") pursuant to which the parties agreed to a 15-year global covenant not to sue ("CNS") for infringement of certain patents in the structural heart space owned or controlled by each other. In consideration for the global CNS, Edwards will pay to Medtronic a one-time, lump sum payment of $300.0 million and annual royalty payments that are tied to net sales of certain Edwards products.

On February 28, 2023, we acquired a majority equity interest in a medical technology company. In addition, we amended and restated our previous option agreement with the medical technology company. The option agreement gives Edwards the option to acquire the remaining equity interest in the medical technology company. For more information, see Note 6 to the "Consolidated Condensed Financial Statements."

At March 31, 2023, there had been no material changes in our cash requirements from known contractual and other obligations, including commitments for capital expenditures, as disclosed in Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations," of our Annual Report on Form 10-K for the year ended December 31, 2022.

34
Consolidated Cash Flows - For the three months ended March 31, 2023 and 2022:
2779 2783 2786
Net cash flows provided by operating activities of $314.1 million for the three months ended March 31, 2023 increased $20.8 million over the same period last year primarily due to a higher bonus payout in 2022 associated with 2021 performance, partially offset by higher operating costs in 2023.

Net cash provided by investing activities of $0.5 million for the three months ended March 31, 2023 consisted primarily of net proceeds from investments of $246.2 million, partially offset by a payment of $141.2 million to acquire a majority interest in another company (see Note 6 to the "Consolidated Condensed Financial Statements") and capital expenditures of $61.5 million.

Net cash provided by investing activities of $229.5 million for the three months ended March 31, 2022 consisted primarily of net proceeds from investments of $299.3 million, partially offset by capital expenditures of $72.7 million.

Net cash used in financing activities of $206.6 million for the three months ended March 31, 2023 consisted primarily of purchases of treasury stock of $249.3 million, partially offset by proceeds from stock plans of $41.9 million.

Net cash used in financing activities of $368.1 million for the three months ended March 31, 2022 consisted primarily of purchases of treasury stock of $405.6 million, partially offset by proceeds from stock plans of $37.5 million.

Critical Accounting Policies and Estimates

The consolidated condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States which require us to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated condensed financial statements and revenues and expenses during the periods reported. Actual results could differ from those estimates. Information with respect to our critical accounting policies and estimates which we believe could have the most significant effect on our reported results and require subjective or complex judgments by management is contained on pages 34-36 in Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations," of our Annual Report on Form 10-K for the year ended December 31, 2022. There have been no significant changes from the information discussed therein.

Item 3.    Quantitative and Qualitative Disclosures About Market Risk

Interest Rate Risk, Foreign Currency Risk, Credit Risk, and Concentrations of Risk

For a complete discussion of our exposure to interest rate risk, foreign currency risk, credit risk, and concentrations of risk, refer to Item 7A "Quantitative and Qualitative Disclosures About Market Risk" in our Annual Report on Form 10-K for the year ended December 31, 2022. There have been no material changes from the information discussed therein.

35
Investment Risk

We are exposed to investment risks related to changes in the underlying financial condition and credit capacity of certain of our investments. As of March 31, 2023, we had $1.3 billion of investments in debt securities of various companies, of which $1.0 billion were long-term. In addition, we had $111.1 million of investments in equity instruments of public and private companies. Should these companies experience a decline in financial performance, financial condition or credit capacity, or fail to meet certain development milestones, a decline in the investments' value may occur, resulting in unrealized or realized losses.

Item 4.    Controls and Procedures

Evaluation of Disclosure Controls and Procedures.    Our management, including the Chief Executive Officer and the Chief Financial Officer, performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of March 31, 2023. Based on their evaluation, the Chief Executive Officer and Chief Financial Officer have concluded as of March 31, 2023 that our disclosure controls and procedures are designed at a reasonable assurance level and effective in providing reasonable assurance that the information we are required to disclose in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting. There have been no changes in our internal control over financial reporting during the quarter ended March 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
36
Part II. Other Information
Item 1.    Legal Proceedings

We are reviewing and investigating whether business activities in Japan and other markets violate certain provisions of the Foreign Corrupt Practices Act ("FCPA"). We voluntarily notified the United States Securities and Exchange Commission ("SEC") and the United States Department of Justice ("DOJ") during 2021 that we have engaged outside counsel to conduct this review and investigation. We have provided status updates to the SEC and DOJ since that time. Any determination that our operations or activities are not in compliance with existing laws, including the FCPA, could result in the imposition of fines, penalties, and equitable remedies. We cannot currently predict the outcome of the review and investigation or the potential impact on our financial statements.

On September 28, 2021, Aortic Innovations LLC, a non-practicing entity, filed a lawsuit against Edwards Lifesciences Corporation and certain of its subsidiaries (“Edwards”) in the United States District Court for the District of Delaware alleging that Edwards’ SAPIEN 3 Ultra product infringes certain of its patents. We are unable to predict the ultimate outcome of this matter or estimate a range of possible exposure; therefore, no amount has been accrued. We intend to vigorously defend ourselves in this litigation.

We are subject to various environmental laws and regulations both within and outside of the United States. Our operations, like those of other medical device companies, involve the use of substances regulated under environmental laws, primarily in manufacturing and sterilization processes. While it is difficult to quantify the potential impact of continuing compliance with environmental protection laws, management believes that such compliance will not have a material impact on our financial results. Our threshold for disclosing material environmental legal proceedings involving a governmental authority where potential monetary sanctions are involved is $1 million.

Item 1A.    Risk Factors

A description of the risk factors associated with our business is contained in the “Risk Factors” section of our Annual Report on Form 10-K for our fiscal year ended December 31, 2022.  There have been no material changes to our risk factors as previously reported.

Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Purchases of Equity Securities
PeriodTotal Number
 of Shares 
(or Units) 
Purchased (a)		Average
Price Paid
per Share
(or Unit)		Total Number of 
Shares (or Units) 
Purchased as Part of Publicly Announced Plans or Programs		Approximate 
Dollar Value of 
Shares that
May Yet Be 
Purchased
Under the Plans
or Programs
(in millions) (b), (c)
January 1, 2023 through January 31, 202379,511 $76.58 79,511 $909.5 
February 1, 2023 through February 28, 2023562,141 76.93 558,925 866.5 
March 1, 2023 through March 31, 20232,522,586 79.28 2,522,586 666.5 
Total3,164,238 78.80 3,161,022 
(a)    The difference between the total number of shares (or units) purchased and the total number of shares (or units) purchased as part of publicly announced plans or programs is due to shares withheld by us to satisfy tax withholding obligations in connection with the vesting of restricted stock units issued to employees.

(b)    In July 2022, the Board of Directors approved a stock repurchase program providing for up to $1.5 billion of repurchases of our common stock, effective July 28, 2022. Repurchases under the program may be made on the open market, including pursuant to a Rule 10b5-1 plan, and in privately negotiated transactions. The repurchase program does not have an expiration date.

(c)    In February 2023, we entered into a $200.0 million accelerated share repurchase ("ASR") agreement and received, on March 1, 2023, and initial delivery of 2.0 million shares of our common stock, representing approximately 80 percent of
37
the total contract value. The ASR concluded and on March 31, 2023 we received an additional 0.5 million shares. Shares purchased pursuant to the ASR agreement are presented in the table above in the periods in which they were received.

Item 6.    Exhibits

The exhibits listed in the Exhibit Index below are filed, furnished, or incorporated by reference as part of this report on Form 10-Q.

Exhibit No.Description
3.1 
3.2 
3.3 
31.1 
31.2 
32 
101.INS
XBRL Inline Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCHXBRL Taxonomy Extension Schema Document
101.CALXBRL Taxonomy Extension Calculation Linkbase Document
101.DEFXBRL Taxonomy Extension Definition Linkbase Document
101.LABXBRL Taxonomy Extension Label Linkbase Document
101.PREXBRL Taxonomy Extension Presentation Linkbase Document
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

38
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 EDWARDS LIFESCIENCES CORPORATION
 (Registrant)
Date: April 28, 2023By:/s/ SCOTT B. ULLEM
Scott B. Ullem
Chief Financial Officer
(Principal Financial Officer; Duly Authorized Officer)
Date: April 28, 2023By:/s/ ROBERT W.A. SELLERS
Robert W.A. Sellers
Corporate Controller
(Principal Accounting Officer)

39
 EX-31.1 2 ex-31110xqq12023.htm EX-31.1 Document

Exhibit 31.1
EDWARDS LIFESCIENCES CORPORATION
CERTIFICATIONS PURSUANT TO
SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002

CERTIFICATION
I, Michael A. Mussallem, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Edwards Lifesciences Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.   The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date:April 28, 2023By:/s/ MICHAEL A. MUSSALLEM
Michael A. Mussallem
Chairman of the Board and
Chief Executive Officer


 EX-31.2 3 ex-31210xqq12023.htm EX-31.2 Document

Exhibit 31.2

EDWARDS LIFESCIENCES CORPORATION
CERTIFICATIONS PURSUANT TO
SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002

CERTIFICATION
I, Scott B. Ullem, certify that:
1.  I have reviewed this quarterly report on Form 10-Q of Edwards Lifesciences Corporation;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date:April 28, 2023By:/s/ SCOTT B. ULLEM
Scott B. Ullem
Chief Financial Officer


 EX-32 4 ex-3210xqq12023.htm EX-32 Document


Exhibit 32
EDWARDS LIFESCIENCES CORPORATION
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Edwards Lifesciences Corporation (the "Company") on Form 10-Q for the period ended March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), we, Michael A. Mussallem, Chairman of the Board and Chief Executive Officer of the Company, and Scott B. Ullem, Corporate Vice President, Chief Financial Officer, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

April 28, 2023/s/ MICHAEL A. MUSSALLEM
Michael A. Mussallem
Chairman of the Board and
Chief Executive Officer
April 28, 2023/s/ SCOTT B. ULLEM
Scott B. Ullem
Chief Financial Officer


 EX-101.SCH 5 ew-20230331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - COVER link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - INTELLECTUAL PROPERTY AGREEMENT AND LITIGATION EXPENSES link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - INVESTMENTS link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - INVESTMENTS IN VARIABLE INTEREST ENTITIES link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - ACQUISITION link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - ACCELERATED SHARE REPURCHASE link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - EARNINGS PER SHARE link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - SEGMENT INFORMATION link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - BASIS OF PRESENTATION (Policies) link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS (Tables) link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - INVESTMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - ACQUISITION (Tables) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - ACCELERATED SHARE REPURCHASE (Tables) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - EARNINGS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - SEGMENT INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS - Accrued Liabilities and Long Term Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS - Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS - Cash, Cash Equivalents, and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - INTELLECTUAL PROPERTY AGREEMENT AND LITIGATION EXPENSES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - INVESTMENTS - Investments in Debt Securities (Details) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - INVESTMENTS - Cost and Fair Value of Investments in Debt Securities, by Contractual Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - INVESTMENTS - Investments in Continuous Loss Position (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - INVESTMENTS - Investments in Unconsolidated Entities (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - INVESTMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - INVESTMENTS IN VARIABLE INTEREST ENTITIES (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - ACQUISITION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - ACQUISITION - Summary of Preliminary Fair Values of Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - FAIR VALUE MEASUREMENTS - Financial Instruments Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - FAIR VALUE MEASUREMENTS - Changes in Fair Value of Contingent Consideration Obligation (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Derivative Financial Instruments Used to Manage Currency Exchange Rate Risk and Interest Rate Risk (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Location and Fair Value Amounts of Derivative Instruments Reported in Consolidated Condensed Balance Sheets (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Effect of Master-Netting Agreements and Rights of Offset, Derivative Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Effect of Derivative Instruments on Consolidated Condensed Statements of Operations and Consolidated Condensed Statements of Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 0000055 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Cash Flow Hedge Effects on Statement of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 0000056 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 0000057 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000058 - Disclosure - STOCK-BASED COMPENSATION - Weighted-Average Assumptions for Options and ESPP Subscriptions Granted (Details) link:presentationLink link:calculationLink link:definitionLink 0000059 - Disclosure - ACCELERATED SHARE REPURCHASE (Details) link:presentationLink link:calculationLink link:definitionLink 0000060 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 0000061 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Activity for Each Component of Accumulated Other Comprehensive Loss (Details) link:presentationLink link:calculationLink link:definitionLink 0000062 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Amounts Reclassified from Accumulated Other Comprehensive Loss (Details) link:presentationLink link:calculationLink link:definitionLink 0000063 - Disclosure - EARNINGS PER SHARE - Computation of Basic and Diluted Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 0000064 - Disclosure - EARNINGS PER SHARE - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000065 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 0000066 - Disclosure - SEGMENT INFORMATION - Information about Reportable Segments (Details) link:presentationLink link:calculationLink link:definitionLink 0000067 - Disclosure - SEGMENT INFORMATION - Reconciliations of Segment Net Sales to Consolidated Net Sales and Segment Pre-Tax Income to Consolidated Pre-Tax Income (Details) link:presentationLink link:calculationLink link:definitionLink 0000068 - Disclosure - SEGMENT INFORMATION - Enterprise-Wide Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 ew-20230331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 ew-20230331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 ew-20230331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Business Acquisition [Axis] Business Acquisition [Axis] Business combination, net of cash (Note 6) Payments To Acquire Businesses, Net Of Cash Acquired, Excluding Options Payments To Acquire Businesses, Net Of Cash Acquired, Excluding Options Due after 1 year through 5 years Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Amortized Cost Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Schedule of Cash and Cash Equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Variable Interest Entity, Primary Beneficiary Variable Interest Entity, Primary Beneficiary [Member] Deferred income taxes Deferred Income Tax Assets, Net Schedule of Gross Unrealized Losses and Fair Values for Investments in Unrealized Loss Position Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block] Zip Code Entity Address, Postal Zip Code Accrued relocation costs Accrued Relocation Costs, Current Accrued Relocation Costs, Current Gross Unrealized Gains Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Debt Instrument [Axis] Debt Instrument [Axis] Derivatives designated as hedging instruments Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Accrued and other liabilities Accrued And Other Liabilities, Current [Member] Accrued And Other Liabilities, Current Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Inventories Inventory, Net [Abstract] Foreign currency contracts Foreign Exchange Contract [Member]  Option Awards Employee and Nonemployee Stock Options [Member] An arrangement whereby an employee or nonemployee (including a member of the entity's Board of Directors) is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Payment for acquisition options (Note 5) Payment for option to acquire company Other Payments to Acquire Businesses Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Investments held for deferred compensation plans Deferred Compensation Plan Assets Fair Value Measurement [Domain] Fair Value Measurement [Domain] Financial Instruments [Domain] Financial Instruments [Domain] Held-to-Maturity Debt Securities, Held-to-Maturity, Maturity [Abstract] Other Payments for (Proceeds from) Other Investing Activities Statistical Measurement [Domain] Statistical Measurement [Domain] Schedule of Enterprise-Wide Information Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Schedule of Effect of Derivative Instruments on Consolidated Condensed Statements of Operations and Consolidated Condensed Statements of Comprehensive Income Derivative Instruments, Gain (Loss) [Table Text Block] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] INTELLECTUAL PROPERTY AGREEMENT AND LITIGATION EXPENSES Legal Matters and Contingencies [Text Block] Additional paid-in capital Additional Paid in Capital, Common Stock Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Equity method investments Equity Method Investment, Financial Statement, Reported Amounts [Abstract] Due in 1 year or less Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value Other Other Noncash Income (Expense) Derivative Liability, Statement of Financial Position [Extensible Enumeration] Derivative Liability, Statement of Financial Position [Extensible Enumeration] Changes to noncontrolling interest Noncontrolling Interest, Increase from Business Combination Purchases of treasury stock Treasury Stock, Value, Acquired, Cost Method Measurement Input Type [Domain] Measurement Input Type [Domain] Anti-dilutive securities Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Schedule of Weighted-Average Assumptions for ESPP Subscriptions Granted Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Anti-dilutive securities excluded from the computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Taxes payable Taxes Payable Subsequent Event Type [Axis] Subsequent Event Type [Axis] Reclassification of realized investment losses to earnings Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax Equity Component [Domain] Equity Component [Domain] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Discount Rate Measurement Input, Discount Rate [Member] Assets Assets, Fair Value Disclosure Investment, Name [Domain] Investment, Name [Domain] Debt and Equity Securities, FV-NI [Line Items] Debt and Equity Securities, FV-NI [Line Items] Related Party [Domain] Related Party [Domain] Treasury stock, at cost, 41.1 and 38.0 shares, respectively Treasury Stock, Common, Value Total stock-based compensation expense, net of tax Share-Based Payment Arrangement, Expense, after Tax Fair Value Fair Value Available-for-sale investments: Debt Securities, Available-for-Sale Accelerated Share Repurchases, Date [Domain] Accelerated Share Repurchases, Date [Domain] Hedging Designation [Domain] Hedging Designation [Domain] Cash paid during the year for: Supplemental Cash Flow Information [Abstract] Derivative Instrument [Axis] Derivative Instrument [Axis] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Level 1 Fair Value, Inputs, Level 1 [Member] Schedule of Derivative Financial Instruments Used to Manage Currency Exchange Rate Risk and Interest Rate Risk Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]  ESPP Employee Stock [Member] Probability of Milestone Achievement Measurement Input, Probability Of Milestone Achievement [Member] Measurement Input, Probability Of Milestone Achievement [Member] Due in 1 year or less Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Amortized Cost Accounts and other receivables, net Increase (Decrease) in Accounts and Other Receivables Award Type [Axis] Award Type [Axis] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Operating lease liabilities Operating Lease, Liability, Current Derivatives Fair value of derivative assets Net Amounts Presented in the Consolidated Balance Sheet Derivative Asset Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Intellectual property agreement accrual Increase (Decrease) In Legal Settlement Accrual Increase (Decrease) In Legal Settlement Accrual Adjustments to reconcile net income to net cash provided by operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Due after 5 years through 10 years Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after 5 through 10 Years, Fair Value Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Due after 1 year through 5 years Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value Purchases of held-to-maturity investments (Note 4) Payments to Acquire Held-to-Maturity Securities Maximum additional required investment Equity Securities, FV-NI, Maximum Additional Required Equity Securities, FV-NI, Maximum Additional Required Contingent Consideration Obligations [Member] Liability Class [Axis] Liability Class [Axis] Medical Technology Company Medical Technology Company [Member] Medical Technology Company Long-term debt Long-Term Debt, Excluding Current Maturities Variable Interest Entity, Not Primary Beneficiary Variable Interest Entity, Not Primary Beneficiary [Member] Total liabilities Liabilities Option to acquire investment amount Option To Acquire Investment, Amount Option To Acquire Investment, Amount Bank time deposits Bank Time Deposits [Member] Geographical [Axis] Geographical [Axis] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Percentage of interest acquired Business Acquisition, Percentage of Voting Interests Acquired Schedule of Amounts Reclassified from Accumulated Other Comprehensive Loss Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Fair value of derivatives Derivative Liability, Current Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Unrealized Loss on Available-for-sale Investments Loss on available-for-sale investments AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Document Type Document Type Gross Amounts Not Offset in the Consolidated Balance Sheet Derivative Fair Value of Derivative Liability Gross Amounts Not Offset [Abstract] Rest of World Rest of World Segment [Member] Represents the reportable segment of the entity comprised of regions other than the United States, Europe and Japan (Rest of World). Gross Unrealized Losses Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss Amounts included in the measurement of lease liabilities: Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract] Assets Assets, Fair Value Disclosure [Abstract] Segments [Axis] Segments [Axis] Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets Product and Service [Domain] Product and Service [Domain] Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Entity Shell Company Entity Shell Company Transcatheter Mitral and Tricuspid Therapies Transcatheter Mitral And Tricuspid Therapies [Member] Transcatheter Mitral And Tricuspid Therapies [Member] Schedule of Effect of Master-Netting Agreements and Rights of Offset, Derivative Liabilities Offsetting Liabilities [Table Text Block] Financial Instrument [Axis] Financial Instrument [Axis] Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Consolidation Items [Domain] Consolidation Items [Domain] Subsequent Event Subsequent Event [Member] Document Period End Date Document Period End Date Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Schedule of Activity for Each Component of Accumulated Other Comprehensive Loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Total assets Assets Earnings per share: Earnings Per Share [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Carrying value of non-marketable equity securities Equity Securities, FV-NI, Current Schedule of Accrued and Other Liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Due after 5 years through 10 years Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, Rolling after 5 through 10 Years Deferred income tax benefit Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] Accounting Policies [Abstract] Long-term investments (Note 4) Long-Term Investments Amount Paid Stock Repurchase Program, Authorized Amount Employee compensation and withholdings Employee-related Liabilities, Current Asset-backed securities Asset-Backed Securities [Member] Financing receivable Financing Receivable, before Allowance for Credit Loss Income before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Segments [Domain] Segments [Domain] Amortized Cost Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss EARNINGS PER SHARE Earnings Per Share [Text Block] Other liabilities Other Noncurrent Liabilities [Member] Schedule of Weighted-Average Assumptions for Options Granted Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Municipal securities Municipal securities Municipal securities Municipal Bonds [Member] OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS Supplemental Balance Sheet Disclosures [Text Block] Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion) Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Offsetting Liabilities [Line Items] Offsetting Liabilities [Line Items] Award Type [Domain] Award Type [Domain] Unrecognized compensation cost, recognition period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Gross unrealized losses, total Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss Proceeds from stock plans Proceeds from Stock Plans Derivative Contract [Domain] Derivative Contract [Domain] Net investment hedges Net Investment Hedging [Member] Gross profit Gross Profit Less: Noncontrolling interest (a) Business Combination, Acquisition Of Less Than 100 Percent, Noncontrolling Interest, Fair Value, Net Business Combination, Acquisition Of Less Than 100 Percent, Noncontrolling Interest, Fair Value, Net Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Entity Registrant Name Entity Registrant Name Unallocated amounts: Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] Litigation agreement accrual (Note 2) Litigation settlement accrual, noncurrent Estimated Litigation Liability, Noncurrent Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Amortized Cost Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Rolling Maturity [Abstract] Offsetting Assets [Line Items] Offsetting Assets [Line Items] Noncontrolling interest, option adjustment Business Combination, Acquisition Of Less Than 100 Percent, Noncontrolling Interest, Fair Value, Option Adjustment Business Combination, Acquisition Of Less Than 100 Percent, Noncontrolling Interest, Fair Value, Option Adjustment Foreign Currency Translation Adjustments Foreign currency translation adjustments Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Entity Address, City or Town Entity Address, City or Town Value of Shares as % of Contract Value Accelerated Share Repurchases, Value Of Shares Repurchased As Percentage Of Contract Amount Represents the value of the initial shares repurchased as a percentage of the contract amount under accelerated share repurchase agreement. Unrealized Gain on Hedges Gain on hedges Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Instruments not due at a single maturity date Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Fair Value Total stockholders' equity Beginning balance Ending balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Contingent consideration liabilities Obligations, Fair Value Disclosure Consolidation Consolidation, Policy [Policy Text Block] Number of lawsuits that if settled could have a material adverse impact on net income or cash flows Loss Contingency, Claims That If Settled Could Have A Material Adverse Impact, Number Loss Contingency, Claims That If Settled Could Have A Material Adverse Impact, Number Minimum Minimum [Member] Noncontrolling interest Stockholders' Equity Attributable to Noncontrolling Interest Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Raw materials Inventory, Raw Materials, Net of Reserves Tax benefit from employee share-based compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Treasury Stock Treasury Stock, Common [Member] Investment, Name [Axis] Investment, Name [Axis] FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Trading Symbol Trading Symbol Entity File Number Entity File Number Other liability Other Liabilities [Member] Treasury stock (in shares) Treasury stock, beginning balance (in shares) Treasury stock, ending balance (in shares) Treasury Stock, Common, Shares Accumulated Other Comprehensive Loss Accumulated Other Comprehensive Income (Loss) [Line Items] Gross Amounts Not Offset in the Consolidated Balance Sheet Derivative Asset, Subject to Master Netting Arrangement, before Offset of Collateral [Abstract] Research and development expenses Research and Development Expense New Markets Tax Credit New Markets Tax Credit [Member] New Markets Tax Credit Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] INVESTMENTS IN VARIABLE INTEREST ENTITIES Variable Interest Entity Disclosure [Text Block] Effective income tax rate (as a percent) Effective Income Tax Rate Reconciliation, Percent Use of Estimates Use of Estimates, Policy [Policy Text Block] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure ACQUISITION Business Combination Disclosure [Text Block] Other comprehensive loss, net of tax (Note 12): Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Fair value of net assets acquired Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Initial delivery, price per share (in dollars per share) Accelerated Share Repurchases, Initial Price Paid Per Share Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Schedule of Variable Interest Entities [Table] Schedule of Variable Interest Entities [Table] Amortized Cost Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss Unrealized (loss) gain on hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Schedule of Investments in Unconsolidated Affiliates Schedule of Investments in and Advances to Affiliates, Schedule of Investments [Table Text Block] INVESTMENTS Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Liabilities Derivative Liability [Abstract] INCOME TAXES Income Tax Disclosure [Text Block] Finished products Inventory, Finished Goods, Net of Reserves Fair value, twelve months or greater Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Debt Securities, Trading, and Equity Securities, FV-NI [Table] Debt Securities, Trading, and Equity Securities, FV-NI [Table] Intellectual property agreements Accrued Intellectual Property Settlements Accrued Intellectual Property Settlements Basic (in dollars per share) Basic earnings per share (in dollars per share) Earnings Per Share, Basic Europe Europe Segment [Member] Represents the Europe reportable segment of the entity. Enterprise-Wide Information Revenues from External Customers and Long-Lived Assets [Line Items] Corporate items Corporate, Non-Segment [Member] Unrealized Pension Credits Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Schedule of Restricted Cash Restrictions on Cash and Cash Equivalents [Table Text Block] Counterparty Name [Domain] Counterparty Name [Domain] Total Edwards Lifesciences, Inc. stockholders' equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES Derivative Instruments and Hedging Activities Disclosure [Text Block] Prepaid expenses Prepaid Expense, Current Investments taken period Equity Method Investments, Investment Period Equity Method Investments, Investment Period United States United States Segment [Member] Represents the United States reportable segment of the entity. Surgical Structural Heart Surgical Heart Valve Therapy [Member] This element represents the surgical heart valve therapy product line. Derivative Instruments, Gain (Loss) Derivative Instruments, Gain (Loss) [Line Items] Entity Interactive Data Current Entity Interactive Data Current Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Schedule of Changes in Fair Value of Contingent Consideration Obligation Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Changes due to currency rate movements and expenses expected to occur, maximum term Maximum Length of Time, Foreign Currency Cash Flow Hedge Instruments not due at a single maturity date Debt Securities, Held-to-Maturity, Maturity, without Single Maturity Date, Fair Value Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Retained Earnings Retained Earnings [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Other (income) expense, net Other (Income) Expense, net Other Nonoperating Income (Expense) [Member] Common Stock Common Stock [Member] Schedule of Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Other comprehensive loss Other comprehensive loss, net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Common stock issued under stock plans Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Purchases of treasury stock Payments for Repurchase of Common Stock Japan Japan Segment [Member] Represents the Japan reportable segment of the entity. Statement [Table] Statement [Table] Due after 5 years through 10 years Debt Securities, Held-to-Maturity, Maturity, Allocated and Single Maturity Date, Rolling after 5 through 10 Years, Fair Value Document Quarterly Report Document Quarterly Report Current assets Assets, Current [Abstract] Operating lease liabilities Operating Lease, Liability, Noncurrent Statistical Measurement [Axis] Statistical Measurement [Axis] Maximum additional option to acquire investment Equity Securities, FV-NI, Maximum Additional Option To Acquire Investment Equity Securities, FV-NI, Maximum Additional Option To Acquire Investment Purchases of treasury stock (in shares) Shares Received (in shares) Treasury Stock, Shares, Acquired Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Transcatheter Aortic Valve Replacement Transcatheter Aortic Valve Replacement [Member] Transcatheter Aortic Valve Replacement [Member] Retained earnings Retained Earnings (Accumulated Deficit) Accounts receivable, net of allowances of $7.6 and $7.9, respectively Accounts Receivable, after Allowance for Credit Loss, Current U.S government and agency securities U.S. government and agency securities United States government and agency securities US Treasury and Government [Member] Equity Components [Axis] Equity Components [Axis] Fair Value on a Recurring Basis Fair Value, Recurring [Member] Litigation Case [Domain] Litigation Case [Domain] Segment Operating Income Pre-tax Income Reconciliation Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract] Fair value, less than twelve months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Document Fiscal Year Focus Document Fiscal Year Focus Statement [Line Items] Statement [Line Items] Non-operating income (expense) Nonoperating Income (Expense) Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Selling, general, and administrative expenses Selling, general, and administrative expenses Selling, General and Administrative Expense Total purchase price Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest Loss Contingencies [Table] Loss Contingencies [Table] Change in fair value of contingent consideration liabilities, net (Note 7) Change in fair value of contingent consideration liabilities, net (Note 7) Change in fair value of contingent consideration liabilities, net Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Amounts reclassified from accumulated other comprehensive loss Reclassification from AOCI, Current Period, before Tax, Attributable to Parent ACCUMULATED OTHER COMPREHENSIVE LOSS Comprehensive Income (Loss) Note [Text Block] Decrease in non-marketable equity securities due to observable price changes Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount Document Transition Report Document Transition Report Local Phone Number Local Phone Number Intellectual property agreement term Intellectual Property Agreement Term Intellectual Property Agreement Term Operating income Consolidated operating income Operating Income (Loss) Inventories Increase (Decrease) in Inventories New Accounting Standards Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Intellectual property agreement and litigation expenses, net Intellectual Property Litigation Expense Represents the net amount of judgment or settlement awarded to (against) the entity and legal, forensic, accounting, investigative fees and other expenses related to intellectual property litigation. Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Common stock, shares outstanding (in shares) Common stock, beginning balance (in shares) Common stock, ending balance (in shares) Common Stock, Shares, Outstanding Total investments in unconsolidated entities Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures Goodwill Goodwill Goodwill Liabilities Liabilities, Fair Value Disclosure Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Provision for income taxes Provision for income taxes Income Tax Expense (Benefit) Geographical [Domain] Geographical [Domain] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Income Statement [Abstract] Income Statement [Abstract] Hedging Relationship [Axis] Hedging Relationship [Axis] Additional Paid-in Capital Additional Paid-in Capital [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Document Fiscal Period Focus Document Fiscal Period Focus Derivative Asset, Statement of Financial Position [Extensible Enumeration] Derivative Asset, Statement of Financial Position [Extensible Enumeration] Basic: Earnings Per Share, Basic [Abstract] Restricted cash included in other assets Restricted Cash, Noncurrent Cost of sales Cost of sales Cost of sales Cost of Goods and Services Sold Instruments not due at a single maturity date Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, without Single Maturity Date Derivative Financial Instruments Derivative [Line Items] Diluted (in shares) Dilutive weighted-average shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Cash Collateral Received Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset Derivatives Fair value of derivative liabilities Net Amounts Presented in the Consolidated Balance Sheet Derivative Liability Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Gross Amounts Derivative Liability, Subject to Master Netting Arrangement, before Offset Expected term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Rolling Maturity [Abstract] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Common stock, $1.00 par value, 1,050.0 shares authorized, 647.1 and 646.3 shares issued, and 606.0 and 608.3 shares outstanding, respectively Common Stock, Value, Issued Liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Medical Device Company Investee Medical Device Company [Member] Medical Device Company Medtronic Inc Medtronic Inc [Member] Medtronic Inc Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of Financial Instruments Measured at Fair Value on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Uncertain tax positions Liability for Uncertainty in Income Taxes, Noncurrent Operating segments Operating Segments [Member] Cash flow gain to be reclassified in the next twelve months Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Secured promissory note Equity Securities, FV-NI Promissory Note Outstanding Equity Securities, FV-NI Promissory Note Outstanding Decrease in unrecognized tax benefits is reasonably possible Decrease in Unrecognized Tax Benefits is Reasonably Possible Variable Interest Entity [Line Items] Variable Interest Entity [Line Items] Cash, cash equivalents, and restricted cash at beginning of period Cash, cash equivalents, and restricted cash at end of period Total cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Current liabilities Liabilities, Current [Abstract] Foreign currency forward exchange contracts Foreign Exchange Forward [Member] Net income Net income Net of tax Net income attributable to Edwards Lifesciences, Inc. Net Income (Loss) Available to Common Stockholders, Basic Common stock, shares issued (in shares) Common Stock, Shares, Issued Carrying value of equity method investments Equity Method Investments Other liability Other Liabilities, Fair Value Disclosure Capital expenditures accruals Capital Expenditures Incurred but Not yet Paid Schedule of Investments in Debt Securities Unrealized Gain (Loss) on Investments [Table Text Block] Foreign currency Foreign Currency Transaction Gain (Loss), before Tax Total Edwards Lifesciences, Inc. Stockholders' Equity Parent [Member] Amount Reclassified from Accumulated Other Comprehensive Loss Reclassification out of Accumulated Other Comprehensive Income [Member] Assets Derivative Asset [Abstract] Income Statement Location [Domain] Income Statement Location [Domain] Cash flow hedges Cash Flow Hedging [Member] Due after 1 year through 5 years Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, Rolling after One through Five Years Accelerated Share Repurchases, Date [Axis] Accelerated Share Repurchases, Date [Axis] Fair value of financial instruments measured on a recurring basis Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Derivative liabilities Offsetting Derivative Liabilities [Abstract] Fair value, total Debt Securities, Available-for-Sale, Unrealized Loss Position Amendment Flag Amendment Flag Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Investment Type [Axis] Investment Type [Axis] Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Litigation Case [Axis] Litigation Case [Axis] Accrued realignment reserves Restructuring Reserve, Current Schedule of Information about Reportable Segments and Reconciliation of Segment Net Sales and Pre-Tax Income Schedule of Segment Reporting Information, by Segment [Table Text Block] Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Entity Current Reporting Status Entity Current Reporting Status Due in 1 year or less Debt Securities, Held-to-Maturity, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value Deferred tax liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Due in 1 year or less Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, Rolling within One Year Other assets (Note 5) Other Assets, Noncurrent Prepaid royalty asset Prepaid Royalties January 2023 Stock Repurchase Program Shares Sold in February 2023 January 2022 Stock Repurchase Program Shares Sold In February 2022 [Member] January 2022 Stock Repurchase Program Shares Sold In February 2022 Depreciation and amortization Depreciation, Depletion and Amortization Repayments of pre-existing notes Repayments of Notes Payable Available-for-Sale Available-for-Sale Securities, Debt Maturities [Abstract] Japan JAPAN Counterparty Name [Axis] Counterparty Name [Axis] Summary of Preliminary Fair Values of Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Derivative [Table] Derivative [Table] Additional federal tax Income Tax Examination, Estimate of Possible Loss Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] In-process research and development Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Litigation settlement accrual, current Estimated Litigation Liability, Current Accrued marketing expenses Accrued Marketing Costs, Current Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Net Amount Derivative Asset, Including Not Subject to Master Netting Arrangement, after Offset and Deduction Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Property, plant, and equipment, net Property, Plant and Equipment, Net Operating cash flows from operating leases Operating Lease, Payments Changes in fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Unrealized pension costs Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Gain (loss) on cash flow hedging relationships: Effect of Cash Flow Hedges on Results of Operations [Abstract] Other (income) expense, net Other (income) expense, net Other (income) expense, net Other Nonoperating Income (Expense) Balance Sheet Location [Axis] Balance Sheet Location [Axis] Final settlement per share price (in dollars per share) Accelerated Share Repurchases, Final Price Paid Per Share BASIS OF PRESENTATION Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Contingent consideration liabilities (Note 7) Business Combination, Contingent Consideration, Liability, Noncurrent Taxes payable Accrued Income Taxes, Current Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Maximum Maximum [Member] Accumulated other comprehensive loss (Note 12) Accumulated Other Comprehensive Income (Loss), Net of Tax Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Stock compensation plan Share-Based Payment Arrangement [Member] Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Total current assets Assets, Current Derivatives designated as hedging instruments Derivatives designated as hedging instruments Designated as Hedging Instrument [Member] Payments for legal settlements Payments for Legal Settlements Business Acquisition [Line Items] Business Acquisition [Line Items] Property, payroll, and other taxes Accrual for Property Payroll and Other Taxes Other than Income Taxes Current Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes, payroll taxes and other taxes, excluding income taxes payable. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Entity Small Business Entity Small Business Measurement Basis [Axis] Measurement Basis [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] ACCELERATED SHARE REPURCHASE Stockholders' Equity Note Disclosure [Text Block] Non-cash operating lease cost Operating Lease, Right-of-Use Asset, Amortization Expense Segment Net Sales Net Sales Reconciliation Revenues [Abstract] Purchases of available-for-sale investments (Note 4) Payments to Acquire Debt Securities, Available-for-Sale Total remaining unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Schedule of Supplemental Cash Flow Information Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Interest income, net Interest Income [Member] Instruments not due at a single maturity date Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Amortized Cost Income tax benefit Share-Based Payment Arrangement, Expense, Tax Benefit Title of 12(b) Security Title of 12(b) Security Initial Delivery of Shares Settled January 2022 Initial Delivery Of Shares Settled January 2022 [Member] Initial Delivery Of Shares Settled January 2022 Notes payable fair value disclosure Notes Payable, Fair Value Disclosure Consolidated Entities [Axis] Consolidated Entities [Axis] Short-term investments (Note 4) Short-Term Investments Corporate items Costs and Expenses Share information Share Information [Abstract] Accrued and other liabilities Payables and Accruals [Abstract] Business Combination and Asset Acquisition [Abstract] Class of Stock [Line Items] Class of Stock [Line Items] Gross unrealized losses, less than twelve months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Common stock issued under stock plans (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture SEGMENT INFORMATION Segment Reporting Disclosure [Text Block] Selling, general, and administrative expenses Selling, general, and administrative expenses Selling, General and Administrative Expenses [Member] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Other receivables Other Receivables Accrued rebates Accrued Rebates Aggregate carrying amount, as of the balance sheet date, of current obligations associated with sales rebates. Amount of Gain or (Loss) Recognized in Income on Derivative Derivative, Gain (Loss) on Derivative, Net Gross unrealized losses, twelve months or greater Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] Proceeds from held-to-maturity investments (Note 4) Proceeds from Sale and Maturity of Held-to-Maturity Securities Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Increase in non-marketable equity securities due to observable price changes Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount Other comprehensive gain (loss) before reclassifications OCI, before Reclassifications, before Tax, Attributable to Parent Weighted-average number of common shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Fair Value Debt Securities, Available-for-Sale, Maturity, Fair Value, Rolling Maturity [Abstract] Legal and insurance Accrued Litigation And Insurance Reserves Accrued Litigation And Insurance Reserves Inventories (Note 2) Total inventories Inventory, Net Accounts payable Accounts Payable, Current Hedging Relationship [Domain] Hedging Relationship [Domain] Schedule of Cost and Fair Value of Investments in Debt Securities, by Contractual Maturity Investments Classified by Contractual Maturity Date [Table Text Block] Hedging Designation [Axis] Hedging Designation [Axis] Offsetting Assets [Table] Offsetting Assets [Table] Maximum secured promissory note Equity Securities, FV-NI, Maximum Secured Promissory Note Equity Securities, FV-NI, Maximum Secured Promissory Note Entity Filer Category Entity Filer Category Gross Amounts Offset in the Consolidated Balance Sheet Derivative Asset, Subject to Master Netting Arrangement, Liability Offset Basic (in shares) Weighted-average shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Stockholders' equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] United States UNITED STATES Liabilities Liabilities, Fair Value Disclosure [Abstract] Investment percentage (in percent) Equity Method Investment, Ownership Percentage Schedule of Location and Fair Value Amounts of Derivative Instruments Reported in Consolidated Condensed Balance Sheets Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block] Total stock-based compensation expense Share-Based Payment Arrangement, Expense Commitments and contingencies (Note 11) Commitments and Contingencies Security Exchange Name Security Exchange Name Finished products inventories held on consignment Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross Offsetting Liabilities [Table] Offsetting Liabilities [Table] Derivative notional amount Derivative liability, fair value Derivative, Notional Amount Financial instruments Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Issuances of notes receivable Payments to Acquire Receivables Preferred stock, $0.01 par value, authorized 50.0 shares, no shares outstanding           Preferred Stock, Value, Issued Amount of gain (loss) reclassified from accumulated OCI into income Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Restricted cash included in other current assets Restricted Cash, Current Reconciling items Segment Reconciling Items [Member] Financial Instruments Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset Net sales Revenue from Contract with Customer, Excluding Assessed Tax Income taxes Increase (Decrease) in Income Taxes Payable Cover [Abstract] Cover [Abstract] Level 3 Fair Value, Inputs, Level 3 [Member] Segment operating income Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Due after 1 year through 5 years Debt Securities, Held-to-Maturity, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value Research and development accruals Research And Development Accruals Aggregate carrying amount, as of the balance sheet date, of current obligations associated with research and development and clinical trials. STOCK-BASED COMPENSATION Share-Based Payment Arrangement [Text Block] Fair Value Fair Value Debt Securities, Held-to-Maturity, Fair Value Work in process Inventory, Work in Process, Net of Reserves Deferred income taxes Increase (Decrease) in Deferred Income Taxes Less: cash acquired Cash Acquired from Acquisition Segment Reporting [Abstract] Segment Reporting [Abstract] Investments [Domain] Investments [Domain] Noncontrolling Interest Noncontrolling Interest [Member] Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Interest income, net Interest Income (Expense), Net Due after 5 years through 10 years Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after 5 through 10 Years, Amortized Cost Total liabilities and equity Liabilities and Equity Schedule of Accelerated Share Repurchases Accelerated Share Repurchases [Table Text Block] Affected Line on Consolidated Condensed Statements of Operations Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Hedged items Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge Related Party [Axis] Related Party [Axis] February 2021 Stock Repurchase Program Shares Sold in March 2021 February 2023 Stock Repurchase Program Shares Sold In March 2023 [Member] February 2023 Stock Repurchase Program Shares Sold In March 2023 Equity securities Investments, All Other Investments [Abstract] Dilutive effect of stock plans (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Diluted: Earnings Per Share, Diluted [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Derivatives not designated as hedging instruments Not Designated as Hedging Instrument [Member] AOCI Attributable to Parent, Net of Tax AOCI Attributable to Parent, Net of Tax [Roll Forward] Total purchase price, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Collections of notes receivable Proceeds from Collection of Notes Receivable Allocation of stock-based compensation expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Level 2 Fair Value, Inputs, Level 2 [Member] Noncontrolling interest, gross Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value Current Fiscal Year End Date Current Fiscal Year End Date Loans receivables, maximum lending amount Loans Receivables, Maximum Lending Capacity Loans Receivables, Maximum Lending Capacity Net income attributable to Edwards Lifesciences, Inc. Net Income (Loss) Available to Common Stockholders, Diluted Diluted (in dollars per share) Diluted earnings per share (in dollars per share) Earnings Per Share, Diluted Other intangible assets, net (Note 6) Intangible Assets, Net (Excluding Goodwill) Gross Amounts Not Offset in the Consolidated Balance Sheet Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Consolidation Items [Axis] Consolidation Items [Axis] Total current liabilities Liabilities, Current Other current assets Other Assets, Current Critical Care Critical Care [Member] This element represents the critical care product line. Liability for income taxes associated with uncertain tax positions Unrecognized Tax Benefits Equity Securities Equity Securities [Member] Net amounts that would favorably affect effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Held-to-maturity Debt Securities, Held-to-Maturity, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract] Corporate debt securities Corporate debt securities Corporate debt securities Corporate Debt Securities [Member] Gross Amounts Offset in the Consolidated Balance Sheet Derivative Liability, Subject to Master Netting Arrangement, Asset Offset Derivative assets Offsetting Derivative Assets [Abstract] Gross Amounts Derivative Asset, Subject to Master Netting Arrangement, before Offset Entity Address, Address Line One Entity Address, Address Line One Net Amount Derivative Liability, Including Not Subject to Master Netting Arrangement, after Offset and Deduction Other Proceeds from (Payments for) Other Financing Activities Product and Service [Axis] Product and Service [Axis] Europe Europe [Member] Cash Collateral Received Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset Contingent Consideration Contingent Consideration Liability [Member] Contingent Consideration Liability Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Amount of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing) Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred Available-for-sale Debt Securities, Available-for-Sale [Abstract] Unrealized gain (loss) on available-for-sale investments OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Proceeds from available-for-sale investments (Note 4) Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Equity [Abstract] Equity [Abstract] Variable Interest Entities [Abstract] Investments in Variable Interest Entities Entity Tax Identification Number Entity Tax Identification Number Derivatives designated as hedging instruments Derivatives, Fair Value [Line Items] Accrued and other liabilities (Note 2) Total accrued and other liabilities Accrued And Other Liabilities, Current Accrued And Other Liabilities, Current Consolidated Entities [Domain] Consolidated Entities [Domain] Cross currency swap contracts Currency Swap [Member] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Intellectual property agreement and litigation expenses, net (Note 3) Intellectual property litigation expense Litigation Settlement, Expense Net increase in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Contingent consideration liability measurement input Business Combination, Contingent Consideration, Liability, Measurement Input Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Measurement Frequency [Axis] Measurement Frequency [Axis] Rest of World Rest of World [Member] Represents the geographic areas of the world other than the United States, Europe and Japan. Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Other accrued liabilities Other Accrued Liabilities, Current Amount excluded from effectiveness testing recognized in earnings based on an amortization approach Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, after Tax Measurement Input Type [Axis] Measurement Input Type [Axis] Gain (loss) on fair value hedging relationships: Effect of Fair Value Hedges on Results of Operations [Abstract] City Area Code City Area Code Accrued professional services Accrued Professional Fees, Current ASSETS Assets [Abstract] Other Increase (Decrease) in Other Operating Assets and Liabilities, Net Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Fair Value Debt Securities, Held-to-Maturity, Fair Value, Rolling Maturity [Abstract] Limited Liability Company Limited Liability Company [Member] Non-cash investing and financing transactions: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Stock-based compensation (Note 9) Share-Based Payment Arrangement, Noncash Expense Fair value, per option (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Other liabilities Other Liabilities, Noncurrent Capital expenditures Payments to Acquire Property, Plant, and Equipment Research and development expenses Research and Development Expense [Member] Weighted Average Weighted Average [Member] Schedule of Computation of Basic and Diluted Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Initial Delivery of Shares Settled February2023 Initial Delivery Of Shares Settled February 2023 [Member] Initial Delivery Of Shares Settled February 2023 Right-of-use assets obtained in exchange for new lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Cost of sales Cost of sales Cost of Sales [Member] Investment option to acquire Equity Securities, FV-NI, Option To Acquire Investment Equity Securities, FV-NI, Option To Acquire Investment Convertible Promissory Note Convertible Promissory Note [Member] Convertible Promissory Note Schedule of Effect of Master-Netting Agreements and Rights of Offset, Derivative Assets Offsetting Assets [Table Text Block] EX-101.PRE 9 ew-20230331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 10 ew-20230331_g1.jpg begin 644 ew-20230331_g1.jpg M_]C_X 02D9)1@ ! @$ 8 !@ #_[@ .061O8F4 90 !_]L 0P " 0$! M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D* M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H* M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\ $0@" MF@*L P$B (1 0,1 ?_$ !\ $% 0$! 0$! ! @,$!08'" D* M"__$ +40 (! P,"! ,%!00$ !?0$" P $$042(3%!!A-180'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H MJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V M]_CY^O_$ !\! ,! 0$! 0$! 0$ ! @,$!08'" D*"__$ +41 (! M @0$ P0'!00$ $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P M%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_: P# M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@#A?VAOVG?V>?V2_AZ_P 5OVE_C-X=\#^'DG6!=4\1 MZG';1RS,"5ACW',LA"L0B L0I., U7_9N_:R_9H_;!\$2?$?]E[XY>&O'6BP M7'V>ZOO#FJ1W MIL9\J95.Z%\$':X4D$'&"#5+XC_L@_ SXS_&W3/C?\:/ V MF>+[OP]H+:;X5TOQ)IT5Y9Z*\LK/=W<$4JLJW$ZBWC:3&Y4ME52H>0-\1_L9 M_LH^#?@E_P '#_QX\4?LF^%[7PS\-(_@;HT/Q,T/0H!;Z8/&-Y>K<6RI @$: M2BPA:=@@^4WC,0//R0#]*Z\L\:?MN_LC?#KXF-\'?''[0_A;3/$<-S;6]YIU MUJB#[#/WM$N M)/ ?P^UKQ%'!*/EE:RL9KD(<=B8L?C7PY_P2)_9]T7XZ_P#!OB=&^,"#7-8^ M.WA;Q7KWQ!UG4%#SZOJ.J7-YF[E8CF58Q;A6ZKY"$8VB@#]'-:UK1_#>CW?B M'Q%JUM8:?86SW%]?7LZQ0V\**6>21V(5$5026) !)KS[X)_MA_LO_M&ZU<> M&_@A\Z)CP&)K\4'_;P^*_ M[9W_ 1Q_8/_ &7OB#XDN[N[^./Q\TSX?_$R_EG8R:MH6E:LMN\,KYW.98FL M6E8G+F.0-D.<_;/_ <(>/+G]DBT_9;_ &X?AWMT_7/A]^T/I>@RM;*$^T>' MM4M+F/4; XQ^[E2UA&WH"@88*@T ?=WQG_:%^"7[/&D6.M_&KXEZ7X>BU2]^ MQZ1%?3_O]1N=I;R;:%09;B3:&8I&K,%4L1@$UI?"[XL?#/XW>"+/XD_"'QYI M7B30;_>+35M&O4GA=D8HZ;E)PZ.K(R'#*RE6 ((K\_/V4/B'JG[4W_!QI^T; MKGBR0W>E?L]?#/1?"'@2TF.8["75!'=W]RB'A)I)(7B,@^8Q(J$X&*F_8T^( MNI?!G_@X>_:A_8S\/W!B\)>.OAYH_P 4;?2%.(+'5U6QL+Z:->BO=-.DLI_B M:)3VH _1VBBB@ HK@_B#^T]\ /A5XC;PE\1/BII>D:DD*2M9WDZJ[1Z=?QS,@RP0]!0!:HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** /E3_@I)_P58_9N_8%70_A9XR^-?A# M0/B%XVW)X=A\4WI%GI%L,B35K]8SYGV:/:P2)2XO-2O3$T]]K6IS^6D40=E MCB51@)OMX(HUC153ZK\8? ?X'?$+6#XB\?\ P:\*:YJ!B6,WVL>';:YF*+]U M=\B%L#)P,X&:?X+^!_P6^&VJOKWP[^$'A?0+Z2 P27NB^'[:UE:(E6*%XD4E M254D9QE0>PH \,O?VG_V+_\ @I_X)_:"_8(^!WQ\T_6?$>D>']8\%_$#3HK* MYBDTJ2[@N+"1E,T:+<(DGF(9(2Z!DQNY7/R]_P $W_VG=&_9'_X(.:Y\.OCU M>0>'_B-\ -&\0^#/%GA"YG47@UJ*:Y_LVUAC^],UY'-9FW* B;SUV%AS7VE\ M&?V0_#'P^_::\:?M77GA#PKHVO\ BC3AI4-CX2TM(4^RBZDN);N[G$<;WE[< MR-&\DCJ!&L,4:[BLDTOHFK_!3X->(/B%8_%O7OA+X9OO%>F1^7IOB>\T&WEU M"T3GY8KED,D8Y/"L.IH _&#Q7_P3-^,7[$7_ 1S_8S^-FO^#;Z?Q5^S/\8= M-^)GQ1T&VMVDN;72+S4C>:C'Y: LTEK&;59 ,X6"=LX6OI[_ (+6^'M"_P"" MBWC/]E?]AGX%^)+#Q(_B+XQZ9\1/%-YH=XEU%IWA#3;:?SK^5XR5CBF-VD<# M,0)I<*A)SC])G1)%*.H96&"",@BN:^'/P7^#OP>6_7X2?"?PSX6&JW'GZF/# MF@V]C]LEY_>2^2B^8W)^9LGDT ?!OP-^'LO[%G_!PC\9]9\=2)IWA7]J3X>: M3K/@?6;IPEO<:WHZ);WNE!VP#<^6\EV$[Q,2,[2 O[ 7PTNOV@_^"WG[3G_! M2CPVRW/@#3_"^E_"[P-X@A.ZWUV>W2TFU:2W<<2107=JL'F*2C/O )*,!]]_ M$/X8_#;XN^&I/!GQ7^'NA^)]'ED6272?$.DPWML[K]UC%,K(2.QQQ6EH>A:) MX8T:U\.^&M&M-.T^Q@6&RL+&W6&&WB485$1 %10. !0!:HHHH R]6\$>"] M>O#J&N>$-+O;@J%,]WI\+KQO( MET+&T2+SE%NQ"OM W#/.#7T%7A?[6'_);/@?_P!CW+_Z3-0![=_9VG_\^,/_ M 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9 MVG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H M5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ M ,^,/_?H5-10!A^(K6UBU724BMHU#W9#A4 ##;T/K6M_9VG_ //C#_WZ%9OB M7_D+Z/\ ]?I_]!-;% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G M:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ MWZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%' M]G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:? M_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_] M^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4 M?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G M:?\ \^,/_?H4?V=I_P#SXP_]^A4U% &'9VMJWC*\@:VC*+:1E4*# .3SBM;^ MSM/_ .?&'_OT*S;+_D=[W_KRB_F:V* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[] M"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T_P#Y\8?^_0H_L[3_ M /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T_P#Y\8?^ M_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0I\5M;0$F"W1">I1 ,T^B@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH *\+_:P_Y+9\#_ /L>Y?\ TF:O=*\+_:P_Y+9\ M#_\ L>Y?_29J /=**** "BBB@ HHHH **** "BBB@ HHHH Q_$O_ "%]'_Z_ M3_Z":V*Q_$O_ "%]'_Z_3_Z":V* "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** ,>R_Y'>]_P"O*+^9K8K'LO\ D=[W M_KRB_F:V* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ KPO]K#_DMGP/_P"Q[E_])FKW2O"_VL/^2V? _P#['N7_ -)FH ]T MHHHH **** "BBB@ HHHH **** "BBB@#'\2_\A?1_P#K]/\ Z":V*Q_$O_(7 MT?\ Z_3_ .@FMB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@#'LO^1WO?^O*+^9K8K'LO^1WO?^O*+^9K8H **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O"_VL/^ M2V? _P#['N7_ -)FKW2O"_VL/^2V? __ +'N7_TF:@#W2BBB@ HHHH **** M"BBB@ HHHH **** ,?Q+_P A?1_^OT_^@FMBL?Q+_P A?1_^OT_^@FMB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@#'LO^1WO?\ KRB_F:V*Q[+_ )'>]_Z\HOYFMB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *\+_:P_Y+9\#_\ L>Y?_29J M]TKPO]K#_DMGP/\ ^Q[E_P#29J /=**** "BBB@ HHHH **** "BBB@ HHHH M Q_$O_(7T?\ Z_3_ .@FMBL?Q+_R%]'_ .OT_P#H)K8H **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q[+_D=[W_KR MB_F:V*Q[+_D=[W_KRB_F:V* "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH I^(/$ M.@>$]$N_$WBG7+/3--L+=I[[4-0N4A@MXE&6DDD6'Q;^"7Q TKQ3X8U5YUTS7]#O%N+2[\F>2"0Q2KE9%$L4B[E)!VY!(YK" M_:J^&7PZ^+7[/7B_PC\4/ ND>(=,?P[?2?8-:TV*ZA$@MI0) DBD!P&.&'(R M<&OE7_@V=_Y0>? ?_L&:U_Z?=1H ^[*\D^.W[>_[$/[+WB^#X?\ [2'[7/PX M\":[7SY4AD>5@0#]F/#7Q9^%_C'X96WQI\*_$31=0\'WFD_P!J M6OBBUU.)]/EL=A?[4MP&\LP[ 6\S.W;SG%FH&RT^]!EFL7;:EY$K &>V9OE6XCW1,> Q-?"'_!>+XD^'=0^%/[ M)?[!WP9ETVT^'_[0/QP\+>'M2@\.A(K&Y\)0S6Q:S@$.$6V=9K4A4^4QQ[ - MK8K9_P"#A#QY<_LD6G[+?[_8](BOI_W^HW. MTMY-M"H,MQ)M#,4C5F"J6(P":TOA=\6/AG\;O!%G\2?A#X\TKQ)H-_O%IJVC M7J3PNR,4=-RDX='5D9#AE92K $$5^?G[*'Q#U3]J;_@XT_:-USQ9(;O2OV>O MAGHOA#P):3',=A+J@CN[^Y1#PDTDD+Q&0?,8D5"<#%3?L:?$74O@S_P$O'7P\T?XHV^D*<06.KJMC87TT:]%>Z:=)93_$T2GM0!^CM%%% M!7A?[6'_ "6SX'_]CW+_ .DS5[I7A?[6'_);/@?_ -CW+_Z3-0![I1110 44 M44 %%%% !1110 4444 %%%% &/XE_P"0OH__ %^G_P!!-;%8_B7_ )"^C_\ M7Z?_ $$UL4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 8]E_R.][_ ->47\S6Q6/9?\CO>_\ 7E%_,UL4 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110!R7Q]U73-"^!?C/6=:U""TM+7PIJ$MS]?<'C#P/X*^(6C'P[X^\'Z7KFGF19#8ZQI\=S"77[K;)%*Y&3@ MXXJGX&^$OPJ^I?#3X9^'_ Z;T(+TZ%HT%I]HV;MF_P I%W[=S8SG&XXZ MF@#ROX/?\%+/V'?CWXQ^*?@#X3?M :;JVL?!6>XB^)5BME=1-I'D&59G'FQ* M+B-&AE4R0>8H9,9R5SY3^T5^WS_P3I_;0_8.\9^'?AA\;O"/Q5M_B-X0U#1/ M#O@7P_J$=SK&NW\]N\<-G%I[8N(Y_,*-F2-/("^ /V MF/&G[5E]X/\ "NC:_P"*=.&DQ6'A/2TAC^RBZDN);N[G$<;WE['?#-I8S763D^8 M\,:L^3S\Q/- 'YF_\%$OV&OBM^S5_P $Y_V+?BW/#<>)-9_8Q\7>#-9^(,6F M(\[2:+9QVT>JR0*H+2)"8(FX'$$;L<;:[S_@M;X>T+_@HMXS_97_ &&?@7XD ML/$C^(OC'IGQ$\4WFAWB746G>$--MI_.OY7C)6.*8W:1P,Q FEPJ$G./TF=$ MD4HZAE88((R"*YKX<_!?X._!Y;]?A)\)_#/A8:K<>?J8\.:#;V/VR7G]Y+Y* M+YC30!\&_ WX>R_L6?\'"/QGUGQU(FG>%?VI/AYI.L^!]9NG"6]QK> MCHEO>Z4'; -SY;R783O$Q(SM("_L!?#2Z_:#_P""WG[3G_!2CPVRW/@#3_"^ ME_"[P-X@A.ZWUV>W2TFU:2W<<2107=JL'F*2C/O )*,!]]_$/X8_#;XN^&I/ M!GQ7^'NA^)]'ED6272?$.DPWML[K]UC%,K(2.QQQ6EH>A:)X8T:U\.^&M&M- M.T^Q@6&RL+&W6&&WB485$1 %10. !0!:HHHH \O^*W[)7PU^,7BY_&GBC7 M_%%O=O D)CTGQ'-;0[4& =B'&?4]Z\2^+O[+7P\^$/QR^#UQX8USQ+<-J/C0 MQ3C5=?FN0H2$N-@<_*Y?\ TF:@#US_ (0? M2/\ GYO?_ MJ/^$'TC_GYO?_ +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO M?_ MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_ +:MBB@#'_X0?2/^?F] M_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_ +: MMBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** .4USPKIUKJ.FPQSW)$] MR5E:?\ P@^D?\_-[_X%M1XE_P"0OH__ %^G_P!!-;% &/\ \(/I M'_/S>_\ @6U'_"#Z1_S\WO\ X%M6Q10!C_\ "#Z1_P _-[_X%M1_P@^D?\_- M[_X%M6Q10!C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;5L44 8__ @^D?\ M/S>_^!;4?\(/I'_/S>_^!;5L44 8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@ M6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ M@6U'_"#Z1_S\WO\ X%M6Q10!C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M6Q1 M0!C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;5\4_MR_\G':O_P!>EI_Z(2O( M: /TT_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:OS+HH _33_A!](_Y^;W_P " MVH_X0?2/^?F]_P# MJ_,NB@#]-/^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VK\ MRZ* /TAM?"NG2>*;JP:>YV1VT;*1<-NR2>IK3_X0?2/^?F]_\"VK\RZ* /TT M_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK\RZ* /TT_X0?2/^?F]_P# MJ/^ M$'TC_GYO?_ MJ_,NB@#]-/\ A!](_P"?F]_\"VH_X0?2/^?F]_\ MJ_,NB@ M#]-/^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:OS+K]0M"_Y =G_ ->D?_H(H H_ M\(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M6Q10!C_\ "#Z1_P _-[_X%M5K2M L MM'D>2UEG8NN#YLQ8?K5ZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HKSU?VJ?@))^T%/\ LK6_CY9OB!::=%?W?AJWTVYDEM[256:. MXD=8C''$VU@'9@I92N=PQ7C?P)_X+0?\$Y_VE/VF;_\ 9.^#/QZ&L>*;+4Y] M-@NDT.\32M0OH4>26TM;]HA;SRJD\ F@#ZFHHHH **** "BBB M@ HHHH **** "BBB@ KPO]K#_DMGP/\ ^Q[E_P#29J]TKPO]K#_DMGP/_P"Q M[E_])FH ]THHHH **** "BBB@ HHHH **** "BBB@#'\2_\ (7T?_K]/_H)K M8K'\2_\ (7T?_K]/_H)K8H **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@#X1_;E_Y..U?_KTM/\ T0E>0UZ]^W+_ ,G':O\ ]>EI_P"B$KR&@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH *_4+0O^0'9_\ 7I'_ .@BOR]K M]0M"_P"0'9_]>D?_ *"* +5%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110!\*?\%"/@W_P4YM8/BYX%_X)^_##P7JLOQ[CM(+G MXE:YXT_LR]\"A=.@TVX!MS S74(A@,T#Q2;XI[J=C$V%WUO W[$GC']BO]GO MX ?\$]_V=_@A9S^ ?"GCGPWJ_P 2?BOJFN:?9&>\M=0AOGFMK9IC/-%_M8?\ );/@?_V/OT8_9S_Y(/X1_[ %M M_P"BQ0!VE%%% !1110 4444 %%%% 'PC^W+_ ,G':O\ ]>EI_P"B$KR&O7OV MY?\ DX[5_P#KTM/_ $0E>0T %%%% !1110 4444 %%%% !1110 4444 %%%% M !7ZA:%_R [/_KTC_P#017Y>U^H6A?\ (#L_^O2/_P!!% %JBBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _(_P#X+E?LK_\ M!!7P#^TW)^U__P %3=:U:\\3>-O"^FZ5X>\">%+R]&HW\UE)<))?"*RD5F#Q M26L&^4I&OV0!6+N17&?\$J?V1?\ @W,^.W[2'A7XB_\ !/A?%_@?XQ> M7@\ M0Z?X:\)/B3I_ANYMM,\#Z-:R%KYC=W,<;&6\M_,L%2,%)%O'!?("D _2.BBB@ H MHHH **** "BBB@ HHHH **** "O"_P!K#_DMGP/_ .Q[E_\ 29J]TKPO]K#_ M )+9\#_^Q[E_])FH ]THHHH **** /CK_@HY_P E1T+_ + _P#1\E?/%?0_ M_!1S_DJ.A?\ 8 '_ */DKYXH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "OT8_9S_Y(/X1_[ %M_P"BQ7YSU^C'[.?_ "0?PC_V +;_ -%B@#M**** M"BBB@ HHHH **** /A']N7_DX[5_^O2T_P#1"5Y#7KW[>C[C\SH M.ZG) Z=,'YW \<8/$5U3KTW33ZWNOGHK?B?L/$_T7N(\GRJ>+RS&1Q4X*[I\ MCIR:6ZA[TU)]D^5OI=V3^O**;')'-<,@9'4%64Y!!Z$4ZON#^7VFG9A111 M0(**** "OU"T+_D!V?\ UZ1_^@BOR]K]0M"_Y =G_P!>D?\ Z"* +5%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E7QQ^-OQT^&_ MQM^%GPY^&7[+&I^./#?C;5[ZU\<>-++7X+6'P5!# LD-Q-#(I:Y$S,ZA49=O ME'DLR(WJM?+_ /P4C_:(_P""A_P&N/ASIO[ /[)_AGXJWOBW6K[3==MO$7B, MZ:NFM':-=02^865!&R0708L1\XB49+XH \R_;M_;^_:[\%?M):_^QM\+/^", MNI?M!>'(/"^F:Q=ZR/'-C:Z?SN4VEV)$0?"A@*X/X M_MN_MV> ?B1X#^"<'_!!G_AG?P+XJ\>:?9>(O&.F>+])O+#3HI90"7M-/M8P M'F;9 )'("F8$9;:*LC]K3_@Y6$IG'_!(WX/;V4*S_P#"Y+;) S@9\_IR?S-: M'@7]J3_@OGX@^,'@+PY^T?\ \$\OA_X"^'VH^.=,M_&/BOPQ\0(-6O+*S:<8 M"P+,3MDE$43N%;:DC'"_?4 _1"BBB@ HHHH **** "BBB@ HHHH **** "O" M_P!K#_DMGP/_ .Q[E_\ 29J]TKPO]K#_ )+9\#_^Q[E_])FH ]THHHH **** M /CK_@HY_P E1T+_ + _P#1\E?/%?0__!1S_DJ.A?\ 8 '_ */DKYXH *** M* "BBB@ HILDD<,;332*B(I+,QP !U)-?(WQ]_:[\5^+]8N/#OPVU>;3-%A< MH+NV8I/>8ZON'S(A[*,$C[W7 \G-\YPF34%4K:M[);O_ ("ZL_0/#WPXX@\1 M\TEAV_/KNSFO9/@%^UWXK\(:Q;^'?B3J\VIZ+,X0W=RQ>>SST?F M#\[@>.,'B*ZIUZ;II];W7ST5OQ/V#B?Z+W$>3Y5/%Y9C(XJ<%=T^1TY-+?D] MZ:D^R?*WTN[)_7=%-CDCFC6:&171U!5E.00>A!IU?<'\P--.S"BBB@04444 M%?HQ^SG_ ,D'\(_]@"V_]%BOSGK]&/V<_P#D@_A'_L 6W_HL4 =I1110 444 M4 %%%% !1110!\(_MR_\G':O_P!>EI_Z(2O(:]>_;E_Y..U?_KTM/_1"5Y#0 M 4444 %%%% '!_M.:S>:%\!_$E_8.5D:R6#*]0LLB1-_XZYKX3K]#OB+X.M_ MB!X&U7P9=2!%U&R>))",B-\91\=\, ?PK\__ !)X/*-98NE6^QRV^=VW]Z:^X_N#Z*>9Y;+A_'Y>FEB M%551KJZ;A&,6NZC*,K]N97W11HHJ]X;\.:SXNUVU\->'K%[F]O)A';PH.23W M/H .2>@ )-?!QC*$5J52M5E M!;>[*'/A9J%SK>M7UCXTF^*5A?R6NGQ M"T:XMKGS+*56ACS;S0L2C[I+BW4;'=5\.B[NO$5F\""UBM9CS;-'(')(*YWJ22$,;@'QK_QU>_] M60?^7-5_P&O_ ;6AK7V(3#[OVOY/ M(\SR_.QSY6_/R;ZZ_P#;%^#'_!<7XC?M;:T/V*/VU_ WP[^%:>%M+N=-@\4^ M +74ICJ3M:?X\TJ;Q?X6\/>!+?1KN^MOM"J@2X$*DA9FA_C;X9_9W^%6L?%WQ=X=\1ZK8:-9RW,]CX4\.W&IWLJQQM(0D, M"L1\J'YG*H#C+#(KD/V!_P!LKP/_ ,%!/V2_"7[7_P -?"VJZ+H/C);V33-- MUSR_M<45O?7%H#*(F9%9C 7VJS ;L9.,UW7QI ;X.>+589!\,W^0?^O>2OCG M_@V=_P"4'GP'_P"P9K7_ *?=1H ^[*^3-7_X*R>"KCPAX[^//PN^ 7B[QG\' MOACJ]YIWC7XG:)/:>3NLCC4+C3[1Y1/J%K:?-YTR!0?*E\@3E,'U+_@H9\0O M$_PD_8#^./Q6\$W4D&M>&?@_XFU72)X6P\=U;Z5,@Z#)'' M>"_V^Q:_&WP7\ OVEO@%X@^%.N?$VPN;GX=-KVJV-[;ZK-;QK+/ITLEI*ZVN MH)$PD\AMR.H?RY9&1E'X@?L]?%GQ[\6?^":'_!,#X">,]0N+CP_J/[7WV74! M,Y(N[;3]@$2\?**_1+_@Z(\1:A\.?V9_V?OC/X5D:#Q%X M2_:N\*7VA74)Q()1;Z@QC!')#;%RO?:* /L;X^?ML^'/A1\=?#?[)WPW^'^I M>/OBIXIT2XURT\(Z1>06R:;H\$@BDU._N9V"VML966%" \DLK;41L.RZG[*? M[87P^_:KMO%>B:/HFI>'/&'P^\1/H/Q!\#Z]Y7V_0K\*)$#&)WCF@FB998;B M-F26-L@A@Z+\1?\ !.36]5^)G_!Q+^W-XT\52L]QX3\.^$/#>A12'/V:P:U\ MQD3/17D@$I'0M(33_P!G/Q%J'A;_ (.J/V@_A]H4C1Z7XL_9MT37=?AC.%EO M[*?3;2WD<="RP7$B@GG#'WH _32BBB@ KPO]K#_DMGP/_P"Q[E_])FKN/B#^ MT]\ /A5XC;PE\1/BII>D:DD*2M9W*^@/^"AFJ:?JOQ-T2;3KM)E70@K,AZ'SI.*^?Z "BBB@ HHH MH X3]IO6;W0?@/XDO[!RLC62P97J%ED2)O\ QUS7PE7Z'?$7P=;_ ! \"ZKX M,N9 @U&R>))&&1&^,H^.^&"G\*_/_P 2>'-9\(Z[=>&O$-B]M>V/*-98NE6^QRV^=VW]Z:^X_N#Z*>9Y;+A_'Y>FEB%551KJ MZ;A&,6NZC*,K]N97W11HHJ]X;\.:SXNUVU\->'K%[F]O)A';PH.23W/H ,DD M\ DU\'&,IR48J[9_5=:M1PU&56K)1C%-MMV22U;;>R2U;/M[]F36;S7?@/X M;O[]RTBV309;J5BD>)?_ !U!7>5B_#KP=;_#_P "Z5X,MI XTZR2)Y%&!(^, MN^.V6+'\:VJ_H# TZE'!4J=3XE&*?JDKG^2/%&,P>8\38[%X16I5*U64%M[L MIR<=/1H****ZCP@HHHH *_1C]G/_ )(/X1_[ %M_Z+%?G/7Z$?L]^*?#UK\# MO"EM<:M"DB:%;JZD\@[!Q0!Z)16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 M:5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^ M&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 'Q'^W+_R<=J__ M %Z6G_HA*\AKUC]MF^M-1_:&U:[L9UEC:UM0'7H<0)7D] !1110 4444 %<5 M\6?@%\.OC'"LGBC3GBO8DVPZE9N$F1?[I)!##V8'&3C&:[6BL<1AZ&*I.E6B MI1?1GI93G&:9#CX8W+JTJ56.THMIKNM-T^J>C6C1\Z?\.^-'^V;_ /A:%S]G MS_JO[*7?C_>\S'_CM>K?";X!?#KX.0M)X7TYY;V5-LVI7CAYG7^Z" H]E S M@9SBNUHKSL)D.48&K[6A22EWU=O2[=OD?7\0^*OB#Q5@/J69YA.=)[Q2C!2_ MQD?_ *"*_+VOTPT/ MQ?X971;-6UF$$6L8(S_LB@#)IUUXH%R9TU&\ENR-TAM[B*.%HAN$:SV[$1^ M:#*W1O\ @CS\3/@%\6_AW\;_ !'_ ,%=_P!H7Q]8>&/B%I%S/X+^*WCEK[2= M69[E($C,:*O[U6EWQY##>BYV_?7F/VP_V!_@W^VG_P %2O&0_;[_ &L_%.B^ M$=&\!:-)\%_"7ASXC+HMI%O$JZPTP5MWVH3"T?G87AN8N9!'B)W@O_@D+_P2 MO_9P^.'PS^-?P>_:H\47'C'0?B+I4OAG2]:^+C:U#J,\DPA>W%H[,78PRRL& M7!CV;R=BN" ?IM1110!P_P"TGXCE\,_ OQ3=VGA?6]:NKC0KNVL=*\/:1->W M5U/) ZQQJD2G&6P-[;47/S,!S7R[_P &]WP_^*GP)_X)8_#;]FGX[_"/Q/X, M\:>![?48-=TCQ%HTD"_O]5O;B%X9L&*<&*1"=C$H3A@N1G[:HH ^1O@5^V9X MM_;3^/\ \>>33YKR(")/)5 M]RL@5I5993A\HPKP[]F3P9^V!^PA_P $UO$__!+JP_9_\7^,/B)X;M]?\.?! M_P 6Z3I6=#U_3;^:XDT_4[K4,_9].%L+K;/!.R2_Z,?*6;>A;[]\"_!CPGX% M\::_\2X[F^U3Q)XE\F+5-=U:=9)S:0-*UM91A%5(;>'SI=D:*H+2R2/ODDDD M;K: /S2^,/\ P1.\5?#7_@E)\!_V>/V:+NPU?XK?LQ>+](\?>$)IIA;0>(== MMKM[R_M?-D_U,=S+-,8R_"LD "#\$/&OA M#X7?"SXAVWQ%^)5]X_\ #[Z5+?/%FV6,?)-(S*M M??=% 'PWXG_9W\<_L7?\%;_%'_!0KP;\.]?\3_#GXV_#ZTT/XF6WA+2)=1U' M0M>TTQK8ZA]C@#3W%K+:H8&$$'OA[X1U4I]OTGPSI]O%&)KM49A%->31)<&#<6A54#X'4-<\(:7>W!4*9[O3XY'('0;F4G%>&?M.>#?"&A?& MWX)MHGA33;,R^.9!*;6QCCW@6[$ [0,\\U]#UX7^UA_R6SX'_P#8]R_^DS4 M>W?V=I__ #XP_P#?H4?V=I__ #XP_P#?H5-10!#_ &=I_P#SXP_]^A1_9VG_ M //C#_WZ%344 ?''_!1>"&#XH:&L$*H#H()"*!_RWDKYZKZ'_P""CG_)4="_ M[ _]'R5\\4 %%%% !1110 5Q7Q9^ 7PZ^,<*R>*-.>*]B3;#J=DP2=5_NDD M$.OLP.,G&,UVM%8XC#T,52=*M%2B^C/2RG.,UR''PQN75I4JL=I1;3\UINGU M3T:T:/G3_AWOI'VS?_PM&Y^SY_U7]E+OQ_O>9C_QVO5OA-\ OAU\'(6D\+Z< M\M[*FV;4[U@\[K_=! 1?90,X&83G2>\4HP4O\7)&/,O*5]=0HHHKUS\^"BBB@ HHHH *_1/] MG:QLI/@3X2=[.)B=!MB28P2?D%?G97Z,?LY_\D'\(_\ 8 MO_18H Z[^SM/_ M .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B M@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA M_P"_0J:B@#X/_;ABCA_:,U:.*-546MIA5&!_J$KR.O7OVY?^3CM7_P"O2T_] M$)7D- !1110 4444 %%%% !1110 4444 %%%% !1110 5^GFA:?8'1+,FQA_ MX]8_^60_NBOS#K]0M"_Y =G_ ->D?_H(H D_L[3_ /GQA_[]"C^SM/\ ^?&' M_OT*FHH A_L[3_\ GQA_[]"GQ6UM 28+=$)ZE$ S3Z* "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** /DO]IK_@B-_P3E_;-_:>U7]JG]J7 MX V?C'7=3\+Z=HP@N]1O+:*'[)))HY[AXW2 M2,NAW*<;MPP5%1?M@?\ !9'0/VR"HXOP+_ ,%E?VFOB5\9? 7PFU'_ M ()'?'7X:Z;XM\9V&DZIXZ^(NAB#3-*ADD&XL8]V7D"F%-S* \J'+'", ?H% M1110 4444 %%%% !1110 4444 %%%% !7A?[6'_);/@?_P!CW+_Z3-7NE>%_ MM8?\EL^!_P#V/*^A M_P#@HY_R5'0O^P /_1\E?/% !1110 4444 %%%% !1110 4444 %%%% !111 M0 5^C'[.?_)!_"/_ & +;_T6*_.>OT8_9S_Y(/X1_P"P!;?^BQ0!VE%%% !1 M110 4444 %%%% 'PC^W+_P G':O_ ->EI_Z(2O(:]>_;E_Y..U?_ *]+3_T0 ME>0T %%%% !1110 4444 %%%% !1110 4444 %%%% !7ZA:%_P @.S_Z](__ M $$5^7M?J%H7_(#L_P#KTC_]!% %JBBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHKRKXX^$OVO->^-OPLUWX!?%OPOH'@/2=7OI/ MBWH>MZ&UU>:[9M"@M8K.4?\ 'NZ2"0L49-\$EOY@4K%G5\-_M6_\ !-?!:WLS:C(US%=6T;I$[,$%O%,6EI_ MZ(2O(:]>_;E_Y..U?_KTM/\ T0E>0T %%%% !1110 4444 %%%% !1110 44 M44 %%%% !7ZA:%_R [/_ *](_P#T$5^7M?J%H7_(#L_^O2/_ -!% %JBBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKXI_X*T-JW MBOXD? ;X2>-O@]8>)_AUK'Q"EN=5L]5\;Q:/9ZUJ\&F7TEAI5RSH0T196N1& MQVS26T<1#9*L ?:W3K6!X(^*WPN^)LE]%\-_B3H'B!M+G\C4UT/6(+LVDO/R M2^4S>6W!X;!X-?D%_P %"/VV?VJ_VW?B!:?\$*O^"=OP7T7P5K%YIXN/BSK/ M@3QI:7-IX:\-)GS].6>VA2&SFERB,OI-'$0/.;;VMC^POX;_ ."9>M_"/XO? MLC_\$\+7X<>++#QUHGA5]3L_C4+F;QG9ZC<):75AJ$;Q;+HLC/=B0J#!):K( MNU$*$ _6>BH-+GOKK3+>YU.P%KY?\ TF:O=*\+_:P_Y+9\ M#_\ L>Y?_29J /=**** "BBB@#XZ_P""CG_)4="_[ _]'R5\\5]#_\ !1S_ M )*CH7_8 '_H^2OGB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_1C M]G/_ )(/X1_[ %M_Z+%?G/7Z,?LY_P#)!_"/_8 MO_18H [2BBB@ HHHH ** M** "BBB@#X1_;E_Y..U?_KTM/_1"5Y#7KW[EI_Z(2O(: "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ K]0M"_Y =G_ ->D?_H(K\O:_4+0 MO^0'9_\ 7I'_ .@B@"U1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 5QWQ]_9\^"G[4OPHU7X'?M#?#32O%WA/6XE34]$UBW\R*7:P M9&&,,CJP#*ZD,K %2" :[&B@#QC]C?\ X)Y_L7?\$_/#>I^%/V//V?M&\$6N MM7"3:Q-9/-<7-ZR A!+VT#<&?VI M_'?AO6]6\8^#+B2X\*27_C;5Y--TJ>2U>U>>#2S=?8$E,,CJ9!!ORV[.[YJ] M4HH **** "BBB@ HHHH **** "BBB@ HHHH *\+_ &L/^2V? _\ ['N7_P!) MFKW2O"_VL/\ DMGP/_['N7_TF:@#W2BBB@ HHHH ^.O^"CG_ "5'0O\ L #_ M -'R5\\5]#_\%'/^2HZ%_P!@ ?\ H^2OGB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH *_1C]G/_D@_A'_L 6W_ *+%?G/7Z,?LY_\ )!_"/_8 MO\ MT6* .THHHH **** "BBB@ HHHH ^$?VY?^3CM7_Z]+3_ -$)7D->O?MR_P#) MQVK_ /7I:?\ HA*\AH **** "BBB@ HHHH **** "BBB@ HHHH **** "OU" MT+_D!V?_ %Z1_P#H(K\O:_4+0O\ D!V?_7I'_P"@B@"U1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %? M'7[6_P#P6&T+]F/XYZI\"/ ?[ _[1_QKN] @MQXDUSX+?#-M:TW2;V:)9UT^ M><2H%NA;RV\[1X.([F(YRQ ^Q3G'%?D9\;?@5_P6H_X(UVOC+]M?X(?M8:-^ MT7\,3XCU'QC\5_A3K_@N/2;Z.&XF:>]N[&>.2:3]TFXC]X%CCC4>3*L>T 'Z M&_$3]N#X6? W]C2+]M?]HSP[XA\ :(?#]IJ5WX9\0Z0VY'4/Y)YH+A0C3VX-G)!!,H)&[9>RAD.0'7U45V?\ P=$>(M0^ M'/[,_P"S]\9_"LC0>(O"7[5WA2^T*ZA.)!*+?4&,8(Y(;8N5[[10!]C?'S]M MGPY\*/CKX;_9.^&_P_U+Q]\5/%.B7&N6GA'2+R"V33='@D$4FIW]S.P6UMC* MRPH0'DEE;:B-AV74_93_ &POA]^U7;>*]$T?1-2\.>,/A]XB?0?B#X'U[ROM M^A7X42(&,3O'-!-$RRPW$;,DL;9!#!T7XB_X)R:WJOQ,_P"#B7]N;QIXJE9[ MCPGX=\(>&]"BD.?LU@UKYC(F>BO) )2.A:0FG_LY^(M0\+?\'5'[0?P^T*1H M]+\6?LVZ)KNOPQG"RW]E/IMI;R..A98+B103SAC[T ?II1110 5X7^UA_P E ML^!__8]R_P#I,U=Q\0?VGO@!\*O$;>$OB)\5-+TC4DA25K.[D8.$;E6X!X-> M(?'+]I#X&?%/XX_!N#X>_$S3=6>P\;-)>+:2,?*1H"BDY X+$"@#ZKHK-_X3 M'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH TJ*S?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J# M_OJ@#Y,_X*.?\E1T+_L #_T?)7SQ7T!_P4,U33]5^)NB3:==I,JZ$%9D/0^= M)Q7S_0 4444 %%%% !1110 4444 %%%% !1110 4444 %?HQ^SG_ ,D'\(_] M@"V_]%BOSGK]"/V>_%/AZU^!WA2VN-6A21-"MU=2>0=@XH ]$HK-_P"$Q\,? M]!J#_OJC_A,?#'_0:@_[ZH TJ*S?^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJ@# M2HK-_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZH TJ*S?^$Q\,?\ 0:@_[ZH_X3'P MQ_T&H/\ OJ@#XC_;E_Y..U?_ *]+3_T0E>0UZQ^VS?6FH_M#:M=V,ZRQM:VH M#KT.($KR>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_4+0O\ D!V? M_7I'_P"@BOR]K],-#\7^&5T6S5M9A!%K&",_[(H W**S?^$Q\,?]!J#_ +ZH M_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_T&H/^^JL:?K>DZJ[1Z=?QS,@RP0]!0!: MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@#/\6:GK6B^%=3UGPWX!7QSH/[:?[4W[;7[/>O_!K1?^":WQ6^&'C[Q)H]WHFI3_$ZQM8/#N@F>-X7 MO3>>#S)6 0B)&,R_:U% 'P?^WQ_P2HU;7_V!/@M\*/V0H8[O MQS^RQX@\,^)?A1!JMTD!UJ;151&LIIC\L;7,:EMYPOG+'N*KN(J?M;_!_P = M_P#!6WXU_L_>"#\$/&OA#X7?"SXAVWQ%^)5]X_\ #[Z5+?/%FV6,?)-(S*M??=% 'PWXG_9W\<_L7?\%;_%'_!0KP;\.]?\3_#G MXV_#ZTT/XF6WA+2)=1U'0M>TTQK8ZA]C@#3W%K+:H8&$$'OA[X1U4I]OTGPSI]O%&)KM49A% M->31)<&#<6A54#X'4-<\(:7>W!4*9[O3XY'( M'0;F4G%>&?M.>#?"&A?&WX)MHGA33;,R^.9!*;6QCCW@6[$ [0,\\U]#UX7^ MUA_R6SX'_P#8]R_^DS4 >W?V=I__ #XP_P#?H4?V=I__ #XP_P#?H5-10!#_ M &=I_P#SXP_]^A1_9VG_ //C#_WZ%344 ?''_!1>"&#XH:&L$*H#H()"*!_R MWDKYZKZ'_P""CG_)4="_[ _]'R5\\4 %%%% !1110 4454UG6;/0[,WEX_L MB#JY]!6^%PN(QN(C0H1R1;HKSW_A,M9_ MMG^U_-]O(S\FS^[_ /7KM]&UFSURS%Y9O[.AZH?0U]9Q-P-G/#&'IUZ]I0DE M=QVC+^5_H]F?(\+\>9+Q3B:N'P]XSBW92WE'^9?JMT6Z***^,/M@HHHH *** M* "OT3_9VL;*3X$^$G>SB8G0;8DF,$GY!7YV5^C'[.?_ "0?PC_V +;_ -%B M@#KO[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ* (?[.T_\ Y\8?^_0H_L[3_P#G MQA_[]"IJ* (?[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ* (?[.T_\ Y\8?^_0H M_L[3_P#GQA_[]"IJ* /@_P#;ABCA_:,U:.*-546MIA5&!_J$KR.O7OVY?^3C MM7_Z]+3_ -$)7D- !1110 4444 %%%% !147V^S^V?V?]I3S]F[RL\X]:EK2 MI2JTK<\6KJZNK73V:\O,SIU:56_)).SL[.]FMT^S78****S- HHHH **** " MOT\T+3[ Z)9DV,/_ !ZQ_P#+(?W17YAU^H6A?\@.S_Z](_\ T$4 2?V=I_\ MSXP_]^A1_9VG_P#/C#_WZ%344 0_V=I__/C#_P!^A3XK:V@),%NB$]2B 9I] M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 5X7^UA_R6SX'_P#8]R_^DS5[I7A?[6'_ M "6SX'_]CW+_ .DS4 >Z4444 %%%% 'QU_P4<_Y*CH7_ & !_P"CY*^>*^A_ M^"CG_)4="_[ _\ 1\E?/% !1110 4444 17]U]ALY;SR7D\M"VR,9)KS?6= M9O-7C^R(.B#T%>FUR?C+P;]_5](B]YX%'_CP_J*_5?"S.LCRO-)4L9!1 MJ5-(5'LO[O\ =YOYODS\F\5\DS[-C M:S>:'>"\LW]G0]''H:J5UG@WP;]S5]7B]X(&'_CQ_H*_/S M$#;)!@BI:**_CRK*$ZLI0CRIMV5[V717ZV[G]FTHU(4HQG+FDDKNUKOJ[=+] M@HHHK,T"BBB@ K]&/V<_^2#^$?\ L 6W_HL5^<]?HQ^SG_R0?PC_ -@"V_\ M18H [2BBB@ HHHH **** "BBB@#X1_;E_P"3CM7_ .O2T_\ 1"5Y#7KW[7 MUS7[?Q?PAEG$F6TIWJ0J/WX;N M3?5?W^SZ[,]2HJ*P^V?8X_[0V>?L'F^7TS4M?R35I^RJRA=.S:NM4[=4^W8_ ML"E4]K2C.S5TG9Z-7Z-=&NH4445F:!1110 5^H6A?\@.S_Z](_\ T$5^7M?J M%H7_ " [/_KTC_\ 010!:HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KPO M]K#_ )+9\#_^Q[E_])FKW2O"_P!K#_DMGP/_ .Q[E_\ 29J /=**** "BBB@ M#XZ_X*.?\E1T+_L #_T?)7SQ7T/_ ,%'/^2HZ%_V !_Z/DKYXH **** "BBB M@ HHHH R?^$-T;^V?[7\KW\C'R;_ .]_]:M:BBN_'9IF&93E*RM=OJ_ZLN@4445P'H!1110 4444 %?HQ^SG_ M ,D'\(_]@"V_]%BOSGK]&/V<_P#D@_A'_L 6W_HL4 =I1110 4444 %%%% ! M1110!\(_MR_\G':O_P!>EI_Z(2O(:]>_;E_Y..U?_KTM/_1"5Y#0 4444 %% M%% !6-XK\*0Z[#]HMP$ND'RMV<>A_P :V:*]'*LUQV2XZ&+PD^6GT:?1KHSRW[!>?;/[/\ LS^?OV^5CG/I7<^%/"D. MA0_:+@![IQ\S=D'H/\:U/L%G]L_M#[,GG[-OFXYQZ5+7W7%OB1CN(\##"48^ MR@TO:6?Q/M?^3RW?4^!X0\,\!PUCYXRO/VLTW[.ZTC'O;^?SV70****_-#]/ M"BBB@ HHHH *_4+0O^0'9_\ 7I'_ .@BOR]K]0M"_P"0'9_]>D?_ *"* +5% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %>%_M8?\EL^!__ &/Z5 MX7^UA_R6SX'_ /8]R_\ I,U 'NE%%% !1110!\=?\%'/^2HZ%_V !_Z/DKYX MKZ'_ ."CG_)4="_[ _]'R5\\4 %%%% !1110 4444 %%%% !1110 4444 % M%%% !7Z,?LY_\D'\(_\ 8 MO_18K\YZ_1C]G/_D@_A'_ + %M_Z+% ':4444 M %%%% !1110 4444 ?"/[U^H6A?\@.S_ .O2/_T$4 6J*** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH *\+_:P_Y+9\#_ /L>Y?\ TF:O=*\+_:P_Y+9\#_\ L>Y?_29J /=* M*** "BBB@#XZ_P""CG_)4="_[ _]'R5\\5]#_\ !1S_ )*CH7_8 '_H^2OG MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_1C]G/_ )(/X1_[ %M_ MZ+%?G/7Z,?LY_P#)!_"/_8 MO_18H [2BBB@ HHHH **** "BBB@#X1_;E_Y M..U?_KTM/_1"5Y#7KW[EI_Z(2O(: "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ K]0M"_Y =G_ ->D?_H(K\O:_4+0O^0'9_\ 7I'_ .@B M@"U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110!\E?%C]LSXJ?%G_@HC_P[4_95\1:5H&H> M%O 8\7?%CQ[J.D_V@^CP32I%8Z79V[.B&[FWB=I)=T<< X1W<;-7]AO]MKQE M\5?V@_C%^PG^T.FEK\4O@IJ=DUUJFBVC6UGXFT*_@6XL-4B@=W,,FQO*N(@[ MJDH!5L2!%^8_^"9=GJ%C_P '#/[?B>+PPU66R\%RZ<91\S6)T_Y"OJH3[../ M0#M3O@"NIWW_ =@?'2\T<,=-L/V7=+MM:9/N"\>\TJ2 -C^+RA(1GL#0!^G M5%%% !7A?[6'_);/@?\ ]CW+_P"DS5TGQ6^//Q*^'WBY_#GA?]F7Q1XIM%@2 M0:MI,\*PLS#E,.O#_P!H+XN_M ^,];\'_$?2?V*O';2>!=8DU7^S$:!W MU#,101*5)*'GKM;Z4 ?8%%?'/_#RG]K+_I$_\4__ +'_P CT?\ #RG]K+_I M$_\ %/\ \"Q_\CT ?8U%?'/_ \I_:R_Z1/_ !3_ / L?_(]'_#RG]K+_I$_ M\4__ +'_P CT +_ ,%'/^2HZ%_V !_Z/DKYXKI/VCOCO^UE^T#XIL?$O_#M MWXIZ1]BT_P"S>3]E%QO^=GW9V)C[V,8/3K7G?E_M9?\ 1A'Q3_\ !,/\: .@ MHKG_ "_VLO\ HPCXI_\ @F'^-'E_M9?]&$?%/_P3#_&@#H**Y_R_VLO^C"/B MG_X)A_C1Y?[67_1A'Q3_ /!,/\: .@HKG_+_ &LO^C"/BG_X)A_C1Y?[67_1 MA'Q3_P#!,/\ &@#H**XO7O%W[1OAK4M,TC7/V)OB-:7.L71M]-@NM/5'NI0N MXI&#]]L4_M9?](G_BG_X%C_Y'H ^QJ*^.?^'E/[67_2)_XI_^!8_^1Z/^'E/[ M67_2)_XI_P#@6/\ Y'H ^QJ*^.?^'E/[67_2)_XI_P#@6/\ Y'H_X>4_M9?] M(G_BG_X%C_Y'H Y?]N7_ )..U?\ Z]+3_P!$)7D-7_CG\4?VLOC1\1[OX@?\ M.Z_BGIOVJ*%/LGV 3;=D83._:N]:GE_M9?]&$?%/_ ,$P_P : .@HKG_+_:R_Z,(^*?\ X)A_C1Y?[67_ $81 M\4__ 3#_&@#H**Y_P O]K+_ *,(^*?_ ()A_C1Y?[67_1A'Q3_\$P_QH Z" MBN?\O]K+_HPCXI_^"8?XT>7^UE_T81\4_P#P3#_&@#H*_4+0O^0'9_\ 7I'_ M .@BOR=\O]K+_HPCXI_^"8?XU]0V'_!2#]K*RL8;+_AU%\4V\F)4W?:@,X&, M_P#'O0!]ET5\<_\ #RG]K+_I$_\ %/\ \"Q_\CT?\/*?VLO^D3_Q3_\ L?_ M "/0!]C45\<_\/*?VLO^D3_Q3_\ L?_ "/7J?[*G[5GQG_: \4ZGH'Q-_8R M\8_#.VL=/%Q;:GXDG#17/?"_BF>>VTWQ3I0F6>VD-S;QRO: M7=O*@VS>3,'B8Q%5 5AJ?L5_L/S_ +._Q(^*7[3WQ9\56/B3XM?&G7;74/&V MM:;9M!965I:0"VT_2K-)&9_L]M"-OF.=\SEG8+E43Z%HH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@#PO]K#_DMGP/_P"Q[E_])FKW2H+O2],O MYX+F^TZ":2UDWVTDT*LT38QN4D?*<=Q4] !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% 'A?@'_ )2">/\ _L1-*_\ M1C5[I4$>EZ9%J$FK1:= MW+&$ENEA42.HZ*6QD@>E3T %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 445B_$F#Q-<_#K7[;P5(4UF31;I=)=6P5N3"PB.>WS[>: /C[X6_MX?'S M_@H[^T3\1/A7^P1XB\.^$OA=\)==/A[Q;\8M=T)M7N->UU1NFL-'M1-%"D4 MV^9=SF0-YB".$JPEK/\ VC?V[?VD?^"4_P 2_ VH?MT^,O#_ ,0/@;\0/$<7 MAUOBCI/ALZ/JO@S5959H/[2MTFDM[JRD6-SY\2PM%L?T ?37[8'C_XB_"C]DOXH_%+X/V5K<^+?#7P M[UO5?"]O?0F2&74;>PFFMED0$%D,J("H(R"1D5\P?"+]J;_@I1^T9_P3]^ . MM?!/PEX'A^,/Q;^'L/B3Q+XS\66-RGA[PY8>5 _VHVT!,DUU.+JW$-L&5"?. MF7.BZM:)<6MY \%S!(,K)&ZE64^Q!(_&LSP5X.\%?"#X= MZ3\/_!^GPZ1X<\+Z+;Z?I=H9V,=E96T*QQ)OD8G:D:*-S$G"Y)/6@#X&_9"_ M;R_X**?!3_@I79?\$O?^"G>D^!O$E[XX\(W?B/X5_%#X=6$UG!J"6P=[BTNK M>0D(ZI'*<@*4**#Y@E5U] _:8UW_ (+0?'/QEXFOOV ]8^$7PZ\'^%=0N-.T M23XF:3>7NI^,+VV)2XDVQCR["R\]7@B8AY9/*:;Y8WCSL?L__":/]K?]O.X_ MX*=Z_I[1^$?#'@N3P;\"8IXRKZG:SS^=J/B/!Y6*Y8);VO\ ?MHFGQMN(R/? M/VD_C[H_[.WPSE\8S:#=:]K=]<+IW@_PCIK+]M\1:M*K?9["W!X#.59GD;Y( M8DEFD*QQ.R@'A?\ P1P_X*(^//\ @HS^S#K/C/XU_"N'P7\2/A[X[U'P3\2? M#UD[-:PZQ9")I6@W,S",B9/D+,4=77*]3\:_%'6=/0K;WWB/5)O/O&B!Y\F/Y((R0"8X$8@,2*^@* M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK%^),'B:Y^'6OVW@J0IK M,FBW2Z2ZM@K'?"7PN M^$NNGP]XM^,6NZ$VKW&O:ZHW36&CVHFBA2* ;?,NYS(&\Q!'"582UG_M&_MV M_M(_\$I_B7X&U#]NGQEX?^('P-^('B.+PZWQ1TGPV='U7P9JLJLT']I6Z326 M]U92+&Y\^)86BV/N1_D#^)?\&=USI7_#I_5]'AB,6JZ?\8M;A\00R*5E2[^S MV+8D!Y#>4T0Y]/:NV_X.Q)/#:?\ !$[XA)KGE_:G\1^'5T8/U-S_ &K;EMOO MY G_ S0!]O?M4^//C+\-OV?/%'Q$_9_\,>&M:\1Z/H=W?V-IXJU6>ULF$5O M)+EFMX9'D)*J @V AB?,7'/F'_!(+]J[XH_MQ?\ !.+X8_M6_&F+2X_$_C/3 MKV[U6+1;1H+6-DU"ZA1(D9G95$<2#EF)QDDDYK3^'&E>.-"_X)8Z#HGQ-CG3 MQ)9_L_VL'B%;G/F"^30U6_\H2O@'_V+^H?^G:]H ^F MOVP/'_Q%^%'[)?Q1^*7P?LK6Y\6^&OAWK>J^%[>^A,D,NHV]A--;+(@(+(94 M0%01D$C(KY@^$7[4W_!2C]HS_@G[\ =:^"?A+P/#\8?BW\/8?$GB7QGXLL;E M/#WARP\J!_M1MH"9)KJ<75N(;8,J$^M 'P-^R%^WE_P44^"G_!2NR_X)>_\ !3O2? WB M2]\<>$;OQ'\*_BA\.K":S@U!+8.]Q:75O(2$=4CE.0%*%%!\P2JZ^P?MAV7_ M 6$^(6I^(+_ /86\7?"OP#I/AN-DT"R\>Z%/J=_XQND0,Y:2.58M-M2Y,4> M5DEOZ>T?A'PQX*D\&_ F*>,J^IVL\ M_G:EXCP>5BN6"6]K_?MHFGQMN(R/3_V^_@_^U[\=?V=->^&7[&7[1V@_##Q1 MJNF7%L/$.L>%I-1DPZ;0D$J7"?8F(W S^5.R;@R(&4$@'-?\$COVW_%W_!1; M_@GYX _:X\?_ \B\,:YXDM[R#6-+M-_V4W-I>36DDUOO);R9&@+JK%BNXH6 M?;N/TC7Q!_P0(_:7^)7QS_8GU+X/_&KX1:%X*\9_ /Q[J'PN\2Z1X7LUM]-> M?2XX-LMO$ORQ@I,BL%.TNC.H5751]OT %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'P_XD_8.^.G[ _Q MI^)_[9/_ 3!T?1O$,7Q'?\ MCX@_L]^);XV%CK>KIN8W^DZ@H8:;=R[G#QR MQR03,_)BVH5\$_9&^*,'_!?CX["']N[PV/AFW[.OC5-5?]DR^AE-_/JB(!:: MSJUS<)$U[:Q^9(D<$5O$@\1>&=>_P"$&MI[?2O$7AR6X3[?%-=W%R?-@FC'DLGFJH*R.'Y. M$Q@_25C9Q:?90V%N\K1P1+&C3SO*Y"C +.Y+.>.68DD\DDU+0 5\H?\ !43] ME[]OO]K;PSH7PO\ V3?CQ\/?!7A5;D7/C:S\8>'[K4'\0A&S'82I$RI]B. 9 M8CGS_P#5OF(R1R_5]% 'Q1\!?V9O^"TZ?&GPGJ7[5W[?GPWU+X\- M?#OX?/I=]JPBC8V]L;ERQC@\\0M(JX\R-&C.5=@>0^,_[%G_ 6S\8_M=ZY^ MTS\+_P!M#X(Z-:"WDTSP-H>M?#^\U'_A'-+9\ND+.X N)]L;7$X :0QHHVQQ MHB_H-10!\_?L)_!C]N_X:P^*O$_[?/[4NA_$;Q!K%S:PZ#:^$?#YTO2M(L8$ M6GEEFD,DC%B5CA4'"X'T#110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% 'P_XD_8.^.G[ _QI^)_[9/\ P3!T?1O$,7Q'?^V/B#^SWXEO MC86.MZNFYC?Z3J"AAIMW+NWTKQ%X%5N1<^-K/QAX M?NM0?Q"$;,=A*D3*GV(X!EB.?/\ ]6^8C)'+]7T4 ?%'P%_9F_X+3I\:?">I M?M7?M^?#?4OASHVI"\U[PU\._A\^EWVK"*-C;VQN7+&.#SQ"TBKCS(T:,Y5V M![[_ (1S_@KSI'QS\8#3OB9\ ]7^&^J:D\O@N75] U:#6-!MV'RQ3Q02>3?; M.,_O86<@G=&&"K],T4 >6_LB?LK>$_V1_AC?>"M#UVYUO6?$?B?4?%'C?Q1? M0I%/KVNW\QFN[QXX_DB!;:B1+Q'%%&F6V[CZE110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\Q_MH_M"_?% M&P\.?#_Q?_9]E/H$5S+#_9]O+NE,\ZELR1L1PBC&<!4 >I_\ #:O[3/\ T4O_ ,HUE_\ M&:]=_8N_:%^,'Q9^*-_X<^('B_\ M"R@T"6YBA_L^WBVRB>!0V8XU)X=AC.. M?I7R?7OO_!.G_DMNJ?\ 8JS_ /I3;4 ?9]%%% !39IHK:%[B>0*D:EG8] , MDTZB@#S7X6_ME_LE?&[XD:G\'/@_^TKX'\3>+M%MFN-7\+Z)XGMKC4;*)656 MDEMT(SHOQR^"/P-\ M,^)_#VF6UN@C\6Q2:OK\%YIUQC!F>2W@CC0,=KJIA. ZO']!^"?^"D7P>_X* MD_\ !%KXS_&SP19C2]=L_A#XGTOXA>![ULW7A[5DTBY$UM*K %HVY:.0@;T/ M(5U=% /M;X9?%7X;?&CP?:_$'X2^.=+\2:%?*&LM8T:\2XMKA2H8-'(A*NI5 M@002"#6_7@\_[1_@W]F7]EOX4"^T"]UG7/%>GZ)X=\#>$=%$0NM:U*6Q$B01 MF5DCB1(89II)794CB@D8YP%/">'/^"GVK>&/VW=._P""?O[47[.-QX&\>^+? M"MSKOPRNM(\60ZOI/BN.W21Y[2.Y:*V>WNE$4A\N6-5(0G?RF\ ^LZ*_.[_@ MDS^W/^VS^U/^UK^T=I/QM^ 5O9Z3X9^,4GA>4V/C2":V\(0V-B$2U2-E#WC2 M2@R/+&%4O.Q "J%'V'^VO\.OBK\7_P!CKXJ?"CX&>(3I/C/Q+\.]9TOPKJ0N M/)^SZA/92Q0-Y@YB_>,O[P"]0_;!\"V]S:Z MFVFW-[<:VB:?%>JVUK5KYL6HG#?*8O-WAOEQGBO8/ 'Q \$_%3P=8?$+X<>* M++6]#U6'SM,U;3IQ+;W4>XKYD;CAU)!PPR".02#FORC_ ."1G_!6[]BF?]GC MP]_P1P_X*$_">R^"OQ&\$^&(/!6M^!?B)I26VC>)5CB$#.LDH$0EN?\ 6/'- MM\UYBT3S;\U]C>+?BA\'O^")_P#P3F\*:'XGLM4\0Z7X0;3_ CX.T?144W6 MK75S5[6UE@N M8P"Q4Q-&5!Q(!?AC>ZE:>)=.:)FD>W#RP2)$9< EWA[_ (*P? _XQ_"'X&_$3]F/2SXLU3]H MFZO+?X;Z)K&I+I4:R6-O//J'VZ?9-]G%M]GEB<11SNTNU8U=27 !]445Y'^S MC^T5\2/BW\0?'OPI^+7P#G\#:WX#N-/25UU]-1LM8BNX7E2ZLYA%$SP?NV3, MD<;[TD4HNWGUR@ HHHH **** "BBB@ HHHH **** "N<^)_Q>^%OP5\--XP^ M+?Q!TCPYIBMM%YJ]\D"N^,[$W$%V/95R3V%'Q>^)_AKX*_"WQ!\6_&$C+IGA MS2)]0O!'C>ZQH6V+GJS$!5':I+9=$N[_K4_9/"/PCQ MGB9C*M2I5]CA:-E.:5Y2D]5"">E[:MNZBFM'<_:?0O\ @JY_P3V\1:XOA[3_ M -IK2([AGV"2^L+RU@S[S30I$![EL5[[HVM:/XBTJWUWP_JUM?V-W$LMK>6< MZRQ3(1D.CJ2&4CH0<5_,I7V%_P $COV]/&7[-OQRTCX.>*M?FN/ /B[4X[*Y ML+B0M'IEW,P2*[BR<1C>563'!0EB"46OG\JXVJ5\5&EBX)*3M>-]/5-O3SOH M?KG'?T9,)E615WB:2>>>0(D:*,LS,> 22> !7A,7_!47_@G MW)=,M[U[234]#OTNK?SE569%E MC)1R ZYVDCG'4&NBKXG_ &:/CU^P#^RC^SM\9/&W[ 'C/0OBYX6TOQ%JGCN^ M\!_!O7-)NI-"CEM8)+R&(/>1PK'YL,UPJ;D*B<1QQML4-%^QU_P6%\:_MG7' MPB\7_#[_ ()^?$6V^&WQ-TJ_GU3XIS7]JVD^&[FU29V@FZ2/'F)8S<%8X_-< MQQF5HY H!]NT5\>WO_!4_P 9^+/V=M;_ &V?V=/V/M9^('P9T%KZ8^(;3Q/! M9ZSKFGV4LD=UJ6EZ9)$1=6RF*8H)KBWEF6,E(B&0MU^M_P#!3_\ 9_UC]G;X M2_M ? B[C\:0_'7Q)9Z!\+;+[VSW-K/JEJ+94@\Q%50+>>Y422*C.N02 ?3MW=VU MA:2WUY,(X88VDED;HJ@9)/X5X'KG_!5S_@F3X8UZ]\+>)?V__@]IVIZ;*\6H MZ=?_ !#T^&>T=3AEEC>4-&0>"& QWKZ K\I?V!_%_P -_!'_ <4_M[Q^._% M&B:1;W6A^$2JZO?0VZ3(-+A:8_O" P .6^N30!^GOPV^*7PR^,O@^U^(7P@^ M(NA>*] O@39:YX;U>&^L[@ X.R:!F1\'T)K=K\8/^",7BB]^'W_!1C]N;X[_ M +%OPXUWQ3^S-;ZDDOAO0O XM4L=8\0HZ&X.D?:IX+1@H^V$E)%3RFM@"080 M?J[]C7_@M=XP_;E\._"'XE?!#_@G7\3;[P-\2?$&HZ3XB\:Q7MH]GX0DM[JX MAC:X7(>96CACFDD55AC\\1)+-,KQ@ ^\:*^3X_\ @I1X^^*OPY\8?'K]CC]D MO4/BE\/?!6JW^GSZ[!XL@T^[\226#M'>OH=JT,@OXXY$DB5I9;8321,L7F#: MS4/BM_P41L/VB_\ @E)X@_;@_8&T6X\7Z?K'@76;B"=]7BTN[\.F&PNC--,L MF[]_;3Q!6A0DL<,C,N&(!V/Q,_X*V_\ !//X-^+[+PA\4_VB[?0AJ=_=V&E^ M(=1\.ZFF@WMY:EEN;6'6/LW]GS3Q.C1O"EP9%D4H5WC;7JW[-O[27P3_ &O/ M@EH/[1O[.GCJ+Q+X+\3P2S:'K<-G/;BY6.:2"3]W<(DJ%98I$*NBD%3Q7Y\? M\$OO$"ZA_P $//A=JO[1W_!/D>/?!GP^^'ECXH\.PQ7^CZK<:O=6KRSB[@M+ MV2%+>:,;Y 7D#G+*H8MM.U^TC_P54^)$/_! 2;_@HI^PY^SE:>&DU?PK=G2] M/N=4MX(O!]K]MEL!>+'&BB>56 >.&-0H9AN;:I#@'Z2T5XU^P7X]^+_Q"_9A M\(:Q\8_A5+X7O4\-:8MHT_B2'4WU.$V4+?:V>,#878G*-EL\D\U[+0 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% 'QA_P %%O\ DMNE_P#8JP?^E-S7@5? M#O&W@^X_X+1_$#P7;^*+"35X_P!FKPH\FFI=H9T":]K[-E C M#/PG_P %T_V%OCI^PSKOQ)_X*J?\$Z=$\S2/B!X(U3P]^TU\-+9&^RZK87=K M+"=>CB3I-"TOFRNHRK S$%'NMWZP67[/'[/^F^)$\8Z=\#/!T&KQW?VJ/58? M#-HMRL^[=YHE$>X/NYW9SGG-=9?6-EJ=E-INI6<5Q;W$317%O/&'25&&&5E/ M# @D$'@@T ?E/_P6@NH_@W\&/V,/VX/B/\&E\?\ PG^$GB.V_P"%L^'9M&CU M&*/3-3T>.S%]);2J4D$)W;=PQYLD0RI8$>X_LN_';_@B?^T#^T!X';_@GW\# M/@UXV\;HLNHMXC\$_#JSM;KP9IHMY-][<70LUDLG=S';) 2DTCW'W=B2LGW# M/X?T&YT)O"USHEI)ICVAM7TY[93 T!788C&1M*;?EVXQCC&*P?A9\#?@I\"] M,NM%^"7P?\+>#K.]N//O;3PKX?MM/BN)?^>CK;H@=N3\Q!/- 'YV_P#!&CXW M?"3X=?MZ_MK_ +/_ (W^(&F:;XY\1?M3:E?:#X1N+@?VEJ%I+;F1;F*W&9'A M"1N[2@;$4 LR@@G[Q_;-^.&J_LR_L@_%/]H_0]*AOKWP!\.]:\16EE<@^7<2 M65C-M=G:?#[P%8>,[OXCV'@C2(/$-_:I;7VO0Z;$M[<0)C M;%).%WN@P,*20,#BK^KZ1I/B#2KG0=>TNWOK&]@>"\LKR!98IXG!5HW1@0RD M$@@@@@X- 'PM^V3\._\ @B__ ,%COV))OCE\:_B%X#O/#-OXK6] MIJWA+,9-C\]G-E2Z[7C)Q7R%\"OVV_VNOV#/^#=OX"^,_CI#Y6I> M*_BIIWA32O'7CK16O3X-\*W-[<26FO7%M-S(8+>W4VRR?* ]J3N "/\ K7XM M_9%_9/\ '_CR+XI^._V8?AYK?B>"420>(]7\%6%S?QN.C+<21&0$>H;-=AXP M\%^#OB%X9N_!7C[PGIFN:-?Q>7?:3K%A'Y_ GQ-X=G_X.B?CCHD.NVC7B_LS:'$;5;A3) MO2]MY&7;G.0DD;$=0'!Z&OOZS^#WPDT^70)K#X6^'('\*121^%WAT2W4Z.DB MA76U(3_1PR@ B/:" :J6?[/WP&T[Q0/'&G_ 2\(P:TMV;I=8A\-VJW0G+% MC+YHCW[R226SG)SF@#\:O^"6O[07_!*;]E+P1X\_X)^_\%? KX%?LL^-?AD_[/MAXXUC7M=_9UUGP5'#X6O-%U"UFCDMY[:!(8EMI[ M^WN/M@MY$#' 5@MP%V_>?CO]GKX!?%+Q5IGCKXG? [P?XCUO12#HVLZ]X9M; MRZL"&+ PRRQL\6"21M(Y.:O?$3X0_"?XO::NC?%GX8>'?%%FB.B6GB+1(+V- M5?;O 69& #;5R.^T9Z"@#XC_ ."/GQ"_;H\#_M(?'C_@G]^U[\:;?XQZ?\&S MH1\+?&,6(AO;R*^@EF_LV_(+;[J)!&Y#,\B^82[NLD9'W]6'\.OAA\-?@_X6 MA\#?"7X>:'X6T2V9FM]'\.Z3#8VL18Y8K%"JHI)ZX'-;E !1110 4444 %%% M% !1110 4444 ?//_!5W0M;\1?\ !/;XFV'A^-VGCTBWNI!&,GR(+R":8_01 M1R$^P-?@C7]->M:-I7B+1[OP_KNGQ7=C?VTEO>6LZ!DFB=2KHP/52I((]#7X MK?MZ?\$COCG^S=XRU#Q5\&_"&I^+O -Q,TUA583$\/XZK&E4J M5/:TW)I*;<8QE"[TYERIQ7VKNVJ/CVM?P!H6M^*/'FB>&O#,;OJ6HZO;6NGI M&,LT\DJI&![[B*-"\ >//%&N+X8\,^"=7U'4F?8NG6.FRS3EO[HC12V?;%?I MC_P2;_X)-^.OAUXZL/VG_P!I_0/[,O-,_?>%/"EP0T\\?9#P-D-7&8RK'VG*_9T[KFJ M2M[J4=[7MS/9+5GZ64445^[G^504444 ?E?_ ,%Q?V?/C/\ L^?M\?L^_P#! M<3X(_#S5?&%C\'0V@?%G0-!MC/?P^&Y6NA)>P1+S((XM0OU?^Z7B8X02,GZ& M_"/]K3]F7X[_ 9M_P!H;X2?'?PMK?@FXLUNCXDM=9B%M;H5R1.S,/L[KR&2 M3:Z$$, 017H=>5^(?V%?V(_%OBYOB!XK_8Y^%>IZ\\WFOK>H?#W39KQI,YWF M9X"Y;WSF@#\O_P#@@>-)\-_\$/?VKO%EV(+'1[_XD?$*]L=2DQ';7-I_8MHB MSQR'"O%E&4."5RA /%>^_P#!)7PGJ_[0O_!M=X4^$GP@\46JZ]XB^"'B#P[I M=[#=+BSU.9;ZV0.P/R,DKJ3GD8K[^U_X<_#WQ7X7C\$>*/ FC:EHL0C$6D7^ MEQ36J!/N 1.I0;>W'':H_ _PN^&?PQ@N+7X;?#O0O#T5VZO=1Z'I$-HLS*"% M+B)5W$ G!/3)H _/[_@A-^V%\"O!_P#P1[TKX>_M!>*-,\&Z_P# +3=3\-?% M_P +>)IDMKK0WM+B<_OX)"&VRP%&!QAG+H,LK"OGC]C+]AC]G'0/^"(O[/?[ M$_\ P5#BUCP7-\7/B=?:GX!U)M7_ ++U#P7K$\=_?:8T)@$D4CS M;ORV4N<5^M_B/]FK]G/QC\1K7XP^+O@#X)U7Q;8E#9>*=2\*V<^HV^S&S9_#+X;_%31QX>^)_P^T/Q)IX8L+'7M)AO(02I4G9*K+DJS M+TZ$CO0!^9W[)_Q+_:U_8R^,'[2?[ W[-[3QQJ=FO\ M:Z:>ZW"GP]JDFYO-N)H([F1?-=G,:;]VR4)'YWX8^$'Q&_X)2_$SX ?%[_@E MA^V/??%+]F?XZ?%/2O#T/P*\2:D-6CL;;4&>5[[1KDDR1QV\:2RNORM%Y8:= MI1O*?K1X%^!GP3^%W@JY^&WPS^#WA;P[X,KGXC?#;]G[P1X>\0WL1CO->T/PI9VE[.A.2 MKSQ1J[ GJ"2* .WK\DOV -/^!7QB_P"#C']NSPQXSTOPMXHCFTOPJUC8:K;6 M]ZKO:V,$%R420,"T4A$;X&58X.#7ZT7]A8ZK8S:7JEE%U:VU[P_\ L_>"+&^LITGL[VS\*6<4L$JD M%71UC!5@0"""""* -;7;+P?\._AAJ-K86>FZ'HFE:/<-Y4,<=M:V<*QLS' P MD: 9)Z +M+>Z@F#/IEY-K6IO$ M7"\HP6:*4#KM92.HK]&/%/A/PMXXT*?PMXU\-:?K&F76W[3IVJ6:7$$VU@Z[ MHY 5;#*K#(X*@]16=X&^$GPJ^+_#3X9>'O#K7H07AT+18+0SA-VS?Y2+N MV[FQG.-QQUH _.O_ (-O_P!H+P%\$/\ @FG<_L(M,\"?$#]G'Q#KVE? M$G0/$NH16-O"NGZRAM6L-$O-/,%B&23'EB5+=9D4X)6Y3C+8 MK],O'/[-?[.?Q/\ &5E\1?B5\ ?!7B'Q!IFW^S==USPK9W=Y:;3E?+FEC9X\ M$Y&TC%;OC7X?> ?B3I4>A?$7P1H^OV,5P)XK/6M,BNHDE"LHD"2JP# ,PW8S MAB.YH ^'?^"6'B_PK+_P;L> M?3Q%9&QT_X"7T5_=_:5\NW>&VN5F5VSA2C* MP8'H0*O^#*FZMO#3"_DM?AG?_:4M#YAB\CQ'+)-N"]-B*S-GH 2: M_7^R_9R_9ZTW1[[P[IWP(\&6^GZF8CJ5C!X7M$AN_+8M'YJ"/;)L8DKN!VDD MC%:7A;X1?"CP-I%[H'@GX8>'M'L-34KJ5EI6BP6\-V"I4B1(T"R?*2/F!X)% M 'F7_!/7]H+X*?M _LH^!]4^"/Q-TCQ59Z3X-T:TU.^T*[%S;VUU]@A9K9Y4 MR@G0%?,ASYD>Y=ZKN7/MU9OA'P9X/^'_ (>MO"/@+PIINB:39J5M-+TBQCMK M> $EB$CC 5,"OI>%^%\PXIS!8?#JT%K.; MVBOU;Z+KY)-KYCBKBK+N%,N>(Q#O-Z0@MY/]$NKZ>;:3^[/!'CWP;\2?#T?B MOP'XCM=5TZ5W1+NTDW*64X93W!!['V/>M>ORM_99_:F\9?LS>,O[2TTO>Z'> MNHUG1FDPLRCCS$SPLJCHW?H>.GZ:_#7XE>#?BWX-L_'G@/6$O=.O4RCKPT;? MQ1NO574\%3TKTN,^"L9PIBKJ\Z$OAG_[;+M+\&M5U2\S@GC?!<6X2SM#$1^* M'_MT>\?Q3T?1O=HHHKX@^Z"FS316T+W$\@5(U+.QZ 9)IU% 'FOPM_;+_9* M^-WQ(U/X.?!_]I7P/XF\7:+;-<:OX7T3Q/;7&HV42LJM)+;HYDC4,Z EE != M0>HKI/BS\9_A-\!_!\_Q"^-7Q'T;PKH-J";K6=?U!+6U@ !)+RR$*@ !.20* M_*W_ (*^?L3_ +2OQ9_X*@:C^V'_ ,$^/$9T7XY?!'X&^&?$_A[3+:W01^+8 MI-7U^"\TZXQ@S/);P1QH&.UU4PG =7C^@_!/_!2+X/?\%2?^"+7QG^-G@BS& MEZ[9_"'Q/I?Q"\#WK9NO#VK)I%R)K:56 +1MRT0KJZ* ?:WPR^*OPV M^-'@^U^(/PE\*]/T3P[X&\(Z*(A=:UJ4MB)$@C,K)'$B0PS322NRI' M%!(QS@*>$\.?\%/M6\,?MNZ=_P $_?VHOV<;CP-X]\6^%;G7?AE=:1XLAU?2 M?%<=NDCSVD=RT5L]O=*(I#Y>&[KQCXY\16F MDZ58IOO-0OIA'# N<;F8\*/<\5\!?\$F?VY_VV?VI_VM?VCM)^-OP"M[/2?# M/QBD\+RFQ\:036WA"&QL0B6J1LH>\:24&1Y8PJEYV( 50H_1&@#S3X#_ +9O M[)7[4D]U;_LV?M)^"?'S6/%[_P (?XDM]1%N< X(;JS_ &A_%$L/A_P\;6.[OF6WTY1'$;J:" -@ M #S)47"]>E>@^"?^"^_BSXT?L/7W[=G[/7_!-CXD>+/"_AU]6N?&@E\0Z=IZ MZ)IUA+())0]PP:]N/)C:9H+6.58U^5I0V 0#]&**^??$/_!2;]GW2_V3?AS^ MUIH$.L:W9?%]M(M?ACX6TZVC&JZ_J6IH'MK!$DD6..4#>96DD6.)8969PJ9K MFO!W_!276]&_;Q\._P#!/7]IW]G>?P/XQ\<^$KGQ#X!U?0_$@UO2=5AMO-:Y MMI)OL]N]M8VT'F'8LK;7*\G+_P6 ME^ ?B#_@FWKG_!2KX/\ PE\;>,/#_A474/C#PC9165IJ_AN\M@/M-O?Q75S& M(S"60OY1F?9(KHCJ_MI^-/V!/'\?P0\5Z M?H4_B;XC_P!N6*?V"VIQPLK1V#L+J[MXY)A%]H9(%D8!H@Z/&S]=\7/^"O&N M? ;XZ?#CP_\ &/\ 8A\=>&_A+\5?'%KX0\(?%[5=6L4$NJW8;[)Y^E!S=VEO M,48J\_ER!%+/$I&V@#[0HKQSXM?M5ZMH7QG_ .&9O@'\+U\=_$&W\-IX@UG3 MKG7DTO3M$TV262&WDO+LQ3,DEQ)%.L,4<,K-Y$K-Y:+O/)_\$_\ _@H]X(_; MGU/XC?#&\^&^J^ _B7\'_$_]A?$GP%K-Y#=/IT[&3R9X+F$^7-2C3F[QG9*TGTF^J?23^'9^[\ M/XWXG<"XK.E_:N!;E5@K2A=N\5U@NC76*^+=>]\7Y^5]L_\ !+KX1_&30OMG MQ-U'5Y]-\):E 5@TF9,_VG(.%N%!^XJ\@..7Z=!FN*_8B_80U'XEZC%\3OC- MHT]IX>M)S]CTFYC,#@K"",'NQ&!QDU]^VUM;65M'9V=ND4,2!(HH MD"JB@8"@#@ #C%>[XF<>38.TV]*DM&H_P!V/3F[O[/3WOA\'POX$Q:Q M%/.L;>"CK3CJG+^]+KR]E]KK[OQ/HHHK\#/Z""BBB@#Y:\'>-O!]Q_P6C^(' M@NW\46$FKQ_LU>%'DTU+M#.@37M?9LH#D86:%B,<"5#T89^$_P#@NG^PM\=/ MV&==^)/_ 54_P""=.B>9I'Q \$:IX>_::^&ELC?9=5L+NUEA.O1Q)TFA:7S M97495@9B"CW6[]8++]GC]G_3?$B>,=.^!G@Z#5X[O[5'JL/AFT6Y6?=N\T2B M/<'W<[LYSSFNLOK&RU.RFTW4K.*XM[B)HKBWGC#I*C##*RGA@02"#P0: /RG M_P""T%U'\&_@Q^QA^W!\1_@TOC_X3_"3Q';?\+9\.S:-'J,4>F:GH\=F+Z2V ME4I((3NV[ACS9(AE2P(]Q_9=^.W_ 1/_:!_: \#M_P3[^!GP:\;>-T6746\ M1^"?AU9VMUX,TT6\F^]N+H6:R63NYCMD@)2:1[C[NQ)63[AG\/Z#F76B_!+X/^%O! MUG>W'GWMIX5\/VVGQ7$O_/1UMT0.W)^8@GF@#\[?^"-'QN^$GPZ_;U_;7_9_ M\;_$#3--\<^(OVIM2OM!\(W%P/[2U"TEMS(MS%;C,CPA(W=I0-B* 69003^F M][>V>G6:'+X9\<^%M-UK M39V5IM/U:QCN8)"K!E+1R J<$ C(X(!H _+_ /X-+_&W@_4_^"?WQ3DL/%&G MRBT_:$\1W=ULNT_T\.?$Q;N4W*;82XOG4.<_*2DB, >H=3W%?J78?LR_LW:4EQ'IG[/G@> MV6[MS!=+!X3LT$T1()C?$?S*2JG:>,J/2B#]F;]F^UTVXT:V_9]\$1V=V\;W M=I'X4LQ%,T>[8SJ(\,5W-@D<;CCJ: /Q7\6>/O$OP#_X)0?\$UO^"B>CZ%>> M(_ /P,U^UE^)D&BQ_:'L;*ZA-E)=LB\9A*31C.,2S(I(W9'ZG?!+_@J/^QQ^ MUM\3_#?PW_8X^*>D?%'4-1MI+_7KOPT[R1>&-+$+M]IO9#'BWDDF$$"6SE9G M:4MLVPRLON'AWX2?"GPAX'M+TC4M_]HZ7IVBP06UUO38WF1(@5 M\H IW Y'!XJ'X6_!/X-? [1Y_#WP4^$GACP?I]U<&XN;'PMH%OI\,TIZR,D" M(K,?[Q&: /SA_P"#'68C*1YUO(PE)D7*A3$S$>8N?#_!?PNN/!'_ 1W_P""DG[4 M]Q*--\#?&_XA>.->^&*W/[J'4-'DDDAM=0A5L8CNY'(BX^=$B9?C3K&G^(OC'\!O!GBS4-)_Y!=]XF\+VE_-9\[OW3SQLT?//RD